empagliflozin profile

ID Source	ID
PubMed CID	11949646
CHEMBL ID	2107830
CHEBI ID	82720
SCHEMBL ID	899986
MeSH ID	M0571248

Synonym
bi-10773
empagliflozin ,
1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene
empagliflozin [usan:inn]
jardiance
hdc1r2m35u ,
bi10773
864070-44-0
bi 10773
d-glucitol, 1,5-anhydro-1-c-(4-chloro-3-((4-(((3s)-tetrahydro-3-furanyl)oxy)phenyl)methyl)phenyl)-, (1s)-
(1s)-1,5-anhydro-1-c-{4-chloro-3-((4-{((3s)-oxolan-3-yl)oxy}phenyl)methyl)phenyl}-d-glucitol
unii-hdc1r2m35u
HY-15409
jardiance (tn)
empagliflozin (jan/usan/inn)
D10459
(2s,3r,4r,5s,6r)-2-[4-chloro-3-[[4-[(3s)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
PB23119
CS-0940
CHEMBL2107830
chebi:82720 ,
S8022
c23h27clo7
(2s,3r,4r,5s,6r)-2-[4-chloro-3-({4-[(3s)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
gtpl4754
SCHEMBL899986
empagliflozin [usan]
empagliflozin [mi]
empagliflozin [who-dd]
empagliflozin [orange book]
empagliflozin [vandf]
trijardy xr component empagliflozin
empagliflozin [inn]
glyxambi component empagliflozin
(1s)-1,5-anhydro-1-c-(4-chloro-3-((4-(((3s)-oxan-3-yl)oxy)phenyl)methyl)phenyl)-d-glucitol
empagliflozin component of trijardy xr
empagliflozin component of glyxambi
empagliflozin [jan]
empagliflozin component of synjardy
(1s)-1,5-anhydro-1-(4-chloro-3-{4-[(3s)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-d-glucitol
empagliflozin (bi 10773)
us8980829, empagliflozin
bdbm150162
HB4638
(2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-(((s)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
AC-27643
AKOS024464680
DB09038
mfcd22566222
bi-10773;empagliflozin
EX-A414
(1s)-1,5-anhydro-1-c-[4-chloro-3-[[4-[[(3s)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-d-glucitol
SW219120-1
empagliflozin (bi-10773;bi 10773;bi10773)
DS-9824
Q5373824
(2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
empagliflozin (bi10773)
AMY1858
7R3 ,
(2s,3r,4r,5s,6r)-2-[4-chloranyl-3-[[4-[(3s)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
CCG-269242
C22194
(2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2h-pyran-3,4,5-triol
A852380
AU-004/43508285
1,5-anhydro-1-{4-chloro-3-[4-(tetrahydro-3-furanyloxy)benzyl]phenyl}hexitol
EN300-7422890
DTXSID601026093
d-glucitol, 1,5-anhydro-1-c-[4-chloro-3-[[4-[[(3s)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, (1s)-; (1s)-1,5-anhydro-1-c-[4-chloro-3-[[4-[[(3s)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-d-glucitol; bi 10773; empagliflozin; jardiance
Z2235802079
empagliflozina
(1s)-1,5-anhydro-1-(4-chloro-3-(4-((3s)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-d-glucitol
empagliflozine
a10bk03
(1s)-1,5-anhydro-1-c-(4-chloro-3-((4-(((3s)-oxolan-3-yl)oxy)phenyl)methyl)phenyl)-d-glucitol
empagliflozinum

Excerpt	Reference	Relevance
"Empagliflozin is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor in clinical development for the treatment of type 2 diabetes mellitus. "	( Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Bakker, RA; Eckhardt, M; Eickelmann, P; Grempler, R; Himmelsbach, F; Klein, T; Mark, M; Sauer, A; Sharp, DE; Thomas, L, 2012)	3.26
"Empagliflozin is a potent and competitive SGLT-2 inhibitor with an excellent selectivity profile and the highest selectivity window of the tested SGLT-2 inhibitors over hSGLT-1. "	( Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Bakker, RA; Eckhardt, M; Eickelmann, P; Grempler, R; Himmelsbach, F; Klein, T; Mark, M; Sauer, A; Sharp, DE; Thomas, L, 2012)	3.26
"Empagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used to lower blood sugar in adults with type 2 diabetes. "	( Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death. Abbott, GW; Du, L; Hu, Z; Ju, F, 2021)	3.51
"Empagliflozin is a selective inhibitor of sodium glucose co-transporter II, given as mono therapy or an add-on treatment to reduce the glycated hemoglobin levels in type 2 diabetes. "	( Optimization of empagliflozin immediate release tablets (10 mg) using central composite rotatable design with response surface methodology. Alam, S; Ali, SI; Bushra, R; Ghayas, S; Iffat, W; Ismail, NE; M Hanif, A; Perveen, S; Riaz, H; Un-Nisa, Z, 2021)	2.41
"Empagliflozin is a selective SGLT2 inhibitor and provides a significant reduction in hospitalizations in heart failure patients and a reduction in combined cardiovascular deaths regardless of diabetes. "	( The effect of empagliflozin on P wave peak time and other P wave parameters in patients with diabetes mellitus. Akyüz, A; Araç, E; Aslan, B; Boyraz, B; Çap, M; İnci, Ü; Işık, F; Karahan, MZ; Kaya, İ; Okşul, M; Yıldız, H, 2022)	2.52
"Empagliflozin is a safe and potent glucose-lowering drug in routine use among Korean patients with type 2 diabetes mellitus. "	( Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance. Cho, J; Cho, JH; Chung, DJ; Jeong, IK; Kim, NH; Lee, DW; Lee, SH; Lee, SW; Mok, JO; Moon, JS; Na, JO; Won, KC, 2023)	2.65
"Empagliflozin is a sodium-glucose cotransporter-2 inhibitor widely used in the treatment of diabetes mellitus and heart failure. "	( Short-Term Treatment with Empagliflozin Resulted in Dehydration and Cardiac Arrest in an Elderly Patient with Specific Complications: A Case Report and Literature Review. Nishikawa, Y; Supakul, S; Takase, T; Teramura, M, 2022)	2.46
"Empagliflozin (EMPA) is a novel sodium-glucose cotransporter 2 inhibitor (SGLT2i) that produces protective cardiovascular-renal outcomes in patients with diabetes. "	( Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1-Adiponectin Axis. Chen, B; Han, F; Kan, C; Kuang, Z; Ma, Y; Shi, J; Sun, X; Wu, D; Xu, Q; Ye, T; Zhang, J, 2022)	3.61
"Empagliflozin is a new antidiabetic agent with broad clinical application prospect in cardiovascular and renal diseases."	( A metabonomics-based renoprotective mechanism analysis of empagliflozin in obese mice. Ban, J; Chen, S; Chen, X; Jia, Z; Li, Z; Niu, S; Pan, X; Ren, Q; Yue, L; Zhen, R; Zhu, R, 2022)	1.69
"Empagliflozin is a newly developed inhibitor of sodium-glucose cotransporter-2 (SGLT2) approved as an antidiabetic medication for patients with type 2 diabetes mellitus."	( Empagliflozin protects against renal ischemia/reperfusion injury in mice. Abbott, GW; Hu, Z; Ju, F; Li, J; Liu, T; Wang, Q; Zuo, Y, 2022)	2.89
"Empagliflozin is a new antidiabetic drug with positive effects on glucose regulation and the prevention of cardiovascular diseases (CVD). "	( The effect of empagliflozin on index of cardio-electrophysiological balance in patients with diabetes mellitus. Güzel, T; İnci, Ü, 2023)	2.71
"Empagliflozin (EMPA) is an anti-diabetic drug that has been shown to improve cognitive dysfunctions and exerted antioxidant and anti-inflammatory effects in different models."	( Empagliflozin enhances neuroplasticity in rotenone-induced parkinsonism: Role of BDNF, CREB and Npas4. Mousa, HH; Nader, MA; Sharawy, MH, 2023)	3.07
"Empagliflozin is a selective sodium-glucose co-transporter (SGLT2) inhibitor that is approved for the treatment of type 2 diabetes. "	( Evaluation of the effects of empagliflozin on acute lung injury in rat intestinal ischemia-reperfusion model. Culha, C; Erel, O; Gokbulut, P; Koc, G; Kuskonmaz, SM; Nural, AS; Onder, CE; Yumusak, N, 2023)	2.64
"Empagliflozin is a sodium-glucose co-transporter 2 inhibitor with a convincing evidence base for the treatment of all categories of patients with chronic heart failure, regardless of diabetes status."	( CLINICAL EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE. Bletskan, ММ; Ivano, NV; Korabelschykova, MO; Rudakova, SO; Rоsul, ММ, 2023)	1.93
"Empagliflozin (EMP) is an oral antihyperglycemic agent for type 2 diabetic patients. "	( Combined experimental/computational aspects for the molecular interaction of empagliflozin with bovine serum albumin: Quantification and application to human plasma. GadAllah, MI; Hosny, NM; Qayed, WS, 2023)	2.58
"Empagliflozin (EMPA) is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that has been shown to have anti-inflammatory and antioxidative effects."	( Biochemical and histopathological evidence for beneficial effects of Empagliflozin pretreatment on acetic acid-induced colitis in rats. Esmaeilzadeh, Z; Ghasemnejad-Berenji, M; Jafari, A; Nazari-Khanamiri, F, 2023)	1.87
"Empagliflozin (EMPA) is a promising novel antidiabetic drug; however, doubts have been raised regarding its use and the increased risk of urinary bladder carcinoma. "	( Dysplastic urothelial changes accompany empagliflozin administration in urinary bladder of experimental diabetes. Abdel-Hamid, AAM; Firgany, AEL, 2019)	2.22
"Empagliflozin (EMP) is a sodium-glucose co-transporter 2 inhibitor, the newest class of antidiabetic agents."	( Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes. Alves-Martinez, P; Carranza-Naval, MJ; Del Marco, A; Garcia-Alloza, M; Herrera, M; Hierro-Bujalance, C; Infante-Garcia, C; Lubian-Lopez, S; Suarez, J, 2020)	2.72
"Empagliflozin is an inhibitor of sodium‑glucose cotransporter 2 (SGLT2) and has a positive effect on cardiovascular outcomes."	( Empagliflozin significantly attenuates sotalol-induced QTc prolongation in rats. Dinçsoy, B; Erdemb, A; Gedikli, E; Özgür Barış, V, 2021)	2.79
"Empagliflozin (EMPA), is a novel hypoglycaemic drug which possesses multiple pharmacologically relevant protective effects, including anti-apoptotic, anti-inflammatory and antioxidant effects."	( Empagliflozin alleviates ethanol-induced cardiomyocyte injury through inhibition of mitochondrial apoptosis via a SIRT1/PTEN/Akt pathway. Deng, H; Shi, X; Tian, G; Yang, L; Yu, B; Yu, Y, 2021)	2.79
"Empagliflozin is a SGLT2 inhibitor that reduces the concentration of blood glucose by inhibiting glucose reabsorption and promoting glucose excretion. "	( The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway. Chen, L; Cheng, Y; Fang, T; Han, L; Li, T; Liu, X; Meng, Z; Sun, B, 2021)	2.39
"Empagliflozin was estimated to be a highly cost-effective treatment option compared to dapagliflozin for the treatment of T2DM patients with established CVD in Greece."	( Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece. Diogo, V; Gourzoulidis, G; Ioannidis, I; Karpouzos, G; Kourlaba, G; Papageorgiou, G; Tsimihodimos, V; Tzanetakos, C, 2021)	2.38
"Empagliflozin is an effective sodium glucose cotransporter-2 (SGLT2) inhibitor to improve glycemic control in adults with type 2 diabetes. "	( Isolation and characterization of novel process-related impurities in empagliflozin. Chen, Y; Hong, H; Li, H; Peng, X; Tao, H; Xu, G, 2021)	2.3
"Empagliflozin (EMPA) is a SGLT-2 inhibitor that has positive effects on cardiovascular outcomes. "	( Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways. Barış, VÖ; Dinçsoy, AB; Erdem, A; Gedikli, E; Müftüoğlu, S; Zırh, S, 2021)	3.51
"Empagliflozin (EMPA) is a sodium-glucose transporter 2 (SGLT2) inhibitor that functions as a new-generation glucose-lowering agent and has been proven to be beneficial for patients with cardiovascular diseases. "	( Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin. Chou, TW; Jhuo, SJ; Lai, WT; Lee, KT; Lin, YH; Liu, IH; Tasi, WC; Wu, BN, 2021)	2.28
"Empagliflozin is a sodium-glucose-cotransporter-2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type-2 diabetes. "	( Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. Abbas, J; Atkin, SL; Deshmukh, H; Javed, Z; Khan, AY; Kilpatrick, ES; Papageorgiou, M; Qamar, U; Rigby, AS; Sathyapalan, T, 2019)	2.35
"Empagliflozin is a potent SGLT2 inhibitor used to improve glycemic control in adults with T2DM."	( A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus. Chaudhary, KK; Chawla, G, )	1.17
"Empagliflozin is an oral sodium glucose co-transporter-2 inhibitor for type 2 diabetes mellitus. "	( Binding properties of sodium glucose co-transporter-2 inhibitor empagliflozin to human serum albumin: spectroscopic methods and computer simulations. Gan, N; Li, H; Sun, Q; Suo, Z; Tang, P; Wang, W; Wu, D; Zhao, L, 2020)	2.24
"Empagliflozin is a sodium glucose cotransporter 2 inhibitor in clinical development as a treatment for type 2 diabetes mellitus."	( Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Broedl, UC; Macha, S; Pinnetti, S; Rose, P; Schoene, K; Sennewald, R; Woerle, HJ, 2013)	2.08
"Empagliflozin is a potent, selective inhibitor of sodium glucose cotransporter 2 in development for the treatment of patients with type 2 diabetes mellitus. "	( Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers. Broedl, UC; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ, 2013)	2.23
"Empagliflozin is a potent, selective sodium glucose cotransporter 2 (SGLT2) inhibitor in development as an oral antidiabetic treatment. "	( The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study. Brand, T; Breithaupt-Groegler, K; Broedl, UC; Macha, S; Ring, A; Simons, G; Walter, B; Woerle, HJ, 2013)	2.09
"Empagliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that inhibits renal glucose reabsorption and is being investigated for the treatment of type 2 diabetes mellitus (T2DM)."	( Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Broedl, UC; Halabi, A; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ, 2014)	2.1
"Empagliflozin is a sodium glucose cotransporter 2 (SGLT2) inhibitor in development for the treatment of T2DM."	( Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Broedl, UC; Kim, G; Ridderstråle, M; Svaerd, R; Woerle, HJ; Zeller, C, 2013)	1.33
"Empagliflozin is an orally available, potent and highly selective inhibitor of the sodium glucose cotransporter 2 (SGLT2). "	( Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers. Hobson, D; Hohl, K; Jungnik, A; Macha, S; Salsali, A; Woerle, HJ, 2013)	2.1
"Empagliflozin is an orally active, potent and selective inhibitor of sodium glucose co-transporter 2 (SGLT2), currently in clinical development to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM). "	( Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Scheen, AJ, 2014)	2.1
"Empagliflozin is a potent, oral, selective inhibitor of sodium glucose cotransporter 2 in development for the treatment of type 2 diabetes mellitus."	( Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers. Broedl, UC; Hummel, N; Koenen, R; Macha, S; Riedmaier, S; Salsali, A; Schöne, K; Sennewald, R; Woerle, HJ, 2014)	2.06
"Empagliflozin is a potent, selective sodium glucose cotransporter 2 inhibitor approved for the treatment of type 2 diabetes mellitus. "	( Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study. Broedl, UC; Heise, T; Macha, S; Mattheus, M; Woerle, HJ, 2015)	2.08
"Empagliflozin is a new once-daily oral SGLT2 inhibitor with a mechanism of action that is independent of β-cell function and the insulin pathway. "	( Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence. White, JR, 2015)	3.3
"Empagliflozin is a new medicine used to reduce hyperglycemia in patients with type 2 diabetes. "	( [Empagliflozin - the new representative of SGLT2 transporter inhibitors for the treatment of patients with diabetes 2 type]. Prázný, M; Slíva, J, 2015)	2.77
"Empagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces hyperglycemia in type 2 diabetes mellitus (T2DM) by decreasing renal glucose reabsorption and promoting urinary glucose excretion. "	( Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus. Dailey, GE, 2015)	3.3
"Empagliflozin is a direct inhibitor of sodium-glucose cotransporter 2 (SGLT2), which acts to lower the renal threshold and increase urinary glucose excretion. "	( Empagliflozin: a sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. Dixit, D; Mansukhani, RP; Volino, LR; Yoon, Y, 2015)	3.3
"Empagliflozin is a new inhibitor of sodiumglucose cotransporters type 2 (SGLT2) for the treatment of type 2 diabetes mellitus (T2DM). "	( [EMPAGLIFLOZIN (JARDIANCE) :Nw SGLT2 COTRANSPORTER INHIBITOR FOR TREATING TYPE 2 DIABETES]. Scheen, AJ, 2015)	2.77
"Empagliflozin is a sodium glucose co-transporter 2 inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) by enhancing urinary glucose excretion. "	( A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes. McGuire, DK; Neeland, IJ; Salahuddin, U, 2016)	2.19
"Empagliflozin is a potent, selective sodium glucose co-transporter-2 inhibitor that is in development for the treatment of type 2 diabetes. "	( Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Eckhardt, M; Eickelmann, P; Grempler, R; Himmelsbach, F; Klein, T; Mark, M; Sauer, A; Thomas, L, 2012)	2.13
"Empagliflozin is a potent and selective SGLT-2 inhibitor that lowers blood glucose levels by inhibiting renal glucose reabsorption, leading to an increase in urinary glucose excretion."	( Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Brand, T; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ, 2012)	1.42
"Empagliflozin is an oral, potent, and selective inhibitor of sodium glucose cotransporter 2, inhibition of which reduces renal glucose reabsorption and results in increased urinary glucose excretion. "	( A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Friedrich, C; Mattheus, M; Metzmann, K; Pinnetti, S; Rose, P; Woerle, HJ, 2013)	2.06

Excerpt	Reference	Relevance
"Empagliflozin has an IC(50) of 3.1 nM for hSGLT-2. "	( Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Bakker, RA; Eckhardt, M; Eickelmann, P; Grempler, R; Himmelsbach, F; Klein, T; Mark, M; Sauer, A; Sharp, DE; Thomas, L, 2012)	3.26
"Empagliflozin has a favorable effect on neutropenia/neutrophil dysfunction-related symptoms and safety profile in individuals with GSD Ib."	( Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire. Adrian, K; Al-Thihli, K; Ballhausen, D; Bidiuk, J; Bordugo, A; Boyer, M; Bratkovic, D; Brunner-Krainz, M; Burlina, A; Chakrapani, A; Corpeleijn, W; Cozens, A; Dawson, C; Derks, TGJ; Dhamko, H; Eiroa, H; Finezilber, Y; Fraile, PQ; Fung, LH; Garcia-Jiménez, MC; Gasperini, S; Grünert, SC; Haas, D; Häberle, J; Halligan, R; Hörbe-Blindt, A; Horka, LM; Huemer, M; Kecman, B; Kilavuz, S; Kriván, G; Lindner, M; Lüsebrink, N; Maier, EM; Maiorana, A; Makrilakis, K; McCandless, SE; Mei-Kwun Kwok, A; Milosevic, MD; Mitchell, JJ; Mizumoto, H; Moura de Souza, CF; Mundy, H; Ochoa, C; Pierce, K; Regier, D; Rossi, A; Santer, R; Schrier Vergano, SA; Schuman, HC; Sobieraj, P; Spenger, J; Spiegel, R; Stepien, KM; Tal, G; Tanšek, MZ; Tchan, M; Thyagu, S; Torkar, AD; Uçar, SK; Vucko, E; Weinhold, N; Wortmann, SB; Zsidegh, P, 2022)	2.47
"Empagliflozin has a low permeability and is very slightly soluble in aqueous media between pH 1-7.5."	( Architecting novel multilayer nanosponges for co-administration of two drugs managing high-risk type II diabetes mellitus patients suffering from cardiovascular diseases. Abdelmalak, NS; Hammad, RW; Latif, R; Sanad, RA, 2022)	1.44
"Empagliflozin has a favorable effect on amelioration of proteinuria in patients with glomerulonephritis. "	( Effect of sodium-glucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: a pilot superiority randomized controlled trial. Abdelaziz, TS; Fayed, A; Hammad, H; Philips, MV; Shaaban, A, 2023)	2.61
"Empagliflozin has a native fluorescence nature, therefore can be directly determined by measuring emission peak at 305 nm after excitation at 234 nm."	( Flourimetric study on antidiabetic combined drugs; empagliflozin and linagliptin in their pharmaceutical formulation and human plasma. Elmasry, MS; Hasan, MA; Hassan, WS; Merey, HA; Nour, IM, 2021)	1.59
"Empagliflozin has been reported to protect endothelial cell function, regardless of diabetes status. "	( Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis. Chen, X; Du, N; Ma, L; Qiu, J; Shi, W; Zhou, H; Zhou, N; Zou, R, 2022)	3.61
"Empagliflozin has been shown to reduce the risk of adverse cardiovascular outcomes in patients with type 2 diabetes and in those with heart failure. "	( Baseline characteristics of patients enrolled in the EMPACT-MI trial. Andersen, KR; Anker, SD; Bhatt, DL; Butler, J; Harrington, J; Hernandez, AF; Jones, WS; Petrie, MC; Sumin, M; Udell, JA; Zwiener, I, 2023)	2.35
"Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. "	( Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. , 2023)	3.8
"Empagliflozin has been shown to reduce all-cause mortality in type 2 diabetic patients at high cardiovascular risk and to reduce episodes of cardiac decompensation and is nephroprotective in diabetic and non-diabetic subjects."	( [Empagliflozin in the elderly]. Berrut, G; Boureau, AS; de Decker, L; Genet, B; Hanon, O; Trochu, JN, 2021)	2.25
"Empagliflozin has been shown to reduce cardiovascular mortality, but the underlying pathogenetic mechanisms are poorly understood. "	( How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. Bosch, A; Dienemann, T; Jung, S; Kannenkeril, D; Karg, MV; Ott, C; Schmieder, RE; Striepe, K, 2019)	2.37
"Empagliflozin has shown efficacy in lowering HbA1c and blood glucose levels both as monotherapy and as an add-on to existing therapy. "	( Empagliflozin: a sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. Dixit, D; Mansukhani, RP; Volino, LR; Yoon, Y, 2015)	3.3
"Empagliflozin has shown a cardiovascular protection in the EMPA-REG OUTCOME trial."	( [EMPAGLIFLOZIN (JARDIANCE) :Nw SGLT2 COTRANSPORTER INHIBITOR FOR TREATING TYPE 2 DIABETES]. Scheen, AJ, 2015)	2.05

Excerpt	Reference	Relevance
"Empagliflozin did not increase the risk of bone fracture compared with placebo in a pooled analysis of >12,000 patients or compared with glimepiride in a 4-year head-to-head study."	( Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride. Kaspers, S; Kohler, S; Salsali, A; Woerle, HJ; Zeller, C, 2018)	2.16
"Empagliflozin did not increase urinary glucose/creatinine ratios in Akita, indicating the reduction in filtered glucose balanced the inhibition of glucose reabsorption."	( SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Gerasimova, M; Koepsell, H; Masuda, T; Mayoux, E; Rieg, T; Rose, MA; Satriano, J; Thomson, SC; Vallon, V, 2014)	1.47
"Empagliflozin does not cause clinically significant dehydration or hypotension in patients about 60 years of age, but some caution in empagliflozin treatment should be in elderly and fragile patients."	( [New SGLT2 inhibitor empagliflozin: modern and safe treatment of diabetes]. Rušavý, Z, 2014)	1.44

Excerpt	Reference	Relevance
"Empagliflozin treatment significantly reduced SBV compared with placebo after 12 weeks of treatment in patients with stable chronic heart failure and reduced ejection fraction during sub maximal exercise."	( Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial. Borlaug, BA; Burkhoff, D; Frederiksen, PH; Gustafsson, F; Jensen, J; Kistorp, C; Køber, L; Møller, JE; Omar, M; Poulsen, MK; Schou, M; Videbæk, L, 2022)	2.57
"Empagliflozin treatment reduced neutral triacylglycerols and lipotoxic diacylglycerols in the liver and was accompanied by significant changes in relative mRNA expression of lipogenic enzymes ("	( In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia. Haluzik, M; Hüttl, M; Malinska, H; Markova, I; Miklankova, D; Poruba, M; Vaněčkova, I; Zapletalova, I, 2021)	1.65
"Empagliflozin-treated patients had a 27% lower risk of all-cause hospitalization compared with DPP-4 inhibitor-treated patients (rate ratio [RR] 0.73, 95% CI 0.67-0.79), and 23% reduced risk for first hospitalization (hazard ratio 0.77, 95% CI 0.73-0.81)."	( Healthcare resource utilization in patients treated with empagliflozin in East Asia. Chung, WJ; Deruaz-Luyet, A; Ha, KH; Kim, DJ; Klement, R; Kyaw, MH; Lee, S; Lei, WY; Nangaku, M; Node, K; Seino, Y; Sheu, WH; Tan, EC; Ustyugova, A; Yabe, D; Yasui, A, 2022)	1.69
"Empagliflozin treatment was associated with lower inpatient care needs and other healthcare resource utilization than DPP-4 inhibitors in routine clinical practice in East Asia in this study."	( Healthcare resource utilization in patients treated with empagliflozin in East Asia. Chung, WJ; Deruaz-Luyet, A; Ha, KH; Kim, DJ; Klement, R; Kyaw, MH; Lee, S; Lei, WY; Nangaku, M; Node, K; Seino, Y; Sheu, WH; Tan, EC; Ustyugova, A; Yabe, D; Yasui, A, 2022)	2.41
"Empagliflozin treatment increased urinary glucose excretion, in parallel to empagliflozin plasma levels, in a dose-dependent manner starting at doses of 1 mg/kg in the pilot study."	( Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5/6 nephrectomised rats on high salt diet. Cao, Y; Chen, X; Chu, C; Delic, D; Frankenreiter, S; Gaballa, MMS; Hasan, AA; Hocher, B; Klein, T; Krämer, BK; Luo, T; Stadermann, K; Xiong, Y; Xue, Y; Yin, L; Zeng, S, 2022)	1.69
"Empagliflozin treatment reduced liver fat in small type 2 diabetes cohorts. "	( Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. Inzucchi, SE; Kahl, S; Ofstad, AP; Roden, M; Sattar, N; Schüler, E; Wanner, C; Zinman, B, 2022)	2.55
"Empagliflozin treatment decreased hyperglycemia in diabetic rats whereas blood pressure remained elevated in hypertensive rats."	( Effect of Empagliflozin on Sphingolipid Catabolism in Diabetic and Hypertensive Rats. Bautista-Pérez, R; Escalante, B; Flores-Estrada, J; Franco, M; Mercado, A; Pérez-Méndez, O; Pérez-Villavicencio, R, 2022)	1.85
"Empagliflozin-treated patients experienced greater clinical benefit across the range of KCCQ-TSS, with no treatment effect heterogeneity (win ratio [95% CIs] from lowest to highest tertile: 1.49 [1.01-2.20], 1.37 [0.94-1.99], and 1.48 [1.00-2.20], respectively;"	( Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. Angermann, CE; Biegus, J; Blatchford, JP; Brueckmann, M; Collins, SP; Comin-Colet, J; Ferreira, JP; Kosiborod, MN; Mentz, RJ; Nassif, ME; Ponikowski, P; Psotka, MA; Salsali, A; Teerlink, JR; Tromp, J; Voors, AA, 2022)	1.83
"Empagliflozin treatment showed a restorative effect on all biochemical alterations and improved the motor function of rats tested by open field, grip strength and footprint gait analysis."	( Empagliflozin alleviates endoplasmic reticulum stress and augments autophagy in rotenone-induced Parkinson's disease in rats: Targeting the GRP78/PERK/eIF2α/CHOP pathway and miR-211-5p. Abdelraouf, SM; Al-Kady, RH; Motawi, TK; Senousy, MA, 2022)	2.89
"Empagliflozin added to GM treatment led to lower measured levels of TGF-B, NF-κB and caspase 3, and only the higher dose increased PAX2 levels indicating an improvement in tubular regeneration."	( Protective effect of empagliflozin on gentamicin-induced acute renal injury via regulation of SIRT1/NF-κB signaling pathway. Anter, A; Botros, SR; Heeba, GH; Khalifa, MMA; Matouk, AI, 2022)	1.76
"Empagliflozin treatment is significantly associated with lower risk of cardiovascular events in patients with diabetes mellitus (DM) independent of its antihyperglycemic effect. "	( Empagliflozin has favourable effect on frontal plane QRS-T angle in diabetic patients with cardiovascular disease. Celik, A; Eyuboglu, M, 2022)	3.61
"Empagliflozin treatment lead a significant decrease in the mean fQRST angle throughout the study period and mean fQRST angle was significantly lower at 3- and 6-month follow-up visits compared to baseline values (62° ± 17.4° vs."	( Empagliflozin has favourable effect on frontal plane QRS-T angle in diabetic patients with cardiovascular disease. Celik, A; Eyuboglu, M, 2022)	2.89
"Empagliflozin treatment did not affect the Ang II-induced hypertensive response."	( Empagliflozin prevents angiotensin II-induced hypertension related micro and macrovascular endothelial cell activation and diastolic dysfunction in rats despite persistent hypertension: Role of endothelial SGLT1 and 2. Algara-Suarez, P; Amissi, S; Auger, C; Belcastro, E; Bruckert, C; Chaker, AB; Houngue, U; Jesel, L; Matsushita, K; Morel, O; Mroueh, A; Ohlmann, P; Park, SH; Remila, L; Schini-Kerth, VB, 2022)	2.89
"Empagliflozin treatment decreased BUN, creatinine and urinary albumin excretion compared to placebo by 39.8%, 34.1%, and 55%, respectively (p < 0.01 in all cases). "	( Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy. Dai, Y; Delic, D; Hasan, AA; Hocher, B; Klein, T; Krämer, BK; Li, XT; Lu, YP; Reichetzeder, C; Wang, XH; Wu, HW; Yard, B; Yin, LH; Zhang, ZY; Zheng, ZH; Zhu, T; Zuo, J, 2022)	3.61
"Empagliflozin treatment had no significant effect on biochemical parameters."	( Evaluation of the effects of empagliflozin on acute lung injury in rat intestinal ischemia-reperfusion model. Culha, C; Erel, O; Gokbulut, P; Koc, G; Kuskonmaz, SM; Nural, AS; Onder, CE; Yumusak, N, 2023)	1.92
"Empagliflozin treatment also shows an effect on lipolysis increasing the expression of hormone-sensitive lipase (HSL) in SAT and VAT and of adipose triglyceride lipase (ATGL) in VAT, together with a decrease in the adipose content of the FA transporter cluster of differentiation 36 (CD36)."	( The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats. Anido-Varela, L; Aragón-Herrera, A; Campos-Toimil, M; Feijóo-Bandín, S; García-Caballero, L; García-Seara, J; González-Juanatey, JR; Gualillo, O; Lage, R; Lago, F; Moraña-Fernández, S; Otero-Santiago, M; Portolés, M; Rodríguez, J; Román, A; Roselló-Lletí, E; Seijas, J; Tarazón, E, 2023)	1.84
"Empagliflozin treatment significantly increased cytosolic and mitochondrial ATP levels in the hearts of db/db mice."	( The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice. Choi, J; Imamura, H; Kitai, Y; Kotobuki, Y; Matoba, N; Nishiya, Y; Ohnishi, Y; Oomachi, A; Pieper, MP; Setoyama, D; Watanabe, D; Yamamoto, M; Yanagita, M; Yasui, R, 2023)	1.96
"Empagliflozin treatment increased BOHB levels."	( Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction. Badimon, JJ; Fardman, B; Fuster, V; Ishikawa, K; Mazurek, R; Picatoste, B; Pieper, M; Requena-Ibáñez, JA; Rodriguez-Capitán, J; Santos-Gallego, CG; Sartori, S, 2023)	1.93
"Empagliflozin treated Akimba mice exhibited metabolic benefits suggested by healthy body weight gain and significantly reduced fasting blood glucose levels. "	( Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy. Herat, LY; Matthews, JR; Matthews, VB; Rakoczy, EP; Schlaich, MP, 2023)	2.58
"Empagliflozin-treated AS mice show decreased serum blood urea nitrogen and creatinine levels in association with reduced triglyceride and cholesterol ester content in kidney cortices when compared to AS mice."	( Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome. Ahmad, A; Al-Ali, H; Fontanesi, F; Fornoni, A; Ge, M; Kim, JJ; Mallela, SK; Merscher, S; Mitrofanova, A; Molina, J; Sharma, K; Varona Santos, J, 2023)	3.07
"The empagliflozin treatment group will receive 10 mg of empagliflozin per day for 6 months in addition to guideline-directed medical treatment, while the control group will receive placebo oral administration with guideline-directed medical therapy for 6 months."	( Effects of empagliflozin on cardiac structure, function and biomarkers in patients with heart failure with preserved ejection fraction: study protocol for a randomised, placebo-controlled prospective trial. Chai, K; Cheng, Y; Li, Y; Liu, Y; Luo, Y; Meng, C; Wang, H; Yang, J; Zhang, M; Zhu, W, 2023)	1.78
"Empagliflozin can be a treatment option for neutropenia, which is resistant to G-CSF treatment."	( Assessment of the diagnosis, treatment, and follow-up of a group of Turkish pediatric glycogen storage disease type 1b patients with varying clinical presentations and a novel mutation. Bilginer Gürbüz, B; Engin Erdal, A; Kasapkara, ÇS; Küçükçongar Yavaş, A; Ünlüsoy Aksu, A, 2023)	1.63
"Empagliflozin treatment activated the cardioprotective master regulator of cellular energyhomeostasis AMP-activatedproteinkinase (AMPK) and enhanced autophagy at cardiac level, while it decreased significantly the cardiac mRNA levels of the pro-inflammatory cytokines interleukin-6 (IL-6), chemerin, TNF-α and MCP-1, reinforcing the hypothesis of a direct role for empagliflozin in attenuating cardiac inflammation."	( Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Aragón-Herrera, A; Barral, L; Campos-Toimil, M; Costa Pereira, TM; Feijóo-Bandín, S; García-Caballero, T; Gil-Longo, J; González-Juanatey, JR; Gualillo, O; Lago, F; Otero Santiago, M; Portolés, M; Rodríguez, J; Rodríguez-Segade, S; Roselló-Lletí, E; Tarazón, E, 2019)	2.68
"Empagliflozin treatment significantly prevented the development of these abnormalities in DM rats, likely via the peroxisome proliferator-activated receptor-c coactivator 1α (PGC-1α)/nuclear respiratory factor-1 (NRF-1)/mitochondrial transcription factor A (Tfam) signaling pathway."	( Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats. Gong, M; Lee, S; Li, G; Liu, T; Meng, L; Shao, Q; Tse, G; Zhang, Z; Zhao, J; Zhao, Y, 2019)	2.68
"Empagliflozin treatment resulted in reduced right ventricular hypertrophy and fibrosis."	( The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. Al-Omran, M; Bhatt, DL; Chowdhury, B; Connelly, KA; Hess, DA; Kabir, MG; Luu, AZ; Luu, VZ; Mazer, CD; Pan, Y; Quan, A; Sabongui, S; Teoh, H; Verma, S, 2020)	1.6
"Empagliflozin treatment was superior with respect to physical tolerance compared with fosinopril, bisoprolol, and spironolactone."	( Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A, 2020)	1.59
"Empagliflozin treatment preserves mitochondrial fatty acid oxidation in the heart under conditions of chronic lipid overload."	( Empagliflozin Protects Cardiac Mitochondrial Fatty Acid Metabolism in a Mouse Model of Diet-Induced Lipid Overload. Cirule, H; Dambrova, M; Korzh, S; Kuka, J; Liepinsh, E; Makrecka-Kuka, M; Videja, M; Vilks, K, 2020)	3.44
"Empagliflozin treatment was more effective than metformin alone, with a combination of the two drugs demonstrating the greatest effects."	( SGLT2-i improves markers of islet endothelial cell function in db/db diabetic mice. Aplin, AC; Castillo, JJ; Esser, N; Hackney, DJ; Hogan, MF; Hull, RL; Larmore, MJ; Mundinger, TO; Zraika, S, 2021)	1.34
"Empagliflozin treatment resulted in reductions in estimated extracellular volume (adjusted mean difference -0·12 L, 95% CI -0·18 to -0·05; p=0·00056), estimated plasma volume (-7·3%, -10·3 to -4·3; p<0·0001), and measured GFR (-7·5 mL/min, -11·2 to -3·8; p=0·00010) compared with placebo."	( Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. Bruun, NE; Faber, J; Forman, JL; Fosbøl, EL; Gustafsson, F; Gustafsson, I; Jensen, J; Jensen, LT; Kistorp, C; Køber, L; Malik, ME; Møller, JE; Omar, M; Schou, M; Tuxen, C, 2021)	1.73
"Empagliflozin treatment of patients with T2D has no significant effect on hemodynamic parameters after 1 or 3 days, nor after 3 months, but leads to rapid and sustained significant improvement of diastolic function. "	( Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study. Altiok, E; Böhm, M; Hartmann, NK; Keszei, AP; Lehrke, M; Marx, N; Möllmann, J; Rau, M; Schuh, A; Thiele, K, 2021)	3.51
"Both empagliflozin-treated and liraglutide-treated diabetic rats exhibited attenuated myocardial fibrosis and apoptosis."	( Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats. Chen, YJ; Cheng, WL; Chung, CC; Huang, SY; Kao, YH; Lee, TI; Lee, TW; Trang, NN, 2021)	2.52
"Empagliflozin treatment or downregulation of SGLT-2 expression significantly ameliorated these pathological changes."	( Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-β/Smad signaling. Bai, Y; Chen, C; Jiang, H; Li, Y; Lin, R; Shentu, Y; Sun, S; Xie, S; Zhang, Y; Zheng, C; Zhou, Y, 2021)	2.79
"Empagliflozin treatment was associated with reduced risk for HHF, all-cause mortality and ESRD compared with DPP-4 inhibitors in routine clinical practice in Japan, South Korea and Taiwan."	( Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study. Brodovicz, KG; Chung, WJ; Deruaz-Luyet, A; H-H Sheu, W; Ha, KH; Kim, DJ; Klement, R; Kyaw, MH; Lee, S; Lei, WY; Nangaku, M; Node, K; Seino, Y; Tan, EC; Yabe, D; Yasui, A, 2021)	2.33
"The empagliflozin treatment decreased the plasma concentrations of glucose by 14% (P < 0.01), FFA by 23% (P < 0.01), and the insulin/glucagon ratio by 26% (P < 0.01), and it increased β-hydroxybutyrate by 44% (P < 0.05). "	( Growth hormone directly favors hepatic ketogenesis in persons with prediabetes or type 2 diabetes mellitus treated with empagliflozin. Calefi, GS; Carrilho, AJF; da Rocha, AF; de Faria, EC; Marquezine, GF; Mazzuco, TL; Morimoto, HK; Pereira Junior, PS; Urbano, MR, 2021)	1.39
"Empagliflozin treatment resulted in statistically significant reductions in weight, glycosylated hemoglobin, and systolic and diastolic blood pressures along with favorable lipid profile outcomes over a 4-month period."	( The effects of empagliflozin on cardiometabolic risk factors in patients with type 2 diabetes: A short-term observational study. Chacko, J; Dhandapani, S; Jahagiridhar, V; Swaminathan, K, )	1.21
"Empagliflozin treatment of patients with T2D increased LDL-C and LDL apolipoprotein B levels but had no effect on calculated LDL particle size."	( Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study. Böhm, M; Korbinian Hartmann, NU; Lehrke, M; Marx, N; März, W; Möllmann, J; Rau, M; Scharnagl, H; Thiele, K; Wied, S, 2021)	2.45
"Empagliflozin treatment also attenuated the increase in a number of urine metabolites observed with acute hyperglycaemia."	( Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes. Ali, MT; Cherney, DZI; Kim, J; Lawler, PR; Liu, H; Lovblom, LE; Lytvyn, Y; Montemayor, D; Perkins, BA; Scarr, D; Sharma, K; Sridhar, VS; Ye, H, 2021)	1.59
"Empagliflozin's treatment effect was consistent in predicted HFpEF, HFmrEF/HFrEF and no-HF for each outcome (HR [95% CI] for the primary outcome 0.60 [0.31-1.17], 0.79 [0.51-1.23], and 0.63 [0.50-0.78], respectively; P interaction = 0.62)."	( Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. Anker, SD; Asselbergs, F; Butler, J; Fitchett, D; Inzucchi, SE; Koudstaal, S; Lund, LH; Ofstad, AP; Savarese, G; Schrage, B; Uijl, A; Vedin, O; Wanner, C; Zannad, F; Zwiener, I, 2021)	2.79
"Empagliflozin treatment started from day 0 of oxalate feeding had no effect on the decline of glomerular filtration rate, crystal deposition, blood urea nitrogen or serum creatinine levels on day 7 and 14."	( Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease. Anders, HJ; Ma, Q; Steiger, S, 2017)	1.18
"Empagliflozin treatment also resulted in dose-dependent increases in serum ketone bodies and free fatty acids."	( Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial. George, J; Hanafusa, T; Lee, G; Marquard, J; Sarashina, A; Shiki, K; Shimada, A; Soleymanlou, N; Taneda, Y; Yasui, A, 2018)	2.64
"In empagliflozin-treated participants, oral glucose insulin sensitivity decreased and beta-cell glucose sensitivity increased at the 4-week and 12-month OGTTs."	( Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Antlanger, M; Burghart, L; Hecking, M; Kopecky, C; Pacini, G; Ristl, R; Säemann, MD; Schmaldienst, S; Schwaiger, E; Signorini, L; Tura, A; Werzowa, J; Wrba, T, 2019)	2.47
"Empagliflozin treatment in the obese animals was associated with decreased body weight, attenuated the loss of F-actin from the renal tubules and improved renal structure and function. "	( Long-Term Treatment with Empagliflozin Attenuates Renal Damage in Obese Zucker Rat. Arvapalli, R; Bandarupalli, VVK; Blough, ER; Ginjupalli, GK; Graffeo, VA; Manne, NDPK; Rice, KM, 2020)	2.3
"Empagliflozin-treated pigs did not consume glucose (reduction in myocardial glucose uptake, and glucose-related enzymes) but instead switched toward utilization of KB, FFA, and BCAA (increased myocardial uptake of these 3 metabolites, and enhanced expression/activity of the enzymes implicated in the metabolism of KB/FFA/BCAA)."	( Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. Badimon, JJ; Flores, E; Fuster, V; Garcia-Ropero, A; Hajjar, RJ; Ishikawa, K; Picatoste, B; Requena-Ibanez, JA; San Antonio, R; Santos-Gallego, CG; Sanz, J; Watanabe, S, 2019)	2.68
"Empagliflozin treatment appeared to have no intrinsic risk of hypoglycaemia, although hypoglycaemia occurred more frequently when empagliflozin was coadministered with insulin and/or a sulfonylurea."	( Empagliflozin: a review of its use in patients with type 2 diabetes mellitus. Scott, LJ, 2014)	2.57
"Empagliflozin treatment was associated with increases in UGE and reductions in FPG compared with placebo."	( Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus. Broedl, UC; Cui, Y; Lang, B; Macha, S; Pinnetti, S; Salsali, A; Zhao, S; Zhao, X, 2015)	1.35
"Empagliflozin-treated mice also showed an increase in insulin mRNA expression."	( The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. Chen, L; Cheng, ST; Leung, PS; Li, SY; Mayoux, E, 2016)	1.51
"Empagliflozin treatment reduced weight and fat mass, lipid droplets in the liver, fat cell size, mRNA expression of Tnf, Il6 and Mcp-1 (also known as Ccl2) and the infiltration of inflammatory cells in plaque and adipose tissue compared with the control or glimepiride group."	( The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE Choi, SH; Han, JH; Jang, HC; Kim, KM; Kim, YB; Lee, DH; Lee, G; Lee, HS; Lim, S; Maeng, HJ; Oh, TJ; Park, KS, 2017)	1.48
"When treated with empagliflozin, patients with SBP <110 mm Hg did not have an increased rate of symptomatic hypotension."	( Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. Anker, SD; Böhm, M; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Mahfoud, F; Ofstad, AP; Packer, M; Pocock, SJ; Ponikowski, P; Schüler, E; Wanner, C; Zannad, F, 2021)	2.39
"Pretreatment with empagliflozin protects the heart from subsequent severe lethal ventricular arrhythmia induced by myocardial ischemia and reperfusion injury. "	( Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death. Abbott, GW; Du, L; Hu, Z; Ju, F, 2021)	2.4
"Treatment with empagliflozin for 8 weeks was able to restore hypothalamic insulin sensitivity, a favorable response that could contribute to the beneficial effects of SGLT2 inhibitors."	( Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial. Birkenfeld, AL; Dannecker, C; Fritsche, A; Fritsche, L; Häring, HU; Heni, M; Hummel, J; Kantartzis, K; Kullmann, S; Machann, J; Peter, A; Preissl, H; Stefan, N; Veit, R; Vosseler, A; Wagner, R, 2022)	2.5
"Treatment with empagliflozin resulted in an increased podocyte number and podocyte density, improvement in the degree of podocyte foot process effacement and parietal epithelial cell activation."	( Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice. Alpers, CE; Holland, AL; Hudkins, KL; Li, X; Swaminathan, S, 2022)	1.31
"Treatment with empagliflozin and dapagliflozin was associated with a reduction of plasma hArg by 17.5% and 13.7% (both p < 0.001), respectively, and increase in plasma SDMA concentration of 6.7% and 3.6%, respectively (p < 0.001 and p < 0.05), while plasma Arg and ADMA concentrations were not significantly altered. "	( Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. Bosch, A; Fromm, MF; Gemeinhardt, A; Gessner, A; Kannenkeril, D; Maas, R; Mayr, A; Schmieder, RE; Staerk, C, 2022)	1.07
"Treatment with empagliflozin for 13 weeks in patients with T2D at high CV risk did not reduce left heart filling pressure more than placebo at submaximal exercise."	( Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial. Brandt, NH; Ersbøll, M; Faber, J; Gustafsson, F; Gæde, PH; Hasbak, P; Inzucchi, SE; Jürgens, M; Kistorp, CM; Kjær, A; Rossing, P; Schou, M; Wolsk, E; Zerahn, B, 2022)	1.31
"Treatment with empagliflozin was associated with lower incidence of new macroalbuminuria (HR, 0.81; 95% CI, 0.70-0.94; P = .005) and an increase in rate of remission to sustained normoalbuminuria or microalbuminuria (HR, 1.31; 95% CI, 1.07-1.59; P = .009) but not with a reduction in UACR in the overall population; however, UACR was reduced in patients with diabetes, who had higher UACR levels than patients without diabetes (geometric mean for diabetes at baseline, 0.91; 95% CI, 0.85-0.98 and for no diabetes at baseline, 1.08; 95% CI, 1.01-1.16; interaction P = .008)."	( Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled. Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Packer, M; Pocock, SJ; Schueler, E; Steubl, D; Zannad, F, 2022)	1.41
"Treatment with empagliflozin did not affect ketone body concentrations in patients with acute HF."	( Longitudinal Changes in Circulating Ketone Body Levels in Patients With Acute Heart Failure: A Post Hoc Analysis of the EMPA-Response-AHF Trial. Beusekamp, JC; Boorsma, EM; Connelly, MA; Damman, K; DE-Boer, RA; Dullaart, RPF; VAN-DER-Meer, P; VAN-Veldhuisen, DJ; Voorrips, SN; Voors, AA; Westenbrink, BD, 2023)	1.25
"Treatment with empagliflozin alone or combined significantly decreased blood glucose compared to vehicle-treated db/db."	( Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice. Benito, B; Bermejo, S; Dominguez-Báez, P; Jacobs-Cacha, C; Llorens-Cebria, C; Martinez-Diaz, I; Martos, N; Ortiz, A; Pieper, MP; Soler, MJ; Van den Bosch, MM; Vergara, A, 2022)	1.06
"Treatment with Empagliflozin reduced retinal vascular lesions in both Kimba and Akimba mice."	( Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy. Herat, LY; Matthews, JR; Matthews, VB; Rakoczy, EP; Schlaich, MP, 2023)	1.48
"Treatment with empagliflozin reduced mGFR by -7.9 mL/min (95% confidence interval [CI] -11.1 to -4.7; P < 0.001), estimated ECV by -192.5 mL (95% CI -318.0 to -66.9; P = 0.003) and estimated PV by -128.9 mL (95% CI -218.0 to 39.8; P = 0.005) at Week 13."	( The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes. Brandt-Jacobsen, NH; Faber, J; Gaede, P; Gustafsson, F; Hasbak, P; Inzucchi, SE; Jürgens, M; Kistorp, C; Kjaer, A; Rossing, P; Schou, M; Wolsk, E; Zerahn, B, 2023)	1.6
"Treatment with empagliflozin for 13 weeks reduced mGFR, estimated ECV and estimated PV in patients with T2D and high risk of cardiovascular events."	( The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes. Brandt-Jacobsen, NH; Faber, J; Gaede, P; Gustafsson, F; Hasbak, P; Inzucchi, SE; Jürgens, M; Kistorp, C; Kjaer, A; Rossing, P; Schou, M; Wolsk, E; Zerahn, B, 2023)	1.62
"Treatment with empagliflozin was estimated to increase life expectancy by 6.2 years and 2.7 QALYs, whereas total cost increased by 1,115,475 yen compared with treatment with SoC alone. "	( Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian subpopulation in the EMPA-REG OUTCOME Trial. Chin, R; Haneda, M; Hayashi, N; Hirase, T; Kaku, K; Kansal, A; Kaspers, S; Murata, T; Okamura, T; Sakamaki, H; Shibahara, T; Ustyugova, A; Yasui, A, 2019)	1.15
"Treatment with empagliflozin for 8 weeks markedly increased glucose excretion in urine, and suppressed HFD-induced weight gain, insulin resistance and hepatic steatosis. "	( Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet. Chen, G; Kaneko, S; Nagashimada, M; Nagata, N; Ni, Y; Ota, T; Sakai, Y; Xu, L; Zhuge, F, 2019)	2.31
"Treatment with empagliflozin attenuated weight gain by increasing energy expenditure and adipose tissue browning, and alleviated obesity-associated inflammation and insulin resistance by alternative macrophage activation in the WAT and liver of obese mice."	( Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet. Chen, G; Kaneko, S; Nagashimada, M; Nagata, N; Ni, Y; Ota, T; Sakai, Y; Xu, L; Zhuge, F, 2019)	2.31
"Treatment with empagliflozin showed a significant amelioration of behavioral/neurological functions and histopathological changes observed in brain tissues of hyperglycemic rats subjected to cerebral I/R injury."	( Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway. Abdel-Latif, RG; Amin, EF; Rifaai, RA, 2020)	2.34
"Pretreatment with empagliflozin of OLETF for 2 weeks improved hyperglycemia, increased blood β-hydroxybutyrate level, and suppressed MI-induced expression of NGAL and KIM-1."	( Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats. Kimura, Y; Kuno, A; Miki, T; Miura, T; Mizuno, M; Moniwa, N; Oshima, H; Sato, T; Tanaka, M; Tanno, M; Yano, T, 2020)	2.32
"Treatment with empagliflozin significantly increased glycosuria, improved glucose metabolism, ameliorated left ventricular diastolic function and reduced mortality of mice. "	( Empagliflozin improves left ventricular diastolic function of db/db mice. Adamski, J; Artati, A; Boor, P; Droste, P; Haj-Yehia, E; Kappel, B; Klinkhammer, BM; Lehrke, M; Lopaschuk, GD; Marx, N; Maxeiner, S; Moellmann, J; Schütt, K; Verma, S, 2020)	2.35
"Treatment with empagliflozin slowed the progression of left ventricular dysfunction: LV sizes and ejection fraction were not changed and the minute volume was significantly increased (from 52.0 ± 15.5 to 61.2 ± 21.2 ml/min) as compared with baseline."	( Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A, 2020)	1.2
"Treatment with empagliflozin increased palmitate uptake and decreased the accumulation of metabolites of incomplete fatty acid oxidation in cardiac tissues, but not other tissues, compared with those of the HFD control group."	( Empagliflozin Protects Cardiac Mitochondrial Fatty Acid Metabolism in a Mouse Model of Diet-Induced Lipid Overload. Cirule, H; Dambrova, M; Korzh, S; Kuka, J; Liepinsh, E; Makrecka-Kuka, M; Videja, M; Vilks, K, 2020)	2.34
"Treatment with empagliflozin for 24 weeks in patients with type 2 diabetes and cardiovascular disease did not affect peripheral endothelial function, and was not related to changes in clinical variables, including glycemic parameters. "	( Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial func Higashi, Y; Hisauchi, I; Machii, N; Matsuzawa, Y; Node, K; Okada, Y; Shima, KR; Shimabukuro, M; Taguchi, I; Takamura, T; Tanaka, A; Teragawa, H; Tomiyama, H; Toyoda, S; Ueda, S; Yamaoka-Tojo, M, 2020)	1.16
"Treatment with empagliflozin had no effect on the primary endpoint of systemic vascular resistance index, nor on cardiac index, stroke volume index or pulse rate at any time point."	( Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study. Altiok, E; Böhm, M; Hartmann, NK; Keszei, AP; Lehrke, M; Marx, N; Möllmann, J; Rau, M; Schuh, A; Thiele, K, 2021)	2.4
"Treatment with empagliflozin was associated with less discontinuation of MRAs."	( Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Packer, M; Pocock, SJ; Schueler, E; Steubl, D; Zannad, F, 2021)	1.21
"Treatment with empagliflozin in CsA-treated rats reduced glomerular (p < 0.01) and tubulo-interstitial fibrosis (p < 0.05), type I and type IV collagen expression (p < 0.01), inflammatory cell infiltration (p < 0.01) and tyrosine hydroxylase expression (p < 0.05), as compared to rats treated with CsA."	( Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy. Barzaghi, F; Carletti, R; Castoldi, G; Colzani, M; di Gioia, CRT; Ippolito, S; Perseghin, G; Stella, A; Zatti, G; Zerbini, G, 2021)	0.96
"Treatment with empagliflozin reduced blood glucose concentration and food intake in diabetic rats, but inhibited loss of adeps renis and led to body weight gain. "	( Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK). Domon, A; Katayama, K; Sato, T; Suzuki, H; Tazaki, H; Tochigi, Y, 2021)	2.42
"Treatment with empagliflozin (an SGLT2 inhibitor) and treatment with liraglutide (a GLP-1 RA) both significantly reduced the risk of MACE, mortality from CV causes, and mortality from any cause when compared with placebo."	( Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Kaul, S, 2017)	0.79
"Treatment with empagliflozin resulted in a superior reduction in SUA (WMD -45.83 μmol/L, 95% CI [-53.03, -38.63])."	( Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. Chen, L; Tian, D; Wang, L; Xia, P; Xu, L; Zhao, Y; Zheng, H, 2018)	0.82
"Treatment with empagliflozin (10 mg/kg per day, 14 days) before MI reduced blood glucose and increased blood and myocardial"	( Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats. Abe, K; Kimura, Y; Kuno, A; Miki, T; Miura, T; Mizuno, M; Nakata, K; Ohwada, W; Oshima, H; Sato, T; Tanno, M; Yano, T, 2019)	2.3
"Treatment with empagliflozin reduced blood glucose levels, normalized endothelial function (aortic rings) and reduced oxidative stress in aortic vessels (dihydroethidium staining) and in blood (phorbol ester/zymosan A-stimulated chemiluminescence) of diabetic rats. "	( The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. Agdauletova, S; Bottari, SP; Daiber, A; Gottschlich, A; Hausding, M; Jansen, T; Kröller-Schön, S; Mader, M; Mayoux, E; Mikhed, Y; Münzel, T; Oelze, M; Schulz, E; Stamm, P; Steven, S; Welschof, P; Zinßius, E, 2014)	1.01

Excerpt	Reference	Relevance
" Nine adverse events, all of mild intensity, were reported by 8 subjects (7 with empagliflozin and 1 with the placebo)."	( Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Dugi, KA; Koiwai, K; Negishi, T; Sarashina, A; Seman, LJ; Sesoko, S; Taniguchi, A; Woerle, HJ; Yamamura, N, 2013)	0.84
" Assessments included adverse events (AEs) and pharmacokinetic and pharmacodynamic endpoints."	( Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Hantel, S; Heise, T; Macha, S; Pinnetti, S; Seewaldt-Becker, E; Seman, L; Woerle, HJ, 2013)	0.61
"The use of currently available antihyperglycemic agents can be limited by contraindications; cost; renal and hepatic dosage adjustments; dosing schedules; and adverse effects such as gastrointestinal upset, weight gain, and hypoglycemia."	( The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Harris, KB; Riser Taylor, S, 2013)	0.39
" Empagliflozin was well tolerated, with no increase in adverse events associated with renal impairment."	( Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Broedl, UC; Halabi, A; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ, 2014)	1.57
" Adverse events, all mild or moderate in intensity, were reported in three subjects with moderate hepatic impairment, two subjects with severe hepatic impairment and six subjects with normal hepatic function."	( Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. Broedl, UC; Cinca, R; Macha, S; Mattheus, M; Pinnetti, S; Rose, P; Woerle, HJ, 2014)	0.66
" Frequency of adverse events was generally similar with empagliflozin (29."	( Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Hach, T; Hantel, S; Jelaska, A; Pinnetti, S; Rosenstock, J; Seman, LJ; Woerle, HJ, 2013)	0.95
" Adverse events (AEs) were reported in 63."	( Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Berk, A; Broedl, UC; Ferrannini, E; Hach, T; Hantel, S; Pinnetti, S; Woerle, HJ, 2013)	0.67
" In patients with stage 2 CKD, adverse events were reported over 52 weeks by 83 patients (87%) on placebo (15 severe [16%] and 11 serious [12%]), 86 (88%) on empagliflozin 10 mg (six severe [6%] and six serious [6%]) and 78 (80%) on empagliflozin 25 mg (eight severe [8%] and seven serious [7%])."	( Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Barnett, AH; Broedl, UC; Jones, R; Manassie, J; Mithal, A; Rattunde, H; Woerle, HJ, 2014)	0.91
" Only 2 patients (6%) had adverse events; both were mild."	( Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus. Broedl, UC; Koiwai, K; Macha, S; Sakamoto, W; Salsali, A; Sarashina, A; Sasaki, T; Tanaka, Y; Ueki, K; Woerle, HJ, 2014)	0.63
" The drug is effective and safe until eGFR 45 ml / s, in lower values the treatment should be discontinued."	( [New SGLT2 inhibitor empagliflozin: modern and safe treatment of diabetes]. Rušavý, Z, 2014)	0.72
" Adverse events were reported in 70."	( Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study. Broedl, UC; Haneda, M; Inagaki, N; Kadowaki, T; Koiwai, K; Rattunde, H; Taniguchi, A; Terauchi, Y; Woerle, HJ, 2015)	0.73
" Adverse events (AEs) were reported in 76."	( Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Broedl, UC; Christiansen, AV; Kim, G; Merker, L; Roden, M; Roux, F; Salsali, A; Stella, P; Woerle, HJ, 2015)	0.65
" Protection against cardiovascular events has also been reported, as have possible increased risks of adverse outcomes such as ketoacidosis and bone fracture."	( Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Blomster, J; Foote, C; Neal, B; Perkovic, V; Sundström, J; Toyama, T; Wu, JH, 2016)	0.43
" The primary outcome was major adverse cardiovascular events."	( Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Blomster, J; Foote, C; Neal, B; Perkovic, V; Sundström, J; Toyama, T; Wu, JH, 2016)	0.43
" SGLT2 inhibitors protected against the risk of major adverse cardiovascular events (relative risk 0·84 [95% CI 0·75-0·95]; p=0·006), cardiovascular death (0·63 [0·51-0·77]; p<0·0001), heart failure (0·65 [0·50-0·85]; p=0·002), and death from any cause (0·71 [0·61-0·83]; p<0·0001)."	( Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Blomster, J; Foote, C; Neal, B; Perkovic, V; Sundström, J; Toyama, T; Wu, JH, 2016)	0.43
" Adverse events were more difficult to quantify than was efficacy, with the effects of individual drugs in the class seeming to differ for some safety outcomes."	( Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Blomster, J; Foote, C; Neal, B; Perkovic, V; Sundström, J; Toyama, T; Wu, JH, 2016)	0.43
" Adverse events (AEs) were assessed descriptively in patients who took ≥1 dose of the study drug."	( Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes. Broedl, UC; Hantel, S; Kaspers, S; Kim, G; Kohler, S; Salsali, A; Woerle, HJ, 2016)	0.73
" The proportion of patients reporting ≥1 adverse event was similar across treatment groups, but events consistent with genital infection were more common in patients treated with empagliflozin 10 mg (3."	( Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials. Crowe, S; Hach, T; Lee, J; Nishimura, R; Salsali, A; Woerle, HJ; Yoon, KH, 2016)	0.94
" The primary endpoint was a composite of CV death, non-fatal myocardial infarction (MI), non-fatal stroke and hospitalization for unstable angina [4-point major adverse CV events (MACE)]."	( Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials. Broedl, UC; Hantel, S; Kim, G; Salsali, A; Woerle, HJ, 2016)	0.74
"The safety profile of SGLT2 inhibitors is well defined, and the adverse event profile is largely consistent with their mechanism of action."	( Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus. Carlson, CJ; Santamarina, ML, 2016)	0.43
" Adverse effect rates were 64% with placebo, 63."	( Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus. Ampudia-Blasco, FJ; Ariño, B; Giljanovic Kis, S; Naderali, E; Pérez, A; Pfarr, E; Romera, I, 2016)	0.74
"This meta-analysis shows empagliflozin is safe and effective for the treatment of T2DM along with existing diabetes pharmacotherapy."	( Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Abdulsalim, S; Chakraborty, I; Devi, R; Mali, G; Unnikrishnan, MK, 2017)	1.07
"The incidence of renal-related adverse events (AEs) with canagliflozin in patients with type 2 diabetes mellitus from a pooled population of patients in 7 active- and placebo-controlled trials (N = 5598) and in a 104-week study vs glimepiride (N = 1450) was low and similar in canagliflozin and non-canagliflozin groups."	( Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Balis, D; Canovatchel, W; Desai, M; Rosenthal, N; Sun, D; Xie, J; Yavin, Y, 2017)	0.46
" In terms of safety, the rate of adverse events in patients with T2D who received empagliflozin plus metformin was relatively lower when compared with saxagliptin plus metformin (OR=0."	( A network meta-analysis for efficacy and safety of seven regimens in the treatment of type II diabetes. Hua, WC; Li, CM; Liu, Q; Wang, H; Wang, LG, 2017)	0.68
" Adverse events (AEs) were assessed descriptively in participants who took at least one dose of study drug."	( Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials. Iliev, H; Kaspers, S; Kohler, S; Zeller, C, 2017)	0.75
" Adverse events were observed in approximately 70-80% patients in BMI and age subgroups of both empagliflozin groups."	( Efficacy and safety of empagliflozin in Japanese patients with type 2 diabetes mellitus: A sub-analysis by body mass index and age of pooled data from three clinical trials. Ishii, S; Koiwai, K; Mitsuyoshi, R; Okamura, T; Pfarr, E; Shiba, T, 2017)	0.98
" Our discovery of canagliflozin-mediated simultaneous inhibition of GDH and ETC complex I in renal cells at clinically relevant concentrations, and their particular susceptibility to necrotic cell death during proliferation, provides a mechanistic rationale for the adverse effects observed especially in patients with preexisting chronic kidney disease or previous kidney injury characterized by sustained regenerative tubular epithelial cell proliferation."	( Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect. Beneke, S; Delp, J; Dietrich, DR; Gutbier, S; Leist, M; Schlichenmaier, N; Secker, PF, 2018)	0.48
" The adverse events that were more frequent with Empa/Lina were known empagliflozin-associated events (eg, increased urination, increased blood ketones)."	( Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial. Cheng, G; George, J; Haneda, M; Kawamori, R; Lee, C; Lee, J; Miyamoto, Y; Shiki, K; Solimando, F; Suzaki, K, 2018)	2.16
" Adverse events (AEs) were assessed descriptively in patients who took ≥ 1 dose of study drug."	( Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials. DeFronzo, RA; Kohler, S; Lee, C, 2018)	0.74
" Hypoglycaemic adverse events were significantly higher in the INS group compared to the EMPA group (P = 0."	( Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type 2 diabetes: An observational study in clinical practice. Jeon, HJ; Ku, EJ; Lee, DH; Oh, TK, 2019)	0.81
" Empa/Lina was well tolerated, with no unexpected adverse events or diabetic ketoacidosis."	( Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial. George, J; Haneda, M; Kaku, K; Lee, C; Lee, G; Lee, J; Miyamoto, Y; Shiki, K; Solimando, F; Tanaka, Y, 2019)	0.82
" Adverse events (AEs) were analyzed in the subgroup of trial participants from East Asian countries/regions."	( Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials. Chang, TJ; Ji, L; Kaspers, S; Kohler, S; Lee, J; Lee, MK; Ma, RCW; Okamura, T; Seino, Y; Yabe, D; Yasui, A; Zeller, C, 2019)	0.81
"To assess the association between the use of sodium glucose cotransporter 2 (SGLT2) inhibitors and seven serious adverse events of current concern."	( Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. Eliasson, B; Franzén, S; Gudbjörnsdottir, S; Hveem, K; Jonasson, C; Melbye, M; Pasternak, B; Svanström, H; Svensson, AM; Ueda, P, 2018)	0.48
"In this analysis of nationwide registers from two countries, use of SGLT2 inhibitors, as compared with GLP1 receptor agonists, was associated with an increased risk of lower limb amputation and diabetic ketoacidosis, but not with other serious adverse events of current concern."	( Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. Eliasson, B; Franzén, S; Gudbjörnsdottir, S; Hveem, K; Jonasson, C; Melbye, M; Pasternak, B; Svanström, H; Svensson, AM; Ueda, P, 2018)	0.48
" However, wide CIs for many comparisons suggest limited precision, and therefore clinically important adverse events cannot be ruled out."	( Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. Aubrey-Bassler, K; Chibrikov, E; Curnew, D; Donnan, JR; Gamble, JM; Grandy, CA; Hache, J; Johnston, K; Marra, CA; Nguyen, H; Swab, M, 2019)	0.51
" In post hoc analyses, risks of 3-point major adverse CV events (3P-MACE: composite of CV death, non-fatal myocardial infarction (MI) or non-fatal stroke), CV death, hospitalisation for heart failure, all-cause mortality, all-cause hospitalisation and incident/worsening nephropathy were evaluated for empagliflozin versus placebo by baseline age (<65, 65 to <75, ≥75 years)."	( Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial. Bergenstal, RM; Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Kaspers, S; Kiš, SG; Monteiro, P; Toural, E; Zinman, B, 2019)	1
" At 52 weeks, the frequency of adverse events (AEs) and serious AEs was similar in the three treatment groups; confirmed hypoglycaemia was reported slightly more in participants in the empagliflozin 10 mg and 25 mg groups (23."	( Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Kaneko, T; Lee, J; Pfarr, E; Shiki, K; Sone, H; Tachibana, Y; Tajima, N, 2020)	1.06
"A well-known metabolic side effect from treatment with glucocorticoids is glucocorticoid-induced diabetes mellitus (GIDM)."	( Study rationale and design of the EANITIATE study (EmpAgliflozin compared to NPH Insulin for sTeroId diAbeTEs) - a randomized, controlled, multicenter trial of safety and efficacy of treatment with empagliflozin compared with NPH-insulin in patients with Almdal, TP; Bagge Hansen, K; Holm Schultz, H; Klarskov, CK; Lommer Kristensen, P; Møller Christensen, T; Pedersen-Bjergaard, U; Persson, F; Snorgaard, O, 2020)	0.81
" Data for adverse events and laboratory parameters were evaluated."	( Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials. Heilmann, C; Taniguchi, A; Watada, H; Yamamoto, F; Yamauchi, T; Yarush, L; Yasui, A, 2020)	0.86
" Overall, the incidence of adverse events with the empagliflozin/linagliptin combination was similar to that with empagliflozin or linagliptin alone."	( Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials. Heilmann, C; Taniguchi, A; Watada, H; Yamamoto, F; Yamauchi, T; Yarush, L; Yasui, A, 2020)	1.11
" However, ICIs are associated with immune-related adverse events involving cardiotoxicity."	( NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells. Berretta, M; Bonelli, A; Botti, G; Caronna, A; Cocco, S; Conforti, G; De Laurentiis, M; Lombari, MC; Maurea, N; Quagliariello, V; Rea, G, 2020)	0.56
" The incidences of hypoglycemic episodes, hypotension, and metabolic adverse events were similar in the two groups."	( Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study. Hoshide, S; Ishibashi, S; Kanegae, H; Kario, K; Kato, M; Okada, K, 2021)	0.93
" However no significant adverse effects were recorded in both study groups."	( Comparison Of Efficacy And Safety Profile Of Empagliflozin As A Combination Therapy In Obese Type 2 Diabetic Patients. Ahmad, M; Akhtar, L; Babar, M; Hussain, M, )	0.39
" EMPA and NHD can constrain oxidative stress liberation, inflammatory mediators proliferation, and apoptotic reactions in the renal tissue, which may be promising for further clinical applications to protect against MTX-induced renal injury or at least to reduce its adverse effects."	( Empagliﬂozin and neohesperidin protect against methotrexate-induced renal toxicity via suppression of oxidative stress and inflammation in male rats. Abo-Youssef, AM; Hassan, MIA; Hemeida, RAM; Osman, AT; Sharkawi, SMZ, 2021)	0.62
" We analysed the pharmacodynamics, adverse effects (AEs), and pharmacokinetics of empagliflozin at different doses."	( Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: A network meta-analysis based on randomized controlled trials. Fang, Z; Hu, L; Li, C; Liu, M; Wu, Q; Zhang, W; Zou, F, 2022)	1.26
" HbA1c, fasting plasma glucose (FPG), body weight, and other cardiometabolic variables and adverse events were evaluated."	( Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study. Jeon, HJ; Ku, EJ; Lee, DH; Oh, TK, 2021)	0.85
" The overall incidence of adverse events, cardiovascular events and mortality did not differ between the two groups."	( Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study. Jeon, HJ; Ku, EJ; Lee, DH; Oh, TK, 2021)	0.85
" The tolerability profile of both drugs was quite good and no major adverse effects were reported in both study groups."	( Comparison Of Efficacy And Safety Profile Of Empagliflozin Versus Dapagliflozin As Add On Therapy In Type 2 Diabetic Patients. Akhtar, L; Atif, M; Babar, M; Hussain, M, )	0.39
" Time to first occurrence of adverse events (AEs) was evaluated using Kaplan-Meier analysis and multivariable Cox regression models."	( Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Agarwal, R; Elsäßer, A; Hauske, SJ; Kadowaki, T; Levin, A; Nangaku, M; Ritter, I; Steubl, D; Tuttle, KR; Wanner, C; Wheeler, DC, 2022)	1.12
" The most common adverse event during empagliflozin treatment was hypoglycemia, occurring in 18% of individuals."	( Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire. Adrian, K; Al-Thihli, K; Ballhausen, D; Bidiuk, J; Bordugo, A; Boyer, M; Bratkovic, D; Brunner-Krainz, M; Burlina, A; Chakrapani, A; Corpeleijn, W; Cozens, A; Dawson, C; Derks, TGJ; Dhamko, H; Eiroa, H; Finezilber, Y; Fraile, PQ; Fung, LH; Garcia-Jiménez, MC; Gasperini, S; Grünert, SC; Haas, D; Häberle, J; Halligan, R; Hörbe-Blindt, A; Horka, LM; Huemer, M; Kecman, B; Kilavuz, S; Kriván, G; Lindner, M; Lüsebrink, N; Maier, EM; Maiorana, A; Makrilakis, K; McCandless, SE; Mei-Kwun Kwok, A; Milosevic, MD; Mitchell, JJ; Mizumoto, H; Moura de Souza, CF; Mundy, H; Ochoa, C; Pierce, K; Regier, D; Rossi, A; Santer, R; Schrier Vergano, SA; Schuman, HC; Sobieraj, P; Spenger, J; Spiegel, R; Stepien, KM; Tal, G; Tanšek, MZ; Tchan, M; Thyagu, S; Torkar, AD; Uçar, SK; Vucko, E; Weinhold, N; Wortmann, SB; Zsidegh, P, 2022)	1.3
" For all patients in the study, drugs were evaluated for safety by documenting adverse drug reactions."	( Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes. Chen, HC; Yang, AY, 2022)	0.94
" The incidence of adverse drug reactions was approximately 7-8%."	( Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes. Chen, HC; Yang, AY, 2022)	0.94
" Information on adverse events and adverse drug reactions (ADRs) was collected as safety data sets."	( Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance. Cho, J; Cho, JH; Chung, DJ; Jeong, IK; Kim, NH; Lee, DW; Lee, SH; Lee, SW; Mok, JO; Moon, JS; Na, JO; Won, KC, 2023)	1.2
"Empagliflozin is a safe and potent glucose-lowering drug in routine use among Korean patients with type 2 diabetes mellitus."	( Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance. Cho, J; Cho, JH; Chung, DJ; Jeong, IK; Kim, NH; Lee, DW; Lee, SH; Lee, SW; Mok, JO; Moon, JS; Na, JO; Won, KC, 2023)	2.65
" The primary outcome was incidence of adverse drug reactions (ADRs)."	( Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study. Inagaki, N; Nishimoto, T; Nishiya, Y; Nitta, D, 2023)	1.2
" Sodium glucose co-transporter -2 inhibitors (SGLT2i) are considered safe with a low risk of hypoglycemia."	( Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study. Aamir, AH; Ahmed, I; Asghar, A; Ghaffar, T; Ishtiaq, O; Khan, S; Kumar, S; Masood, F; Raja, UY; Randhawa, FA; Raza, A; Rehman, T; Sherin, A; Wahab, MU, 2022)	0.99
"SGLT-2 inhibitors combined with metformin for patients with diabetes during Ramadan fasting is as effective, safe and well tolerated as DPP4 combined with metformin."	( Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study. Aamir, AH; Ahmed, I; Asghar, A; Ghaffar, T; Ishtiaq, O; Khan, S; Kumar, S; Masood, F; Raja, UY; Randhawa, FA; Raza, A; Rehman, T; Sherin, A; Wahab, MU, 2022)	0.99
" The proportion of the people who had hypoglycaemia, or any adverse event related to the study drug was assessed after-Ramadan."	( Efficacy and safety of empagliflozin in people with type 2 diabetes during Ramadan fasting. Ahmedani, MY; Yousuf, S, 2022)	1.03
"Empagliflozin was found to be safe and effective in fasting people with T2DM."	( Efficacy and safety of empagliflozin in people with type 2 diabetes during Ramadan fasting. Ahmedani, MY; Yousuf, S, 2022)	2.47
"Empagliflozin was a safe drug compared to standard care in Pakistani Muslim patients with diabetes."	( Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial. Aamir, AH; Ahmed, I; Asghar, A; Baqar, JB; Ghaffar, T; Hasan, MI; Khan, J; Khosa, IA; Mahar, SA; Qureshi, FM; Raja, UY; Raza, SA; Riaz, A; Zafar, J, 2022)	2.47
" Real-world data on their effect on improving glucose and cardiovascular risk factors, and adverse effects in South Asians are limited."	( Empagliflozin in South Asians with type 2 diabetes: Real world data on effects on cardiometabolic parameters, safety and determinants of response to therapy from a diabetes practice in Sri Lanka. Bandara, P; De Silva, L; Dilrukshi, S; Dissanayake, H; Katulanda, P; Ratnasamy, V; Samarathunga, T; Soysa, P, 2023)	2.35
"Methotrexate (MTX) administration causes hepatotoxicity, a serious side effect limiting its clinical use."	( Empagliflozin mitigates methotrexate-induced hepatotoxicity: Targeting ASK-1/JNK/Caspase-3 pathway. El-Kashef, DH; Sewilam, HM, 2023)	2.35
" Fasting did not increase the incidence of adverse events."	( Efficacy and safety of empagliflozin: a "real-world" experience from Saudi Arabia. Abothenain, FFM; Alagla, NAM; Albalwi, R; AlHaqbani, L; Aljamei, H; Butt, MI; Riazuddin, M; Waheed, N, )	0.44
"Empagliflozin is safe and effective in our local population."	( Efficacy and safety of empagliflozin: a "real-world" experience from Saudi Arabia. Abothenain, FFM; Alagla, NAM; Albalwi, R; AlHaqbani, L; Aljamei, H; Butt, MI; Riazuddin, M; Waheed, N, )	1.88
" We evaluated adverse drug reactions (ADRs) (the primary endpoint) and glycemic effectiveness with or without other glucose-lowering drugs."	( Safety and effectiveness of empagliflozin in clinical practice as monotherapy or with other glucose-lowering drugs in Japanese patients with type 2 diabetes: subgroup analysis of a 3-year post-marketing surveillance study. Kaku, K; Kanasaki, K; Naito, Y; Nakayama, Y; Yabuuchi, J, )	0.43
" Cardiotoxicity is a critical and common adverse effect of cancer-related chemotherapy."	( Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications. Alijanizadeh, P; Aram, C; Azadmehr, A; Pourahmad, R; Saleki, K; Vaziri, Z; Ziaei, N, 2023)	2.35

Excerpt	Reference	Relevance
" Assessments included adverse events (AEs) and pharmacokinetic and pharmacodynamic endpoints."	( Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Hantel, S; Heise, T; Macha, S; Pinnetti, S; Seewaldt-Becker, E; Seman, L; Woerle, HJ, 2013)	0.61
" There were no relevant changes in the time to reach peak levels (t (max,ss)) or terminal elimination half-life (t (½,ss)) of EE and LNG between test and reference treatments."	( Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers. Broedl, UC; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ, 2013)	0.79
" The pharmacokinetic results of this study indicate that no dose adjustment of empagliflozin is required in patients with renal impairment."	( Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Broedl, UC; Halabi, A; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ, 2014)	0.88
"; ≤12 weeks) were used to develop a population pharmacokinetic (PK) model for empagliflozin."	( Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. Bergsma, TT; Gastonguay, MR; MacGregor, TR; Macha, S; Riggs, MM; Seman, L; Staab, A, 2013)	0.9
" The increases in AUC0-∞ and Cmax for 10 mg vs."	( Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers. Hobson, D; Hohl, K; Jungnik, A; Macha, S; Salsali, A; Woerle, HJ, 2013)	0.65
"An extensive literature search was performed to analyze the pharmacokinetic characteristics, toxicological issues and safety concerns of SGLT2 inhibitors in humans."	( Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Scheen, AJ, 2014)	0.4
"The three pharmacological agents share an excellent oral bioavailability, long half-life allowing once-daily administration, low accumulation index and renal clearance, the absence of active metabolites and a limited propensity to drug-drug interactions."	( Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Scheen, AJ, 2014)	0.4
"No relevant drug-drug interaction was observed, and pharmacokinetic results suggest that no dose adjustments for either drug are necessary when empagliflozin and simvastatin are co-administered."	( Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers. Broedl, UC; Lang, B; Macha, S; Pinnetti, S, 2014)	0.93
" The available SGLT2 inhibitors share similar pharmacokinetic characteristics, with a rapid oral absorption, a long elimination half-life allowing once-daily administration, an extensive hepatic metabolism mainly via glucuronidation to inactive metabolites, the absence of clinically relevant drug-drug interactions and a low renal elimination as parent drug."	( Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Scheen, AJ, 2015)	0.42
" This study investigated potential pharmacokinetic drug-drug interactions between empagliflozin and hydrochlorothiazide (HCTZ) or torasemide (TOR)."	( Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study. Broedl, UC; Heise, T; Macha, S; Mattheus, M; Woerle, HJ, 2015)	0.86
" Pharmacokinetic parameters of empagliflozin, HCTZ, and TOR were assessed and standard bioequivalence criteria (80%-125%) were applied."	( Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study. Broedl, UC; Heise, T; Macha, S; Mattheus, M; Woerle, HJ, 2015)	0.92
" Geometric mean ratios (90% CIs) for empagliflozin AUC over a uniform dosing interval and Cmax at steady state were 107."	( Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study. Broedl, UC; Heise, T; Macha, S; Mattheus, M; Woerle, HJ, 2015)	0.91
"No pharmacokinetic drug-drug interaction was observed between empagliflozin and HCTZ or TOR."	( Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study. Broedl, UC; Heise, T; Macha, S; Mattheus, M; Woerle, HJ, 2015)	0.88
" These SGLT2 inhibitors share similar pharmacokinetic characteristics with a rapid oral absorption, a long elimination half-life allowing once-daily administration, an extensive hepatic metabolism mainly via glucuronidation to inactive metabolites and a low renal elimination as a parent drug."	( Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Scheen, AJ, 2015)	0.42
" The geometric mean ratio (GMR) for pioglitazone Cmax at steady state (Cmax,ss) and for AUC during the dosing interval at steady state (AUCτ,ss) when coadministered with empagliflozin versus administration alone was 187."	( Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers. Broedl, UC; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ, 2015)	0.93
"The aim of this study was to investigate the pharmacokinetic and pharmacodynamic properties and tolerability of the oral once-daily sodium glucose cotransporter 2 inhibitor empagliflozin, given in single and multiple 10 and 25 mg doses in Chinese patients with type 2 diabetes mellitus (T2DM)."	( Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus. Broedl, UC; Cui, Y; Lang, B; Macha, S; Pinnetti, S; Salsali, A; Zhao, S; Zhao, X, 2015)	0.83
" Mean terminal elimination half-life values at steady state were 13."	( Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus. Broedl, UC; Cui, Y; Lang, B; Macha, S; Pinnetti, S; Salsali, A; Zhao, S; Zhao, X, 2015)	0.63
"Results with single and multiple doses of empagliflozin 10 and 25 mg suggest linear pharmacokinetic properties in Chinese patients with T2DM, with a safety profile similar to that of placebo."	( Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus. Broedl, UC; Cui, Y; Lang, B; Macha, S; Pinnetti, S; Salsali, A; Zhao, S; Zhao, X, 2015)	0.9
"This study was undertaken to compare the steady-state pharmacokinetic and pharmacodynamic properties of empagliflozin 5 mg twice daily (BID) and 10 mg once daily (QD) in healthy subjects."	( Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects. Brand, T; Broedl, UC; Link, J; Macha, S; Meinicke, T, 2015)	0.86
"There were no clinically relevant differences in pharmacokinetic or pharmacodynamic properties between BID and QD dose regimens of empagliflozin in healthy subjects."	( Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects. Brand, T; Broedl, UC; Link, J; Macha, S; Meinicke, T, 2015)	0.85
" Duration and onset of the pharmacologic effects seemed to be closely correlated with the pharmacokinetic properties of each SGLT2 inhibitor, particularly with respect to high distribution and long retention in the target organ, the kidney."	( Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. Imamura, M; Kurosaki, E; Tahara, A; Takasu, T; Yokono, M, 2016)	0.43
" Areas covered: The aim of the review is to present the available data on pharmacokinetic properties/pharmacodynamics, metabolic and cardiovascular effects of empagliflozin plus linagliptin combination."	( Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes. Elisaf, MS; Filippatos, TD; Rizos, CV, 2018)	0.95
"To assess the pharmacokinetic and pharmacodynamic profile of a single dose of empagliflozin in young people with Type 2 diabetes to identify the appropriate doses for further paediatric development."	( Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial. Hobson, D; Hughan, KS; Kaspers, S; Laffel, LMB; Marquard, J; Nock, V; Simons, G; Tamborlane, WV; Wu, J; Yver, A, 2018)	0.93
"To evaluate the pharmacokinetic properties and safety of empagliflozin, and the bioequivalence of test formulation empagliflozin tablet compared with the brand-name drug Jardiance (reference formulation) after single oral administration under fasting and fed conditions in healthy Chinese subjects."	( Pharmacokinetics, Safety, and Bioequivalence of Two Empagliflozin Formulations after Single Oral Administration under Fasting and Fed Conditions in Healthy Chinese Subjects: An Open-label Randomized Single-dose Two-sequence, Two-treatment, Two-period Cros Chen, G; Du, A; Liu, X; Liu, Y; Wang, J; Wang, Z; Yang, S; Zang, S; Zhang, D; Zhang, L; Zhang, Y; Zhen, H, 2020)	1.05
" This study was conducted to evaluate the pharmacokinetic (PK) drug-drug interactions between empagliflozin and lobeglitazone in healthy subjects."	( No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects. Hwang, JG; Kim, YK; Park, MK, 2021)	1.05
"Co-intake of ATR with Acai berry resulted in slight decrease in Cmax from 41."	( Investigation of the effect of Acai berry on the pharmacokinetics of Atorvastatin, Alogliptin and Empagliflozin: a herb-drug interaction study. Nanjappan, SK; Ravichandiran, V; Somabattini, RA, 2022)	0.94
"There was a significant change in the AUC0-t and Cmax of ATR, ALO and EMPA after co-administration with Acai berry."	( Investigation of the effect of Acai berry on the pharmacokinetics of Atorvastatin, Alogliptin and Empagliflozin: a herb-drug interaction study. Nanjappan, SK; Ravichandiran, V; Somabattini, RA, 2022)	0.94
" This study evaluated the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between EV and sodium glucose cotransporter-2 inhibitors (SGLT2i) in healthy volunteers since combination therapy of DPP4i and SGLT2i has been considered as an effective option for T2DM treatment."	( Pharmacokinetic and pharmacodynamic drug-drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers. Choi, M; Hong, T; Jin, BH; Kim, CO; Kim, D; Park, MS; Yoo, BW, 2023)	1.14
" The pharmacokinetic (PK) parameters were calculated using a noncompartmental method."	( Pharmacokinetic Comparison Between a Fixed-Dose Combination of Empagliflozin L-Proline/Metformin and Empagliflozin/Metformin in Healthy Korean Subjects. Chung, JY; Lee, H; Lee, S; Park, SJ; Yu, KS, 2023)	1.15

Excerpt	Reference	Relevance
" This study investigated effects of the SGLT-2 inhibitor, empagliflozin, alone and in combination with insulin, on glucose homeostasis in an animal model of T1DM."	( Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Grempler, R; Klein, T; Luippold, G; Mark, M, 2012)	2.07
" Empagliflozin combined with low-dose insulin showed comparable glucose-lowering efficacy to treatment with high-dose insulin."	( Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Grempler, R; Klein, T; Luippold, G; Mark, M, 2012)	2.73
"This randomized, open-label, crossover study investigated potential drug-drug interactions between the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin and the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin."	( Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Brand, T; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ, 2012)	0.9
"To investigate potential drug-drug interactions between empagliflozin and warfarin."	( Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Macha, S; Mattheus, M; Pinnetti, S; Rose, P; Woerle, HJ, 2013)	0.91
"No drug-drug interactions were observed between empagliflozin and warfarin, indicating that empagliflozin and warfarin can be co-administered without dosage adjustments of either drug."	( Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Macha, S; Mattheus, M; Pinnetti, S; Rose, P; Woerle, HJ, 2013)	0.92
"The goal of this study was to investigate potential drug-drug interactions between empagliflozin and verapamil, ramipril, and digoxin in healthy volunteers."	( Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Broedl, UC; Macha, S; Pinnetti, S; Rose, P; Schoene, K; Sennewald, R; Woerle, HJ, 2013)	0.86
"The potential drug-drug interactions were evaluated in 3 separate trials."	( Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Broedl, UC; Macha, S; Pinnetti, S; Rose, P; Schoene, K; Sennewald, R; Woerle, HJ, 2013)	0.63
"In this specific population, empagliflozin in combination with other oral agents, significantly reduced HbA1c and body weight and was well tolerated."	( Empagliflozin in combination with oral agents in young and overweight/obese Type 2 diabetes mellitus patients: A pooled analysis of three randomized trials. Aranda, U; Crowe, S; de Pablos-Velasco, P; García, A; Gomis, R; Kis, SG; Naderali, E; Romera, I, )	1.87
"To analyze the efficacy and safety of empagliflozin combined with other oral hypoglycemic agents in patients with type 2 diabetes mellitus."	( Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus. Ampudia-Blasco, FJ; Ariño, B; Giljanovic Kis, S; Naderali, E; Pérez, A; Pfarr, E; Romera, I, 2016)	1.02
"Pooled analysis of three phase III trials in patients with type 2 diabetes mellitus (n=1,801) who received placebo or empagliflozin 10 or 25mg once daily for 24 weeks, in combination with metformin, metformin+sulphonylurea or pioglitazone ± metformin."	( Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus. Ampudia-Blasco, FJ; Ariño, B; Giljanovic Kis, S; Naderali, E; Pérez, A; Pfarr, E; Romera, I, 2016)	0.95
"Empagliflozin combined with other oral treatments decreased HbA1c, body weight, and SBP/DBP as compared to placebo, with a good safety and tolerability profile."	( Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus. Ampudia-Blasco, FJ; Ariño, B; Giljanovic Kis, S; Naderali, E; Pérez, A; Pfarr, E; Romera, I, 2016)	2.19
"To assess the effect of SGLT2 inhibitors when used in combination with a loop diuretic, the RECEDE-CHF (Renal and Cardiovascular Effects of SGLT2 inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure) trial is a single-centre, randomised, double-blind, placebo-controlled, cross-over trial conducted in a secondary care setting within NHS Tayside, Scotland."	( Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. Baig, F; Choy, AM; Lang, CC; McCrimmon, RJ; Mordi, IR; Mordi, NA; Singh, JS; Struthers, AD, 2017)	0.46
" This study was conducted to evaluate the pharmacokinetic (PK) drug-drug interactions between empagliflozin and lobeglitazone in healthy subjects."	( No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects. Hwang, JG; Kim, YK; Park, MK, 2021)	1.05
" First three groups were treated with Acai berry (PO; 250 mg/kg); fourth, fifth and sixth groups received sodium CMC (vehicle) for 10 days and on eleventh day, first and fourth groups were administered with ATR (PO; 10 mg/kg); second and fifth groups with ALO (PO; 25 mg/kg) and third and sixth groups received EMPA (PO; 25 mg/kg)."	( Investigation of the effect of Acai berry on the pharmacokinetics of Atorvastatin, Alogliptin and Empagliflozin: a herb-drug interaction study. Nanjappan, SK; Ravichandiran, V; Somabattini, RA, 2022)	0.94
" This study investigated a dual amylin and calcitonin receptor agonist (DACRA); KBP-066A in combination with the GLP-1R agonist semaglutide or the sodium-glucose co transporter-2 inhibitor (SGLT2i) empagliflozin for anti-obesity and anti-diabetic treatment."	( Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin. Henriksen, K; Karsdal, MA; Katri, A; Melander, SA, 2023)	1.31
"To evaluate the efficacy and safety of empagliflozin in combination with insulin ± oral antidiabetic drugs (OADs) over 24 weeks, in Chinese patients with type 2 diabetes (T2D) who had insufficient glycaemic control."	( Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double-blind, placebo-controlled, parallel study. Fu, L; Ji, L; Lei, T; Li, L; Li, Q; Li, X; Lu, Y; Luo, Y; Meinicke, T; Shi, B; Ye, S, 2023)	1.49
"In Chinese patients with T2D, empagliflozin combined with insulin ± OADs improved glycaemic control and was well tolerated, without an increased risk of hypoglycaemia."	( Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double-blind, placebo-controlled, parallel study. Fu, L; Ji, L; Lei, T; Li, L; Li, Q; Li, X; Lu, Y; Luo, Y; Meinicke, T; Shi, B; Ye, S, 2023)	1.51

Excerpt	Reference	Relevance
" Empagliflozin pharmacokinetics in ZDF rats were characterised by moderate total plasma clearance (CL) and bioavailability (BA), while in beagle dogs CL was low and BA was high."	( Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Bakker, RA; Eckhardt, M; Eickelmann, P; Grempler, R; Himmelsbach, F; Klein, T; Mark, M; Sauer, A; Sharp, DE; Thomas, L, 2012)	2.73
" Sex and race did not lend additional description to PK variability beyond allometric weight effects, other than ∼25% greater oral absorption rate constant for Asian patients."	( Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. Bergsma, TT; Gastonguay, MR; MacGregor, TR; Macha, S; Riggs, MM; Seman, L; Staab, A, 2013)	0.68
"This relative bioavailability study compared a fixed-dose combination (FDC) tablet of empagliflozin 25 mg/linagliptin 5 mg with the corresponding individual components."	( Relative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed-dose combination tablet . Friedrich, C; Glund, S; Mattheus, M; Rose, P; Runge, F, 2017)	0.96
" Administering the tablet after food or a tablet with a slow-dissolution profile did not have a clinically-relevant impact on the bioavailability of empagliflozin/linagliptin FDC tablets."	( Relative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed-dose combination tablet . Friedrich, C; Glund, S; Mattheus, M; Rose, P; Runge, F, 2017)	0.94
" Based on a statistical approach and data from a bioavailability study, a clinical relevant specification for the disintegration time was established."	( Dissolution or disintegration - substitution of dissolution by disintegration testing for a fixed dose combination product. Brendel, M; Gerlitzki, C; Grube, A, 2019)	0.51
"Nitric oxide (NO) bioavailability was reduced by TNFα and both EMPA and DAPA restored NO levels in TNFα-stimulated HCAECs."	( Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells. Albrecht, M; Boomsma, M; Hollmann, MW; Homayr, A; Juni, RP; Kerindongo, R; Koolwijk, P; Preckel, B; Spin, EL; Uthman, L; van Hinsbergh, VWM; Weber, NC; Zuurbier, CJ, 2019)	1.96
"These data suggest that EMPA and DAPA rather restore NO bioavailability by inhibiting ROS generation than by affecting eNOS expression or signaling, barrier function and adhesion molecules expression in TNFα-induced endothelial cells."	( Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells. Albrecht, M; Boomsma, M; Hollmann, MW; Homayr, A; Juni, RP; Kerindongo, R; Koolwijk, P; Preckel, B; Spin, EL; Uthman, L; van Hinsbergh, VWM; Weber, NC; Zuurbier, CJ, 2019)	1.96
" In vivo experimental studies showed that RA-EMP exhibited significantly enhanced oral bioavailability of EMP and dramatically improved therapeutic efficacy against AP."	( A novel self-nanomicellizing system of empagliflozin for oral treatment of acute pancreatitis: An experimental study. Cao, Q; Chen, P; Li, Q; Wang, M; Wu, X; Yuan, Z, 2022)	0.99
" Linagliptin has a low oral bioavailability due to intestinal degradation and low permeability."	( Architecting novel multilayer nanosponges for co-administration of two drugs managing high-risk type II diabetes mellitus patients suffering from cardiovascular diseases. Abdelmalak, NS; Hammad, RW; Latif, R; Sanad, RA, 2022)	0.72
" The pharmacokinetic test revealed that the bioavailability was improved ∼4."	( Oral empagliflozin-loaded tri-layer core-sheath fibers fabricated using tri-axial electrospinning: Enhanced in vitro and in vivo antidiabetic performance. Duruksu, G; Emin Cam, M; Graça, MPF; Guler, E; Gunduz, O; Kalaskar, DM; Morid Haidari, M; Nur Hazar-Yavuz, A; Sinemcan Ozcan, G; Tatar, E, 2023)	1.42

Excerpt	Relevance	Reference
"Coadministration of sitagliptin with empagliflozin did not have a clinically relevant effect on the area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUC(τ,ss)) (geometric mean ratio [GMR] 110."	( Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Brand, T; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ, 2012)	0.98
"No drug-drug interactions were observed between empagliflozin and warfarin, indicating that empagliflozin and warfarin can be co-administered without dosage adjustments of either drug."	( Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Macha, S; Mattheus, M; Pinnetti, S; Rose, P; Woerle, HJ, 2013)	0.92
"97) or ramipril (AUC over a uniform dosing interval τ at steady state [AUCτ,ss]: GMR, 96."	( Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Broedl, UC; Macha, S; Pinnetti, S; Rose, P; Schoene, K; Sennewald, R; Woerle, HJ, 2013)	0.63
"The pharmacokinetics of EE and LNG at steady state based on the primary endpoints of area under the steady-state plasma concentration-time curve during a dosage interval τ (AUC(τ,ss)) and maximum steady-state plasma concentration during a dosage interval (C (max,ss)) were the main outcome measures."	( Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers. Broedl, UC; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ, 2013)	0.79
"The use of currently available antihyperglycemic agents can be limited by contraindications; cost; renal and hepatic dosage adjustments; dosing schedules; and adverse effects such as gastrointestinal upset, weight gain, and hypoglycemia."	( The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Harris, KB; Riser Taylor, S, 2013)	0.39
" Predictive check plots were consistent with observed data, implying an adequate description of empagliflozin PKs following multiple dosing in patients with T2DM."	( Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. Bergsma, TT; Gastonguay, MR; MacGregor, TR; Macha, S; Riggs, MM; Seman, L; Staab, A, 2013)	0.89
" The dose-response curve was shifted leftward and the maximum response doubled in Sglt1 knockout (Sglt1-/-) mice."	( Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Gerasimova, M; Koepsell, H; Masuda, T; Mayoux, E; Platt, K; Powell, DR; Rieg, T; Thomson, SC; Vallon, V, 2014)	0.4
" Chronic dosing shifted substrate utilization from carbohydrate to lipid."	( Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. Baldi, S; Broedl, UC; Ferrannini, E; Frascerra, S; Heise, T; Mari, A; Muscelli, E; Woerle, HJ, 2014)	0.4
" Findings were similar for the 10-mg dosing regimen."	( Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Athanasiadou, E; Bekiari, E; Karagiannis, T; Liakos, A; Mainou, M; Papatheodorou, K; Sarigianni, M; Tsapas, A, 2014)	0.71
" The big convenience of empagliflozin is its clinically non-significant interactions with other drugs and simple dosage of 1 tablet / day orally."	( [New SGLT2 inhibitor empagliflozin: modern and safe treatment of diabetes]. Rušavý, Z, 2014)	1.03
" Geometric mean ratios (90% CIs) for empagliflozin AUC over a uniform dosing interval and Cmax at steady state were 107."	( Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study. Broedl, UC; Heise, T; Macha, S; Mattheus, M; Woerle, HJ, 2015)	0.91
" Thus, prescribing information should be consulted regarding dosage adjustments or restrictions in the case of renal dysfunction for each SGLT2 inhibitor."	( Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Scheen, AJ, 2015)	0.42
"5% to 1% and fasting plasma glucose by ~15 to 35 mg/dL, depending on the agent and the dosage used, and are also associated with modest reductions in weight (-1."	( The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes. Miller, S; Onge, ES; Whalen, K, 2015)	0.42
" The geometric mean ratio (GMR) for pioglitazone Cmax at steady state (Cmax,ss) and for AUC during the dosing interval at steady state (AUCτ,ss) when coadministered with empagliflozin versus administration alone was 187."	( Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers. Broedl, UC; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ, 2015)	0.93
" For empagliflozin 10 mg QD, mean (%CV) AUC during the dosing interval was 1900 nmol · h/L (20."	( Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects. Brand, T; Broedl, UC; Link, J; Macha, S; Meinicke, T, 2015)	1.16
" Use of STCs in the treatment of T2DM can simplify drug dosing regimen, reduce pill burden and increase treatment adherence."	( Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option. Woo, V, 2015)	1.86
"The pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, adverse effects, dosage and administration, and drug-drug interactions of empagliflozin are reviewed."	( Empagliflozin: a sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. Dixit, D; Mansukhani, RP; Volino, LR; Yoon, Y, 2015)	2.06
" The increased risk of UTIs and genital infections seemed to have a dose-response relationship for dapagliflozin only."	( Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Dong, Y; Fang, Z; Li, D; Shen, S; Tang, H; Wang, T, 2017)	0.46
" Only dapagliflozin had a dose-response relationship with UTIs and genital infections."	( Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Dong, Y; Fang, Z; Li, D; Shen, S; Tang, H; Wang, T, 2017)	0.46
" Histopathologic kidney changes were first detected after 4 weeks of dosing in the male 1,000 mg/kg/day dose group, with progressive increases in the incidence and/or number of findings in this dose group so that they were more readily detected during weeks 8 and 13."	( Pathogenesis of Renal Injury and Gene Expression Changes in the Male CD-1 Mouse Associated with Exposure to Empagliflozin. Hall, J; Hart, SE; Hill, JD; Knight, B; Koegler, S; Ku, WW; Pande, P; Phillips, JA; Yuan, J, 2018)	0.69
" In this study, sensitive and precise spectrophotometric methods were developed for the determination of such hypoglycemic drug combinations in bulk powder and in pharmaceutical dosage form without prior separation."	( Different resolution techniques for management of overlapped spectra: Application for the determination of novel co-formulated hypoglycemic drugs in their combined pharmaceutical dosage form. Fawzy, MG; Mahrouse, MA; Moussa, BA, 2018)	0.48
" As physical and chemical interactions affect the performance of the formulation, this study intended to unveil the drug and excipients interactions which would later help in development of a robust solid dosage form."	( Update on compatibility assessment of empagliflozin with the selected pharmaceutical excipients employed in solid dosage forms by thermal, spectroscopic and chromatographic techniques. Kalia, K; Kate, AS; Niguram, P; Polaka, SN; Rathod, R, 2020)	0.83
" Variations in filtered glucose across clinical studies were shown to drive the apparent differences in the glucosuria dose-response relationships among the gliflozins."	( Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling. Boulton, DW; Chu, L; Greasley, PJ; Helmlinger, G; Johansson, S; Penland, RC; Peskov, K; Sokolov, V; Tang, W; Yakovleva, T, 2020)	0.77
"An efficient, accurate and sensitive spectrofluorimetric method was developed for analysis of empagliflozin (EGF) in pure form, dosage form and human plasma."	( New spectrofluorimetric analysis of empagliflozin in its tablets and human plasma using two level full factorial design. Abdel Hamid, MA; Ahmed, HM; Batakoushy, HA; Omar, MA, 2020)	1.05
"The primary aim of this study was to standardize the correlated effective dosage of the antidiabetic drug empagliflozin (EMPA) and the antipsychotic drug olanzapine (Ola)."	( Standardizing the Effective Correlated Dosage of Olanzapine and Empagliflozin in Female Wistar Rats. Alam, MZ; Alghamdi, BS; Alshehri, FS; Ashraf, GM; Tarazi, FI; Tayeb, HO, 2021)	1.07
"The objective of this study was to standardize the correlated effective dosage of EMPA and Ola."	( Standardizing the Effective Correlated Dosage of Olanzapine and Empagliflozin in Female Wistar Rats. Alam, MZ; Alghamdi, BS; Alshehri, FS; Ashraf, GM; Tarazi, FI; Tayeb, HO, 2021)	0.86
"We conclude that Ola-4 and EMPA-20 were the most effective dosage for experimental purposes in female Wistar rats."	( Standardizing the Effective Correlated Dosage of Olanzapine and Empagliflozin in Female Wistar Rats. Alam, MZ; Alghamdi, BS; Alshehri, FS; Ashraf, GM; Tarazi, FI; Tayeb, HO, 2021)	0.86
" The developed method based on minimal mathematical data processing on the zero order spectrum for solving sever overlapping spectra of the mentioned drugs in their pure forms and pharmaceutical dosage form."	( Simple mathematical data processing method for the determination of sever overlapped spectra of linagliptin and empagliflozin in their pure forms and pharmaceutical formulation: Fourier self deconvulated method. Elmasry, MS; Hassan, WS; Merey, HA; Nour, IM, 2021)	0.83
" The proposed HPLC method was highly robust for method transfer, regulatory flexibility within design space and can be used for assay of pharmaceutical dosage forms comprising these analytes."	( Quality-by-Design Approach for Chromatographic Analysis of Metformin, Empagliflozin and Linagliptin. Anumolu, PD; Cvs, S; Gurrala, S; Raj, S, 2022)	0.96
"To evaluate the effects of empagliflozin versus placebo on subsequent insulin initiation or dosing changes in a large cardiovascular outcomes trial."	( Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. Brueckmann, M; Butler, J; Fitchett, DH; George, JT; Inzucchi, SE; Mattheus, M; Ofstad, AP; Sattar, N; Vaduganathan, M; Verma, S; Wanner, C; Zinman, B, 2021)	1.31
" However, the dosage and administration of empagliflozin are still controversial clinically."	( Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: A network meta-analysis based on randomized controlled trials. Fang, Z; Hu, L; Li, C; Liu, M; Wu, Q; Zhang, W; Zou, F, 2022)	1.29
" For total AEs, there was a dose-response trend in which safety decreased with increasing doses."	( Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: A network meta-analysis based on randomized controlled trials. Fang, Z; Hu, L; Li, C; Liu, M; Wu, Q; Zhang, W; Zou, F, 2022)	1.03
"The current investigation is based on efficient method development for the quantification of empagliflozin in raw and pharmaceutical dosage forms, as no pharmacopoeial method for the drug is available so far."	( Empagliflozin: HPLC based analytical method development and application to pharmaceutical raw material and dosage form. Abedin, S; Ahmed Khan, M; Alam, S; Bano, R; Bushra, R; Ismail, NE; M Hanif, A; Muhammad Arif, H, 2021)	2.28
" We initially performed a dose-response pilot study in normal rats."	( Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5/6 nephrectomised rats on high salt diet. Cao, Y; Chen, X; Chu, C; Delic, D; Frankenreiter, S; Gaballa, MMS; Hasan, AA; Hocher, B; Klein, T; Krämer, BK; Luo, T; Stadermann, K; Xiong, Y; Xue, Y; Yin, L; Zeng, S, 2022)	0.97
" Consequently, EMF is suggested as an unprecedented and promotive treatment approach for T2DM with a higher bioavailability and better antidiabetic effect compared to conventional dosage forms."	( Oral empagliflozin-loaded tri-layer core-sheath fibers fabricated using tri-axial electrospinning: Enhanced in vitro and in vivo antidiabetic performance. Duruksu, G; Emin Cam, M; Graça, MPF; Guler, E; Gunduz, O; Kalaskar, DM; Morid Haidari, M; Nur Hazar-Yavuz, A; Sinemcan Ozcan, G; Tatar, E, 2023)	1.42
" The geometric mean ratio and confidence interval of the main PK parameters (maximum concentration of the drug in plasma at steady state and area under the plasma drug concentration-time curve within a dosing interval at a steady state) between EV and either EP or DP alone were not significantly altered by co-administration."	( Pharmacokinetic and pharmacodynamic drug-drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers. Choi, M; Hong, T; Jin, BH; Kim, CO; Kim, D; Park, MS; Yoo, BW, 2023)	1.14

Role	Description
sodium-glucose transport protein subtype 2 inhibitor	Any inhibitor that interferes with the action of sodium-glucose transport protein subtype 2.
hypoglycemic agent	A drug which lowers the blood glucose level.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
C-glycosyl compound	A glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to a carbon atom, thus creating a C-C bond.
aromatic ether	Any ether in which the oxygen is attached to at least one aryl substituent.
tetrahydrofuryl ether
monochlorobenzenes	Any member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Sodium/glucose cotransporter 2	Homo sapiens (human)	IC50 (µMol)	0.0031	0.0005	0.1653	4.1000	AID1396969; AID1413441
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Sodium/glucose cotransporter 1	Homo sapiens (human)	EC50 (µMol)	8.3000	0.0011	1.2544	8.3000	AID1546902
Sodium/glucose cotransporter 2	Homo sapiens (human)	EC50 (µMol)	0.0030	0.0011	0.1107	1.3900	AID1546903
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
chloride transmembrane transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
glucose transmembrane transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
alpha-glucoside transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
intestinal D-glucose absorption	Sodium/glucose cotransporter 1	Homo sapiens (human)
response to inorganic substance	Sodium/glucose cotransporter 1	Homo sapiens (human)
pentose transmembrane transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
fucose transmembrane transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
galactose transmembrane transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
myo-inositol transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
transepithelial water transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
renal glucose absorption	Sodium/glucose cotransporter 1	Homo sapiens (human)
glucose import across plasma membrane	Sodium/glucose cotransporter 1	Homo sapiens (human)
sodium ion import across plasma membrane	Sodium/glucose cotransporter 1	Homo sapiens (human)
intestinal hexose absorption	Sodium/glucose cotransporter 1	Homo sapiens (human)
transport across blood-brain barrier	Sodium/glucose cotransporter 1	Homo sapiens (human)
glucose transmembrane transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
sodium ion transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
alpha-glucoside transport	Sodium/glucose cotransporter 2	Homo sapiens (human)
carbohydrate metabolic process	Sodium/glucose cotransporter 2	Homo sapiens (human)
hexose transmembrane transport	Sodium/glucose cotransporter 2	Homo sapiens (human)
renal glucose absorption	Sodium/glucose cotransporter 2	Homo sapiens (human)
glucose import across plasma membrane	Sodium/glucose cotransporter 2	Homo sapiens (human)
sodium ion import across plasma membrane	Sodium/glucose cotransporter 2	Homo sapiens (human)
sodium ion transport	Sodium/glucose cotransporter 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
galactose transmembrane transporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
glucose transmembrane transporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
myo-inositol:sodium symporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
water transmembrane transporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
glucose:sodium symporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
protein binding	Sodium/glucose cotransporter 1	Homo sapiens (human)
pentose transmembrane transporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
fucose transmembrane transporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
alpha-glucoside transmembrane transporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
galactose:sodium symporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
D-glucose transmembrane transporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
low-affinity glucose:sodium symporter activity	Sodium/glucose cotransporter 2	Homo sapiens (human)
glucose:sodium symporter activity	Sodium/glucose cotransporter 2	Homo sapiens (human)
protein binding	Sodium/glucose cotransporter 2	Homo sapiens (human)
alpha-glucoside transmembrane transporter activity	Sodium/glucose cotransporter 2	Homo sapiens (human)
D-glucose transmembrane transporter activity	Sodium/glucose cotransporter 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
early endosome	Sodium/glucose cotransporter 1	Homo sapiens (human)
plasma membrane	Sodium/glucose cotransporter 1	Homo sapiens (human)
apical plasma membrane	Sodium/glucose cotransporter 1	Homo sapiens (human)
brush border membrane	Sodium/glucose cotransporter 1	Homo sapiens (human)
intracellular organelle	Sodium/glucose cotransporter 1	Homo sapiens (human)
perinuclear region of cytoplasm	Sodium/glucose cotransporter 1	Homo sapiens (human)
extracellular exosome	Sodium/glucose cotransporter 1	Homo sapiens (human)
intracellular vesicle	Sodium/glucose cotransporter 1	Homo sapiens (human)
plasma membrane	Sodium/glucose cotransporter 1	Homo sapiens (human)
plasma membrane	Sodium/glucose cotransporter 2	Homo sapiens (human)
membrane	Sodium/glucose cotransporter 2	Homo sapiens (human)
apical plasma membrane	Sodium/glucose cotransporter 2	Homo sapiens (human)
extracellular exosome	Sodium/glucose cotransporter 2	Homo sapiens (human)
plasma membrane	Sodium/glucose cotransporter 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1570105	Binding affinity to human SGLT2 assessed as dissociation half-life	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
AID1413441	Inhibition of recombinant human SGLT2 expressed in HEK293 cells assessed as decrease in [14C]-AMG uptake preincubated for 15 mins followed by [14C]-AMG addition and measured after 4 hrs by Topcount method	2018	MedChemComm, Aug-01, Volume: 9, Issue:8	Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class.
AID1546902	Inhibition of SGLT1 (unknown origin)	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
AID1413442	Selectivity ratio of IC50 for recombinant human SGLT1 expressed in HEK293 cells to IC50 for recombinant human SGLT2 expressed in HEK293 cells	2018	MedChemComm, Aug-01, Volume: 9, Issue:8	Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class.
AID1396969	Inhibition of SGLT2 (unknown origin)	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents.
AID1546903	Inhibition of SGLT2 (unknown origin)	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
AID1346965	Human Sodium/glucose cotransporter 2 (Hexose transporter family)	2012	Diabetes, obesity & metabolism, Jan, Volume: 14, Issue:1	Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
AID1346950	Human Sodium/glucose cotransporter 1 (Hexose transporter family)	2012	Diabetes, obesity & metabolism, Jan, Volume: 14, Issue:1	Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	593 (42.51)	24.3611
2020's	802 (57.49)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	313 (21.90%)	5.53%
Reviews	257 (17.98%)	6.00%
Case Studies	50 (3.50%)	4.05%
Observational	29 (2.03%)	0.25%
Other	780 (54.58%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (382)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Participants With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipe [NCT03351478]	Phase 3	770 participants (Actual)	Interventional	2017-11-27	Completed
Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN) [NCT03933956]	Phase 3	2 participants (Actual)	Interventional	2020-01-09	Terminated(stopped due to Study terminated owing to challenges posed by the COVID-19 situation.)
EMPA-VISION: A Randomised, Double-blind, Placebo-controlled, Mechanistic Cardiac Magnetic Resonance Study to Investigate the Effects of Empagliflozin Treatment on Cardiac Physiology and Metabolism in Patients With Heart Failure [NCT03332212]	Phase 3	72 participants (Actual)	Interventional	2018-03-01	Completed
A Phase I, Open-label, Single-dose Trial to Investigate the Metabolism and Pharmacokinetics of 50 mg [14C]-BI 10773 When Administered as Oral Solution to Healthy Male Volunteers [NCT02172274]	Phase 1	8 participants (Actual)	Interventional	2008-06-30	Completed
Randomized, Double Blind, Placebo Controlled, Multicenter Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF) [NCT03200860]	Phase 2	80 participants (Actual)	Interventional	2017-12-18	Completed
A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin 5 mg and Empagliflozin 25 mg or Dapagliflozin 10 mg After Oral Administration in Healthy Male Adults [NCT03766724]	Phase 1	42 participants (Actual)	Interventional	2018-11-22	Completed
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Transthyretin Amyloid (ATTR) Cardiomyopathy [NCT05233163]	Phase 4	15 participants (Actual)	Interventional	2022-03-14	Completed
SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial [NCT05138575]	Phase 2	53 participants (Anticipated)	Interventional	2022-01-24	Recruiting
PEARL-DM: Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD; Randomized Controlled Trial From Pakistan. [NCT05942963]	Phase 4	240 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
Post Marketing Surveillance on Long Term Drug Use of JARDIANCE® Tablets in Patients With Chronic Heart Failure in Japan [NCT05262764]		1,201 participants (Actual)	Observational	2022-04-01	Active, not recruiting
Bioequivalence of a Low Strength Fixed Dose Combination Tablet of Empagliflozin/Linagliptin/Metformin Extended Release Compared to the Free Combination of Empagliflozin, Linagliptin, and Metformin Extended Release Tablets Following Oral Administration in [NCT03629054]	Phase 1	30 participants (Actual)	Interventional	2018-08-27	Completed
A Phase III Randomised, Double-blind Trial to Evaluate the Effect of 12 Weeks Treatment of Once Daily EMPagliflozin 10 mg Compared With Placebo on ExeRcise Ability and Heart Failure Symptoms, In Patients With Chronic HeArt FaiLure With Preserved Ejection [NCT03448406]	Phase 3	315 participants (Actual)	Interventional	2018-03-20	Completed
A Multicentre International Randomized Parallel Group Double-blind Placebo-controlled Clinical Trial of EMPAgliflozin Once Daily to Assess Cardio-renal Outcomes in Patients With Chronic KIDNEY Disease [NCT03594110]	Phase 3	6,609 participants (Actual)	Interventional	2019-01-31	Active, not recruiting
Efficacy and Safety of Empagliflozin Compared With Linagliptin in New-onset Diabetes Mellitus After Kidney Transplantation [NCT03642184]	Phase 4	6 participants (Actual)	Interventional	2018-07-14	Terminated(stopped due to Difficult in enrolling suitable participants)
"EMPA-TROPISM Trial: Are the Cardiac Benefits of Empagliflozin Independent of Its Hypoglycemic Activity?" [NCT03485222]	Phase 4	84 participants (Actual)	Interventional	2018-05-21	Completed
Effect of Sodium Glucose Transporter 2 Inhibitor Empagliflozin on Proteinuria and Kidney Disease Progression in Patients With Non-diabetic Glomerulonephritis- A Randomized Controlled Trial [NCT05283057]	Phase 3	50 participants (Actual)	Interventional	2020-02-20	Completed
National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension [NCT04970108]	Phase 3	0 participants (Actual)	Interventional	2023-08-31	Withdrawn(stopped due to Strategy review)
A Phase 4, Single-center, Randomized, Parallel Group Study to Assess Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus [NCT03753087]	Phase 4	70 participants (Actual)	Interventional	2019-01-16	Completed
Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study [NCT03200782]		12 participants (Actual)	Interventional	2017-05-30	Completed
Impact of Empaglifozine on Cardiac Ectopic Fat [NCT03118336]	Phase 3	56 participants (Actual)	Interventional	2017-06-16	Completed
RACELINES: Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES [NCT03433248]	Phase 4	66 participants (Actual)	Interventional	2017-11-09	Active, not recruiting
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease [NCT03867487]	Phase 2	40 participants (Anticipated)	Interventional	2019-05-01	Recruiting
The Effects of Empagliflozin on Functional and Structural Arterial Wall Characteristics [NCT03639545]	Phase 4	120 participants (Anticipated)	Interventional	2018-03-01	Recruiting
Empagliflozin in Post-Transplantation Diabetes Mellitus [NCT03113110]	Phase 2	16 participants (Anticipated)	Interventional	2017-01-15	Completed
Randomised Evaluation of COVID-19 Therapy [NCT04381936]	Phase 2/Phase 3	50,000 participants (Anticipated)	Interventional	2020-03-19	Recruiting
Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Post-transplantation Diabetes Mellitus [NCT03157414]	Phase 4	49 participants (Actual)	Interventional	2016-11-07	Completed
Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver [NCT03646292]	Phase 4	60 participants (Anticipated)	Interventional	2018-12-19	Recruiting
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus [NCT02863328]	Phase 3	822 participants (Actual)	Interventional	2016-08-10	Completed
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin/Metformin Extended Release Compared to the Free Combination of Empagliflozin, Linagliptin, and Metformin Extended Release Tablets Following Oral Administration in Healthy Male [NCT03259490]	Phase 1	30 participants (Actual)	Interventional	2017-08-31	Completed
Relative Bioavailability of Two FDC Tablet Strengths of Empagliflozin/Linagliptin/Metformin Extended Release Compared to the Free Combination of Empagliflozin, Linagliptin and Metformin Extended Release Following Oral Administration in Healthy Male and Fe [NCT02821910]	Phase 1	50 participants (Actual)	Interventional	2016-07-20	Completed
A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) [NCT03057951]	Phase 3	5,988 participants (Actual)	Interventional	2017-03-02	Completed
A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes [NCT03060980]	Phase 3	245 participants (Actual)	Interventional	2017-03-03	Terminated(stopped due to Decision by Sponsor)
Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES) [NCT03627039]		20,000 participants (Anticipated)	Observational	2018-09-01	Active, not recruiting
An Open-label, Randomized, Multiple-dose, Crossover Study to Evaluate Drug-drug Interaction Following Oral Administration of Gemigliptin and Dapagliflozin or Empagliflozin in Healthy Adult Volunteers [NCT03565458]	Phase 1	48 participants (Actual)	Interventional	2018-04-05	Active, not recruiting
Efficacy of Vildagliptin, Liraglutide and Empagliflozin in the Management of Fatty Liver Disease Among Patients With Type 2 Diabetes [NCT05041673]		120 participants (Anticipated)	Interventional	2021-02-23	Active, not recruiting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (0.5 mg to 800 mg) of BI 10773 as Tablets Administered to Healthy Male Subjects. A Randomised Placebo-controlled (Within-dose Groups) and Double-blind Trial. [NCT02172170]	Phase 1	72 participants (Actual)	Interventional	2007-01-31	Completed
Relative Bioavailability of Both BI 10773 and Metformin After Coadministration Compared to Multiple Oral Doses of BI 10773 (50 mg q.d.) Alone and Metformin (1000 mg b.i.d.) Alone to Healthy Male Volunteers (an Open-label, Randomised, Crossover, Clinical P [NCT02172248]	Phase 1	16 participants (Actual)	Interventional	2009-01-31	Completed
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Desp [NCT01257334]	Phase 3	1,390 participants (Anticipated)	Interventional	2010-09-30	Enrolling by invitation
Empagliflozin in Adolescent Diabetes [NCT04917692]	Phase 4	0 participants (Actual)	Interventional	2021-07-31	Withdrawn(stopped due to Not funded)
Relative Bioavailability of Both BI 10773 and Glimepiride After Co-administration Compared to Multiple Oral Doses of BI 10773 (50 mg q.d.) Alone and a Single Dose of Glimepiride (1 mg) Alone in Healthy Male Volunteers (an Open-label, Randomised, Crossover [NCT02172261]	Phase 1	16 participants (Actual)	Interventional	2009-04-30	Completed
Post-authorization Safety Study in Patients With Type 2 Diabetes Mellitus to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration Among Patients Treated With Empagliflozin or DPP-4 Inhibi [NCT03764631]		1,502 participants (Actual)	Observational	2018-09-26	Completed
Evaluating the Role of EMpagliflozin on the Rate of Post-Operative Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Graft Surgery: a Double-blind Placebo-controlled Randomized Clinical Trial [NCT06124937]	Phase 3	492 participants (Anticipated)	Interventional	2023-11-07	Recruiting
Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Heart Failure [NCT03030222]	Phase 4	65 participants (Actual)	Interventional	2017-07-05	Completed
A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) [NCT03057977]	Phase 3	3,730 participants (Actual)	Interventional	2017-03-06	Completed
Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus [NCT03249506]		25,358 participants (Actual)	Observational	2016-05-12	Completed
Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology and Metabolic Control in Patients With Type 2 Diabetes Mellitus on Stable Metformin Treatment [NCT02401880]	Phase 4	89 participants (Actual)	Interventional	2015-05-31	Completed
Post-authorization Safety Study (PASS) to Assess the Risk of Acute Pancreatitis in Type 2 Diabetes Mellitus (T2DM) Patients Newly Initiating Empagliflozin Compared to Other Oral Non-incretin/Non-sodium Glucose Co-transporter-2 Inhibitors (SGLT2)-Containin [NCT05162014]		72,621 participants (Actual)	Observational	2021-12-20	Completed
Empagliflozin for the Treatment of Postprandial Hypoglycemia [NCT05036317]	Phase 3	62 participants (Anticipated)	Interventional	2022-03-11	Recruiting
A Phase III, Randomised, Double-blind, Parallel Group, 24-week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and Linagliptin 5 mg Fixed Dose Combination Compared With Empagliflozin 10 mg Plus Placebo and a 52-week Study to Evalua [NCT02489968]	Phase 3	880 participants (Actual)	Interventional	2015-05-12	Completed
The Empagliflozin vs. DPP-4 Inhibitors and GLP-1 Receptor Agonists Cost of Care Study: a German Claims Data Analysis [NCT04295005]		24,500 participants (Actual)	Observational	2020-11-16	Completed
A Randomised Trial Examining Therapy to Maintain Remission in Dilated Cardiomyopathy [NCT06091475]		50 participants (Anticipated)	Interventional	2023-10-20	Not yet recruiting
SGLT2 Inhibitors in Prevention of Acute Kidney Injury in Patients With Diabetes Mellitus Undergoing CABG Extracorporeal On-Pump [NCT04523064]	Phase 4	155 participants (Anticipated)	Interventional	2020-09-22	Recruiting
Multi-country Non-interventional Study on the Effectiveness of Empagliflozin in Adult Patients With Type 2 Diabetes in Europe and Asia. [NCT03817463]		171,808 participants (Actual)	Observational	2019-04-15	Completed
A Comparative Clinical Study Evaluating the Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome in Egyptian Women [NCT05200793]	Phase 4	75 participants (Anticipated)	Interventional	2021-12-07	Recruiting
Pharmacokinetics and Bioequivalence of Two Empagliflozin, With Evaluation in Healthy Jordanian Subjects Under Fasting and Fed Conditions [NCT05229796]		26 participants (Actual)	Interventional	2021-05-17	Completed
Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia - a Multicentric Randomized Double-blind Placebo-controlled Trial (the EMPOWER Study) [NCT04447911]	Phase 4	172 participants (Anticipated)	Interventional	2021-02-04	Recruiting
Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation: A Rotation Study of Different Albuminuria Lowering Drug Classes to Study Individual Drug Response in Diabetes [NCT03504566]	Phase 4	0 participants (Actual)	Interventional	2017-11-15	Withdrawn(stopped due to Registered and published incorrectly)
Effects of Empagliflozin on Preventing Fibrosis and Cirrhosis Progression in Nucleos(t)Ide Analogue-treated Chronic Hepatitis B Patients With Significant/Advanced Fibrosis or Cirrhosis: a Randomized, Double-blind Placebo-controlled Trial [NCT05147090]	Phase 4	106 participants (Anticipated)	Interventional	2022-01-02	Recruiting
Effect of Empagliflozin on Liver Fat in Non-alcoholic Fatty Liver Disease Patients Without Diabetes Mellitus: a Randomized, Double-blind, Placebo-controlled Trial [NCT04642261]	Phase 4	98 participants (Actual)	Interventional	2021-01-01	Completed
A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of JARDIANCE® (Empagliflozin, 10mg, 25mg, q.d.) in Korean Patients With Type 2 Diabetes Mellitus [NCT02848833]		3,368 participants (Actual)	Observational	2016-08-10	Completed
Relative Bioavailability of Multiple Doses BI 10773 50 mg and Linagliptin 5 mg After Concomitant Administration Compared to Multiple Doses of BI 10773 50 mg and Linagliptin 5mg Administered Alone to Healthy Male Volunteers (an Open-label, Randomised, Cros [NCT02172222]	Phase 1	16 participants (Actual)	Interventional	2009-07-31	Completed
Pharmacokinetic Evaluation of Empagliflozin in Healthy Egyptian Volunteers Using LC-MS/MS: Compared With Other Ethnic Populations [NCT03059056]	Phase 1	6 participants (Actual)	Interventional	2017-02-02	Completed
Single-center, Open, Randomized, Single-dose, Crossover Bioequivalence Study Evaluating the Use of the Subject Formulation, Empagliflozin And Linagliptin Tablets, Versus the Reference Formulation, Empagliflozin And Linagliptin Tablets (Glyxambi®), in Heal [NCT05956522]	Phase 1	106 participants (Actual)	Interventional	2022-07-01	Completed
Multicenter, Randomized, 2 x 2 Factorial, Phase 3 Study to Assess the Efficacy of Carvedilol and Empagliflozin on Improvement of Right Ventricular Remodeling in Patients With Severe Functional Tricuspid Regurgitation [NCT04345796]	Phase 3	180 participants (Anticipated)	Interventional	2021-02-15	Recruiting
Prevalence of Cardiovascular Disease in Swedish Patients With Type 2 Diabetes and in Patients Initiating on Empagliflozin [NCT04927858]		460,558 participants (Actual)	Observational	2018-04-02	Completed
Effects of Empagliflozin on Natriuresis and Volume Overload in Patients With Cirrhosis and Ascites [NCT05726032]	Phase 2	20 participants (Anticipated)	Interventional	2023-09-11	Recruiting
Evaluation of the Effectiveness of Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines (EMPACT Study). [NCT05271162]	Phase 3	220 participants (Anticipated)	Interventional	2023-09-30	Recruiting
Intraclass Safety and Efficacy Comparison Among SGLT-2 Inhibitors in Elderly Patients With Type 2 Diabetes. A Pragmatic, Phase IV, Multicenter, Open-label, Randomised Controlled Trial. [NCT04796428]	Phase 4	1,167 participants (Anticipated)	Interventional	2021-06-30	Not yet recruiting
Randomized, Double-blind, Placebo Controlled, Parallel-group, Prospective Clinical Study to Analyse the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure [NCT03128528]	Phase 2	84 participants (Actual)	Interventional	2017-07-01	Completed
Impact of Empagliflozin on Functional Capacity in Heart Failure With Preserved Ejection Fraction [NCT05139472]	Phase 3	8 participants (Anticipated)	Interventional	2021-11-09	Recruiting
A 52-week, Randomised, Multi-centre, Parallel Group Study to Investigate the Safety and Efficacy of BI 10773 (10 mg or 25 mg Administered Orally Once Daily) as add-on Therapy to an Oral Antidiabetic Drug (Sulfonylurea, Biguanide, Thiazolidinedione, Alpha [NCT01368081]	Phase 3	1,162 participants (Actual)	Interventional	2011-05-31	Completed
Alleviating Carbohydrate-Counting Burden in Type 1 Diabetes Using Artificial Pancreas and Sodium Glucose-Linked Transporter 2 Inhibition: A Randomized Open-Label Crossover Trial. [NCT03510000]		30 participants (Actual)	Interventional	2018-05-15	Completed
Assessment of the Renin-angiotensin-aldosterone System (RAAS) and Antidiuretic Function in Patients With Type 2 Diabetes Before and During Treatment With Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i): the GliRACo 1 Study [NCT03917758]		30 participants (Anticipated)	Interventional	2018-10-10	Recruiting
EMPOX - A Randomised, Double-blinded, Placebo Controlled Study That Evaluates the Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes [NCT02890745]	Phase 2	31 participants (Actual)	Interventional	2016-11-30	Completed
Relative Bioavailability of Both BI 10773 and Sitagliptin After Co-administration Compared to Multiple Oral Doses of BI 10773 (50 mg q.d.) Alone and Sitagliptin (100 mg q.d.) Alone in Healthy Male Volunteers (an Open-label, Randomised, Crossover, Clinical [NCT02172196]	Phase 1	16 participants (Actual)	Interventional	2009-05-31	Completed
Effect of Empagliflozin Versus Linagliptin on Glycemic Outcomes, Renal Outcomes and Body Composition in Renal Transplant Recipients With Diabetes Mellitus: Randomized Controlled Trial [NCT06098625]		200 participants (Anticipated)	Interventional	2023-11-10	Not yet recruiting
SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis [NCT05960656]	Early Phase 1	30 participants (Anticipated)	Interventional	2023-10-05	Recruiting
A Double-blind, Randomised, Placebo-controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of Empagliflozin and Linagliptin Over 26 Weeks, With a Double-blind Active Treatment Safety Extension Period up to 52 Weeks, in Children and Adolescen [NCT03429543]	Phase 3	175 participants (Actual)	Interventional	2018-03-20	Completed
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure [NCT03152552]	Phase 2	125 participants (Actual)	Interventional	2017-07-25	Terminated(stopped due to This study terminated prematurely because of slow enrollment)
Effect of Empagliflozin on Hepatic Glucose Metabolism: Role of Autonomic Nervous System [NCT03193684]	Phase 4	108 participants (Actual)	Interventional	2018-05-20	Active, not recruiting
The Potential Beneficial Effects of SGLT2 Inhibitors in Patients With Acute Decompensated Heart Failure During Ventilator Weaning: a Prospective Multicenter Cohort Study. [NCT06142474]	Phase 3	450 participants (Anticipated)	Interventional	2022-10-10	Recruiting
Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes: a Randomized Controlled Parallel Trial [NCT06021145]	Phase 1	46 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis [NCT05058417]	Phase 2	50 participants (Anticipated)	Interventional	2021-10-01	Recruiting
Comparison of Canagliflozin vs. Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Patients With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease [NCT03492580]		714,582 participants (Actual)	Observational	2018-02-22	Completed
Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects in Patients With Diabetes Mellitus (or Pre-diabetes) and Heart Failure (SUGAR-DM-HF) [NCT03485092]	Phase 4	105 participants (Actual)	Interventional	2018-03-16	Completed
A Meta-Analysis of Amputation Risk in Empagliflozin Studies (1245.25, 1245.110, 1245.121) [NCT04937816]		14,000 participants (Actual)	Observational	2021-06-01	Completed
A Phase II,Randomized,Cross-over,Double-blind, Placebo- Controlled,Single Center Study of the Effect of Empagliflozin a SGLT-2 Inhibitor,on Endogenous Glucose Production and Plasma Glucagon Levels in Patients With ESRD [NCT03713190]	Phase 2	25 participants (Actual)	Interventional	2018-09-10	Completed
A Phase III Randomised, Double-blind Trial to Evaluate the Effect of 12 Weeks Treatment of Once Daily EMPagliflozin 10 mg Compared With Placebo on ExeRcise Ability and Heart Failure Symptoms, In Patients With Chronic HeArt FaiLure With Reduced Ejection Fr [NCT03448419]	Phase 3	312 participants (Actual)	Interventional	2018-03-20	Completed
A Single-Center, Open-Label, Randomized, Single-Dose, Two-Period, Two-Sequence, Crossover Study to Assess the Bioequivalence of Test Formulation With Reference Formulation in Healthy Adult Subjects. [NCT03771781]		48 participants (Actual)	Interventional	2018-04-16	Completed
The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of Empagliflozin [NCT03895229]	Phase 1	16 participants (Actual)	Interventional	2018-10-01	Completed
Empagliflozin for Patients With Acutely Decompensated Congestive Heart Failure, Diuretic Resistance, and Moderate to Advanced Chronic Kidney Disease [NCT05305495]	Phase 4	25 participants (Anticipated)	Interventional	2022-12-22	Recruiting
A Phase 1, Open-Label, Sequential, Multiple-Dose, Drug-Drug Interaction Study of Dorzagliatin and Empagliflozin in Subjects With Type 2 Diabetes Mellitus [NCT03790787]	Phase 1	16 participants (Actual)	Interventional	2019-04-18	Completed
Effect of Sodium Glucose Cotransporter Inhibitors on Non Diabetic Fatty Liver Disease Patients [NCT05694923]		150 participants (Anticipated)	Interventional	2023-02-01	Not yet recruiting
Empagliflozin and the Preservation of Beta-cell Function in Women With Recent Gestational Diabetes [NCT03215069]	Phase 3	120 participants (Anticipated)	Interventional	2018-07-01	Recruiting
Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes: A Randomized Open Intervention Study That Compares Empagliflozin, Pioglitazone and Semaglutide [NCT05501483]		60 participants (Anticipated)	Interventional	2023-02-08	Recruiting
Relative Bioavailability of Multiple Oral Doses of BI 10773 (25 mg) and Ramipril (5 mg) Administered Together Compared to Multiple Oral Doses of BI 10773 (25 mg) Alone and Ramipril (5 mg) Alone in Healthy Male and Female Volunteers (an Open Label, Randomi [NCT01284621]	Phase 1	23 participants (Actual)	Interventional	2011-01-31	Completed
The Effects and Mechanism of SGLT2 Inhibitors in Stage B of Heart Failure With Hypertension [NCT06055452]	Phase 4	120 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Safety and Efficacy Study of BI 10773 (10 mg and 25 mg) Administered Orally, Once Daily Over 78 Weeks in Type 2 Diabetic Patients Receiving Treatment With Basal Insulin (Glargine, [NCT01011868]	Phase 2	494 participants (Actual)	Interventional	2009-11-30	Completed
Management of Diuretic Refractory Ascites in Cirrhosis With Empagliflozin (DRAin-Em-01) [NCT05013502]	Phase 1	14 participants (Actual)	Interventional	2021-11-15	Completed
Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion [NCT04061473]		20 participants (Actual)	Interventional	2019-04-02	Completed
A Randomized, Open-label, Multiple Dosing, Crossover Study to Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin in Healthy Male Volunteers [NCT02854748]	Phase 1	30 participants (Anticipated)	Interventional	2016-08-31	Not yet recruiting
Impact of Additional Treatment With Empagliflozin or Semaglutide on Endothelial Function and Other Clinical Parameters and Biomarkers in T1DM Patients [NCT05857085]	Phase 4	90 participants (Actual)	Interventional	2021-12-15	Completed
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD [NCT05614115]	Phase 1	75 participants (Anticipated)	Interventional	2023-03-21	Recruiting
Randomized, Double-blind, Placebo-controlled Crossover Trial Assessing the Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers [NCT04911660]	Phase 2	50 participants (Actual)	Interventional	2021-08-25	Completed
Short Term Effect of Empagliflozin on Left Ventricular Relaxation in Non Diabetic Hypertensive Patients [NCT04203914]	Phase 4	15 participants (Actual)	Interventional	2017-01-10	Completed
The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors [NCT02792400]		24 participants (Actual)	Interventional	2016-05-31	Completed
The Effect of Food on the Bioavailability and Pharmacokinetics of BI 10773 Tablet, Administered as a Single Dose of 50 mg With and Without Food to Healthy Male Volunteers in an Open-label, Randomised Intraindividual Crossover Comparison Design [NCT02172209]	Phase 1	14 participants (Actual)	Interventional	2008-01-31	Completed
Effect of EMPAgliflozin on The HeterogeneitY of Ventricular Repolarization in Patients With Diabetes and Coronary HEART Disease. [NCT04117763]	Phase 4	100 participants (Anticipated)	Interventional	2019-10-04	Recruiting
Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in Patients With Type II Diabetes Mellitus [NCT05164263]	Phase 4	156 participants (Anticipated)	Interventional	2021-04-01	Recruiting
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus [NCT01370005]	Phase 3	825 participants (Actual)	Interventional	2011-06-30	Completed
Effect of UGT Genetic Variation on Pharmacokinetics of Empagliflozin [NCT05036421]	Phase 3	18 participants (Actual)	Interventional	2022-02-15	Completed
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Empagliflozin Among Patients Initiating Hemodialysis for the Treatment of End-Stage Kidney Disease [NCT05786443]	Phase 2	60 participants (Anticipated)	Interventional	2023-12-08	Not yet recruiting
EMPACT-MI: A Streamlined, Multicentre, Randomised, Parallel Group, Double-blind Placebo-controlled Superiority Trial to Evaluate the Effect of EMPAgliflozin on Hospitalisation for Heart Failure and Mortality in Patients With aCuTe Myocardial Infarction [NCT04509674]	Phase 3	6,522 participants (Actual)	Interventional	2020-12-16	Completed
A Multicentre, Randomised, Double-blind, 90-day Superiority Trial to Evaluate the Effect on Clinical Benefit, Safety and Tolerability of Once Daily Oral EMPagliflozin 10 mg Compared to Placebo, Initiated in Patients Hospitalised for acUte Heart faiLure (d [NCT04157751]	Phase 3	530 participants (Actual)	Interventional	2020-05-18	Completed
"The Effect of a Circuit Resistance Training, Empagliflozin or Vegeterranean Diet on Physical and Metabolic Function in Elderly Subjects With Type 2 Diabetes: a Study Protocol for a Randomized Control Trial (CEV-65 Trial)" [NCT03560375]	Phase 4	120 participants (Anticipated)	Interventional	2018-05-09	Recruiting
Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction: A Randomized Clinical Trial (Empire HF) [NCT03198585]	Phase 2	190 participants (Actual)	Interventional	2017-06-29	Completed
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Empagliflozin (10 mg and 25 mg) Administered Orally Once Daily in Combination With Insulin With or Without up to Two Oral Anti-diabetic Agents for 24 Weeks in Chinese Type [NCT04233801]	Phase 3	219 participants (Actual)	Interventional	2020-04-15	Completed
A 52-week Randomised, Double-blind, Parallel Group, Safety and Efficacy Study of Empagliflozin Once Daily as add-on Therapy to Glucagon-like Peptide-1 Receptor Agonist in Japanese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control [NCT02589626]	Phase 4	65 participants (Actual)	Interventional	2015-10-29	Completed
Clinical Study to Evaluate the Possible Efficacy and Safety of Empagliflozin in Patients With Ulcerative Colitis [NCT05610956]	Early Phase 1	60 participants (Anticipated)	Interventional	2022-12-01	Not yet recruiting
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease [NCT05510115]	Phase 2	50 participants (Anticipated)	Interventional	2022-11-18	Recruiting
Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study) [NCT02172235]	Phase 1	20 participants (Actual)	Interventional	2010-04-30	Completed
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Crossover Study) [NCT02758171]	Phase 1	56 participants (Actual)	Interventional	2016-05-17	Completed
A Phase I, Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (1 to 100 mg) of BI 10773 in Healthy Male Volunteers [NCT02182453]	Phase 1	48 participants (Actual)	Interventional	2008-06-30	Completed
Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy [NCT05512130]	Early Phase 1	18 participants (Anticipated)	Interventional	2022-08-17	Recruiting
Effect of Empagliflozin Versus Linagliptin on Glycemic Outcomes, Renal Outcomes and Body Composition in Renal Transplant Recipients With Diabetes Mellitus: Randomized Controlled Trial (EmLina Renal Trial) [NCT06095492]		200 participants (Anticipated)	Interventional	2023-10-30	Recruiting
Sodium-glucose Transport 2 Inhibitors (SGLT2i) in Heart Failure Reduced Ejection Fraction (HFrEF) Patients [NCT06065280]		80 participants (Anticipated)	Interventional	2022-09-01	Recruiting
Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure [NCT04049045]	Phase 2	60 participants (Actual)	Interventional	2019-09-29	Completed
Effect of SGLT2 Inhibition on Improving the Glycemic Performance of the Single Hormone Artificial Pancreas Configuration in Type 1 Diabetes in the Outpatient Setting - A Randomized Placebo Controlled Cross-Over Multicentre Clinical Trial [NCT03979352]	Phase 3	28 participants (Actual)	Interventional	2019-08-01	Completed
Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes [NCT02637973]	Phase 4	84 participants (Actual)	Interventional	2015-12-31	Completed
Evaluating the Effect of Pentoxifylline, Ursodiol, and Empagliflozin on Fatty Liver of Patients With Type-2 Diabetes [NCT04910178]	Phase 4	80 participants (Actual)	Interventional	2020-12-01	Completed
A Single-center, Prospective, Placebo-controlled, Double-blind, Randomized, Cross-over Mechanistic Intervention Study to Investigate the Effect of Empagliflozin on Kidney Function in People With Either Preserved or Impaired Kidney Function With or Without [NCT04243850]	Phase 4	0 participants (Actual)	Interventional	2020-07-01	Withdrawn(stopped due to COVID)
The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products [NCT02768220]	Phase 4	0 participants (Actual)	Interventional	2017-12-01	Withdrawn(stopped due to no funding)
A Randomized, Comparator-controlled, Cross-over Intervention Study to Assess Renal Hemodynamics of Mono- and Combination Therapy With SGLT-2 Inhibitor Empagliflozin and RAS-inhibitor Losartan in Patients With Type 2 Diabetes Mellitus [NCT04238702]	Phase 4	24 participants (Actual)	Interventional	2020-11-04	Completed
Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study [NCT02729766]	Phase 2/Phase 3	15 participants (Actual)	Interventional	2016-03-31	Completed
Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment (DEMETER - SIRIO 11) Study [NCT05905965]	Phase 3	200 participants (Anticipated)	Interventional	2023-05-01	Recruiting
A Phase I Study to Evaluate the Drug-Drug Interaction of Chiglitazar With Empagliflozin，Atorvastatin and Valsartan in Healthy Subjects. [NCT05681273]	Phase 1	48 participants (Actual)	Interventional	2023-02-17	Completed
Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabet [NCT04013581]	Phase 4	121 participants (Actual)	Interventional	2019-08-05	Completed
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation: A Randomised Double-blind Placebo-controlled Trial (The SEESAW Study) [NCT02798744]	Phase 4	68 participants (Actual)	Interventional	2016-12-31	Completed
A Multicenter, Open-label, Single-arm, Extension Study With Regard to the Safety and Efficacy of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance (EMPIRE-02) [NCT04221152]	Phase 3	8 participants (Actual)	Interventional	2020-02-01	Active, not recruiting
Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction [NCT03087773]	Phase 3	476 participants (Actual)	Interventional	2017-05-11	Completed
Clinical Efficacy of SGLT-2 Inhibitor After Stent Implantation in Patients With Coronary Heart Disease and Diabetes Mellitus：a Prospective Cohort Study [NCT05333159]		1,424 participants (Anticipated)	Observational	2021-09-01	Recruiting
Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes: A 12-week Randomized Clinical Study [NCT02686476]		100 participants (Actual)	Interventional	2016-03-31	Completed
The Feasibility of Remote Clinical Trial Conduct in Patients With Diabetes and Elevated Albuminuria, Individual Responses to Empagliflozin, and Whether Suboptimal Treatment Responses Can be Overcome by the Addition or Switch With Finerenone [NCT06094920]	Phase 4	10 participants (Anticipated)	Interventional	2024-03-01	Not yet recruiting
Evaluation of the Safety and Efficacy of Empagliflozin Administration as a Treatment for Neutropenia in Patients With Glycogenosis Type 1b and G6PC3 Deficiency [NCT04138251]	Phase 2	5 participants (Anticipated)	Interventional	2019-06-20	Recruiting
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. A Randomized Multicentric Open Trial [NCT05879276]	Phase 3	164 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
An Exploratory Investigation of the Safety of Empagliflozin in Kidney Transplant Recipients (SEKTR) [NCT06013865]		264 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
An Open-label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Two Way Cross-over, Single Oral Dose Bioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets o [NCT06180109]	Phase 1	36 participants (Actual)	Interventional	2023-07-30	Completed
Study of Nasal Insulin to Fight Forgetfulness - Combination Intranasal Insulin and Empagliflozin Trial [NCT05081219]	Phase 2	60 participants (Anticipated)	Interventional	2021-10-14	Recruiting
A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of JARDIANCE DUO® (Empagliflozin/Metformin, 5/500mg, 5/850mg, 5/1000mg, 12.5/500mg, 12.5/850mg, 12.5/1000mg) in Korean Patients With Type 2 Diabetes Mellitus [NCT03642717]		658 participants (Actual)	Observational	2018-08-21	Completed
Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria - A Double Blinded, Randomised, Placebo Controlled, Parallel, Single Center Study [NCT04061200]	Phase 4	80 participants (Anticipated)	Interventional	2019-11-01	Not yet recruiting
Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes: a Prospective Interventional Study [NCT04127084]	Phase 4	70 participants (Anticipated)	Interventional	2019-10-15	Recruiting
EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction [NCT05584319]	Phase 4	100 participants (Anticipated)	Interventional	2022-12-15	Enrolling by invitation
A Phase II, Randomized, Parallel Group Safety, Efficacy, and Pharmacokinetics Study of BI 10773 (1 mg, 5 mg, 10 mg, 25 mg, and 50 mg) Administered Orally Once Daily Over 12 Weeks Compared Double Blind to Placebo With an Additional Open-label Sitagliptin A [NCT00749190]	Phase 2	495 participants (Actual)	Interventional	2008-08-31	Completed
A Phase IIb, Randomized, Parallel Group Safety, Efficacy, and Pharmacokinetics Study of BI 10773 (5 mg, 10 mg and 25 mg) Administered Orally Once Daily Over 12 Weeks Compared Double Blind to Placebo, as Monotherapy, With an Additional Open-label Metformin [NCT00789035]	Phase 2	408 participants (Actual)	Interventional	2008-10-31	Completed
The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors [NCT05360615]	Phase 1	147 participants (Anticipated)	Interventional	2022-07-01	Recruiting
A Phase III Randomised, Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 10773 Compared to Glimepiride Administered Orally During 104 Weeks With a 104 Week Extension Period in Patients With Type 2 Diabetes Mellitus and Insuff [NCT01167881]	Phase 3	1,549 participants (Actual)	Interventional	2010-08-31	Completed
Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors [NCT05885074]	Phase 2	24 participants (Anticipated)	Interventional	2024-01-30	Not yet recruiting
Randomised, Double-blind, Placebo-controlled and Parallel Dose Group Trial to Investigate Efficacy and Safety of Multiple Doses of Oral BI 690517 Over 14 Weeks, Alone and in Combination With Empagliflozin, in Patients With Diabetic and Non-diabetic Chroni [NCT05182840]	Phase 2	714 participants (Actual)	Interventional	2022-01-11	Completed
Polypill Strategy for Prevention of Cardiomyopathy Among Patients With Diabetes at Risk of Heart Failure [NCT06143566]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2023-12-29	Not yet recruiting
Clinical Study to Investigate the Possible Effect of Empagliflozin in Treatment of Peripheral Diabetic Neuropathy in Patients With Diabetes Mellitus Type 2 [NCT05977465]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2022-01-20	Completed
Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease [NCT05671991]	Phase 4	30 participants (Anticipated)	Interventional	2023-03-01	Recruiting
A Phase 2A Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Steatohepatitis (NASH) [NCT04702490]	Phase 2	120 participants (Actual)	Interventional	2020-12-15	Active, not recruiting
Empagliflozin Functional Capacity - Non-Interventional Study [NCT05350202]		3,300 participants (Anticipated)	Observational	2022-12-15	Recruiting
Comparison of Type 2 Diabetes Pharmacotherapy Regimens Using Targeted Learning [NCT05073692]		270,000 participants (Anticipated)	Observational	2021-07-01	Recruiting
Relative Bioavailability of 5 mg BI 10773 Administered Twice Daily Compared to 10 mg BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study) [NCT02782624]	Phase 1	16 participants (Actual)	Interventional	2009-09-30	Completed
Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes vs Best Medical Treatment [NCT02041234]	Phase 4	40 participants (Anticipated)	Interventional	2014-02-28	Completed
A Multicenter, Open-label, Single-arm Study With Regard to the Efficacy and Safety of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance [NCT04018365]	Phase 3	8 participants (Actual)	Interventional	2019-09-01	Active, not recruiting
A 78 Week Open Label Extension to Trials Assessing the Safety and Efficacy of BI 10773 as Monotherapy or in Combination With Metformin in Type 2 Diabetic Patients [NCT00881530]	Phase 2	660 participants (Actual)	Interventional	2009-03-31	Completed
A Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Administration of Fixed Dose Combination of DW6014 and Loose Combination of Each Component in Healthy Adult Volunteers in Fed Condition [NCT05823883]	Phase 1	30 participants (Anticipated)	Interventional	2023-06-30	Not yet recruiting
A Preliminary Clinical Study on the Effects of Oral Hypoglycemic Agents on the Stress Hyperglycemic Ratio in Type 2 Diabetes Patients in the Absence of Serious Illness [NCT05822674]		80 participants (Actual)	Observational	2022-01-01	Completed
Relative Bioavailability Investigations of a 25 mg BI 10773 / 5 mg Linagliptin Fixed Dose Combination (FDC) Tablet (Formulation A1) Including the Comparison With Its Mono-components, the Comparison With a Second FDC Tablet (Formulation A3), and the Invest [NCT01189201]	Phase 1	42 participants (Actual)	Interventional	2010-08-31	Completed
A Randomised, Double-blind, Placebo-controlled, Parallel Group, 52 Weeks Phase IV Trial to Evaluate Efficacy and Safety of Oral, Once Daily Empagliflozin in Elderly Japanese Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control [NCT04531462]	Phase 4	129 participants (Actual)	Interventional	2020-10-05	Completed
The Effect of SGLT2 Inhibition on Adipose Tissue Inflammation and Endothelial Function Pilot [NCT04907214]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2021-07-29	Completed
Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus [NCT04014192]	Phase 4	40 participants (Anticipated)	Interventional	2019-09-01	Recruiting
"An Open-label Clinical Trial to Evaluate the Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan in Adult Patients With Chronic Heart Failure With Reduced Ejection Fraction Associated With Congenital Heart Disease" [NCT05580510]	Phase 2/Phase 3	160 participants (Anticipated)	Interventional	2023-02-06	Not yet recruiting
Comparison of Empaglifozin and Vildagliptin in Efficacy and Safety in Type 2 Diabetes Mellitus [NCT05359432]	Phase 4	120 participants (Actual)	Interventional	2020-07-01	Completed
A Pilot, Phase II, Open-Label, Single-Center Study of Sodium-Glucose Cotransporter-2 Inhibitor Empagliflozin in Major Depressive Disorder [NCT05757791]	Phase 2	16 participants (Anticipated)	Interventional	2023-03-17	Recruiting
Empagliflozin to Elderly and Obese Patients With Cardiovascular Disease (Empire Prevent: Cardiac): A Randomized Controlled Trial [NCT05084235]	Phase 2	204 participants (Anticipated)	Interventional	2021-09-02	Recruiting
Empagliflozin to Elderly and Obese Patients With Cardiovascular Disease (Empire Prevent: Metabolic): A Randomized Controlled Trial [NCT05042973]	Phase 2	120 participants (Anticipated)	Interventional	2021-09-02	Recruiting
Empagliflozin in the Management of Cirrhosis-related Refractory Ascites: a Randomized Controlled Trial [NCT05430243]	Phase 2/Phase 3	42 participants (Actual)	Interventional	2022-04-21	Completed
Double Blind Comparison Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics With Metformin [NCT01001962]	Phase 4	1,054 participants (Anticipated)	Interventional	2016-01-31	Not yet recruiting
National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus [NCT05028140]	Phase 3	480 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
Empagliflozin and Cardiac Remodelling in People Without Diabetes [NCT04461041]	Phase 4	169 participants (Actual)	Interventional	2021-04-01	Completed
Efficacy and Safety of First Line Use of Oral Semaglutide 25 mg or 50 mg Once Daily Versus Empagliflozin 25 mg or Versus Metformin 2000 mg in Newly Diagnosed Treatment naïve Patients With Type 2 Diabetes [NCT06083675]	Phase 3	912 participants (Anticipated)	Interventional	2024-01-26	Not yet recruiting
Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction: A Pilot Trial [NCT05129722]	Phase 4	30 participants (Anticipated)	Interventional	2022-10-01	Recruiting
EMPagliflozin After Aortic Valve Replacement - The EMPAVR Study - A Randomized Clinical Trial [NCT06171802]	Phase 4	205 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Esgliteo (Empagliflozin/Linagliptin, 10/5mg, 25/5mg) in Korean Patients With Type 2 Diabetes Mellitus [NCT05130463]		684 participants (Actual)	Observational	2022-03-22	Active, not recruiting
A Phase IIIb Randomised, Double-blind, Active-controlled, Parallel Group, Efficacy and Safety Study of Once Daily Oral Administration of Empagliflozin 25 mg Compared to Sitagliptin 100 mg During 52 Weeks in Type 2 Diabetes Mellitus Patients Who Are Treatm [NCT01984606]	Phase 3	0 participants (Actual)	Interventional	2015-01-31	Withdrawn
Safety and Efficacy of Empagliflozin on Heart Failure Dialysis Patients [NCT05967156]		15 participants (Anticipated)	Interventional	2023-06-01	Recruiting
Feasibility Study of Empagliflozin as Treatment for Idiopathic Pulmonary Arterial Hypertension [NCT05493371]	Phase 2	8 participants (Anticipated)	Interventional	2023-03-01	Recruiting
A Phase III Double-blind, Extension, Placebo-controlled Parallel Group Safety and Efficacy Trial of BI 10773 (10 and 25mg Once Daily) and Sitagliptin (100mg Once Daily) Given for Minimum 76 Weeks (Incl. 24 Weeks of Preceding Trial) as Monotherapy or With [NCT01289990]	Phase 3	2,705 participants (Actual)	Interventional	2011-02-28	Completed
Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection Fraction [NCT05778084]	Phase 4	60 participants (Anticipated)	Interventional	2022-12-15	Recruiting
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Desp [NCT01159600]	Phase 3	1,504 participants (Actual)	Interventional	2010-07-31	Completed
Efficacy of Empagliflozin in Patients With Heart Failure and Atrial Fibrillation [NCT04583813]	Phase 4	400 participants (Anticipated)	Interventional	2021-09-30	Not yet recruiting
Post Marketing Surveillance in Japan on Long Term Drug Use of JARDIANCE® Tablets in Patients With Type 2 Diabetes Mellitus [NCT02489942]		8,145 participants (Actual)	Observational	2015-06-12	Completed
A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovas [NCT01131676]	Phase 3	7,064 participants (Actual)	Interventional	2010-07-31	Completed
A Phase III Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 and Sitagliptin Administered Orally Over 24 Weeks, in Drug naïve Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despit [NCT01177813]	Phase 3	986 participants (Actual)	Interventional	2010-07-31	Completed
"Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: NATRIURETIC Trial" [NCT04535960]	Phase 2	36 participants (Anticipated)	Interventional	2019-01-24	Recruiting
Assessment of the Effect of 25 mg and 200 mg of BI 10773 as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind, Five-period Crossover Phase-I-study With Moxifloxacin as Positive Control [NCT01195675]	Phase 1	30 participants (Actual)	Interventional	2010-08-31	Completed
The Effect of Empagliflozin on Peripheral Microvascular Dysfunction in Heart Failure With [NCT06046612]	Phase 4	48 participants (Anticipated)	Interventional	2023-02-13	Recruiting
Comparative Cardiovascular and Renal Effectiveness and Safety of Empagliflozin and Other SGLT2i in Patients With Type 2 Diabetes (T2D) With and Without Baseline Kidney Disease in the United States [NCT05465317]		30,400 participants (Actual)	Observational	2022-08-08	Completed
A Double-blind, Randomised, Parallel Group Efficacy and Safety Study of BI 10773 (5 mg, 10 mg, 25 mg, and 50 mg) Compared to Placebo When Administered Orally Once Daily Over 12 Weeks, as Monotherapy, in Patients With Type 2 Diabetes and Insufficient Glyca [NCT01193218]	Phase 2	547 participants (Actual)	Interventional	2010-09-30	Completed
A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel Group Safety and Efficacy Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) During 52 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control on [NCT01306214]	Phase 3	566 participants (Actual)	Interventional	2011-02-28	Completed
Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction [NCT05600387]	Phase 4	100 participants (Anticipated)	Interventional	2022-11-05	Enrolling by invitation
The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD) [NCT06128096]		360 participants (Anticipated)	Observational	2022-06-01	Recruiting
Comparative Study of DPP-4 Inhibitors and SGLT-2 Inhibitors in Egyptian Diabetic Patients [NCT05359341]		175 participants (Actual)	Interventional	2020-09-20	Completed
Comparison Between the Efficacy of Sodium-Glucose Co-transporter 2 Inhibitor Therapy Versus Angiotensin-converting Enzyme Inhibitor in the Treatment of Diabetic Kidney Disease [NCT05373004]	Phase 2/Phase 3	212 participants (Anticipated)	Interventional	2023-03-31	Not yet recruiting
Effect of a Quadruple Therapy on Pancreatic Islet Function, Insulin Resistance and Cardiovascular Function in Patients With Mixed Prediabetes and Obesity: Randomized Clinical Trial [NCT04131582]	Phase 3	34 participants (Anticipated)	Interventional	2019-09-01	Recruiting
SGLT2 Inhibition With Empagliflozin in Patients With Type 2 Diabetes Mellitus: Influences on Left Ventricular Mass, Function, and Cardiac Lipid Content [NCT02728453]	Phase 4	7 participants (Actual)	Interventional	2016-04-27	Terminated(stopped due to Insufficient recruitment.)
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Trial of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite a Backgro [NCT01210001]	Phase 3	499 participants (Actual)	Interventional	2010-09-30	Completed
Effect of Sodium Glucose co Transporter 2 (SGLT2) Inhibition on Optical Coherence Tomography Angiography (OCT-A) Parameters in Diabetic Chronic Kidney Disease (CKD) [NCT04215445]	Phase 4	90 participants (Anticipated)	Interventional	2019-12-01	Recruiting
Investigation of the Effect of Food on the Bioavailability of Empagliflozin / Linagliptin Fixed Dose Combination Tablet in an Open, Randomised, Single Dose, Two Way Cross-over Study in Healthy Japanese Male Subjects [NCT02815644]	Phase 1	22 participants (Actual)	Interventional	2016-07-15	Completed
A Phase II, Randomised, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Once Daily Oral Administration of BI 10773 (1 mg, 5 mg, 10 mg, and 25 mg) for 28 Days in Japanese Pat [NCT00885118]	Phase 2	100 participants (Actual)	Interventional	2009-04-30	Completed
Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study [NCT02874807]	Phase 2/Phase 3	88 participants (Actual)	Interventional	2016-09-05	Completed
A Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Administration of Fixed-dose Combination of DW6014 and Loose Combination of Each Component in Healthy Adult Volunteers in Fasted Condition [NCT05823870]	Phase 1	32 participants (Actual)	Interventional	2023-02-24	Completed
Randomized, Double-blind, Placebo-controlled Crossover Trial Assessing the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass [NCT05057819]	Phase 4	22 participants (Actual)	Interventional	2021-12-01	Completed
The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes [NCT02964715]	Phase 4	25 participants (Anticipated)	Interventional	2016-11-30	Recruiting
ELMI - Prospective, Randomized, Controlled, Parallel-arm Study to Assess the Effects of the Combined Therapy of Empagliflozin and Linagliptin Compared to Metformin and Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes [NCT02752113]	Phase 3	101 participants (Actual)	Interventional	2016-04-30	Completed
A Randomized, Double-blind, Parallel-group, 2-treatment Multiple Dose Study to Assess the Intestinal, Metabolic and Cardiovascular Effects of an 8 Weeks Treatment With Sotagliflozin QD as Compared With Empagliflozin Once a Day (QD) in Type 2 Diabetes Mell [NCT03462069]	Phase 2	41 participants (Actual)	Interventional	2018-03-12	Completed
A Prospective, Randomized, Open Label, Parallel, 12-month Study to Explore and Evaluate the Therapeutic Effects ofLiraglutide, Empagliflozin and Linagliptin on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in T2DM Patients [NCT05313529]		324 participants (Anticipated)	Interventional	2022-10-08	Recruiting
The Impact Of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus [NCT06117137]	Phase 3	150 participants (Anticipated)	Interventional	2023-11-15	Not yet recruiting
A Phase IV, Single-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study on the Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Individuals With Type 2 Diabetes [NCT02932436]	Phase 4	144 participants (Actual)	Interventional	2016-10-10	Completed
Relative Bioavailability of a 12.5 mg BI 10773 / 1000 mg Metformin Fixed Dose Combination Tablet Compared With Its Monocomponents and Administered With and Without Food (an Open-label, Randomised, Single-dose, Three-way Crossover, Phase I Trial in Healthy [NCT01211197]	Phase 1	16 participants (Actual)	Interventional	2010-10-31	Completed
Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus [NCT04665284]	Phase 4	244 participants (Actual)	Interventional	2019-06-01	Completed
Cardiovascular Outcomes, and Mortality in Danish Patients With Type 2 Diabetes Who Initiate Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA): A Danish Nationwide Comparative Effectiveness Study [EMPLACEtm] [NCT03993132]		57,000 participants (Actual)	Observational	2018-10-01	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Empagliflozin in Patients With Acute Heart Failure [NCT05392764]	Phase 3	500 participants (Anticipated)	Interventional	2022-09-10	Recruiting
Effectivity of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes [NCT06145360]	Phase 4	150 participants (Anticipated)	Interventional	2023-12-31	Recruiting
The Efficacy and Safety of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase 4 Inhibitor Added to Premix Insulin Injection Twice Daily in Uncontrolled Type 2 Diabetes Patients [NCT03458715]	Phase 4	120 participants (Anticipated)	Interventional	2017-09-21	Recruiting
Combined Efficacy and Safety of an Early, Intensive, Management Strategy With Finerenone and SGLT2 Inhibitor in Patients Hospitalized With Heart Failure (CONFIRMATION-HF) [NCT06024746]	Phase 3	1,500 participants (Anticipated)	Interventional	2024-02-29	Not yet recruiting
The Physiological and Cardiovascular Effects of Empagliflozine in Type 2 Diabetes [NCT02918591]		10 participants (Anticipated)	Interventional	2017-11-30	Not yet recruiting
Long-term Effectiveness and Safety of Empagliflozin-based Quadruple Oral Antidiabetic Agents Therapy Compared to Basal Insulin-based Combination Therapy in Patients With Type 2 Diabetes [NCT05103306]		300 participants (Anticipated)	Observational [Patient Registry]	2017-01-31	Active, not recruiting
Glucose Metabolism in South Asian Women With IGT or IFG. DIAbetes in South Asians - DIASA 3: A 12-week Intervention Trial With Oral Antidiabetic Medication to Improve Hepatic and Whole Body Insulin Sensitivity [NCT04662866]	Phase 2	64 participants (Anticipated)	Interventional	2021-02-10	Recruiting
Renal Mechanistic Effects of Acute and Chronic Empagliflozin in Heart Failure [NCT05553938]	Phase 1	60 participants (Anticipated)	Interventional	2023-08-04	Recruiting
Effects of Empagliflozin in Reducing Oxidative Stress of Diabetic Recipients After Kidney Transplantation [NCT04918407]		40 participants (Anticipated)	Interventional	2022-01-01	Recruiting
EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction [NCT05020704]	Phase 4	100 participants (Anticipated)	Interventional	2021-11-01	Not yet recruiting
Evaluating the Short-Term Renal and Systemic Effects of SGLT2 Inhibition in Non-Diabetic Patients at Risk of Accelerated GFR Decline Because of Glomerular Hyperfiltration: a Sequential OFF-ON-OFF Study With One-Month Empagliflozin Therapy Followed by One- [NCT04143581]	Phase 2	0 participants (Actual)	Interventional	2021-09-03	Withdrawn(stopped due to Lack of funds)
Bioequivalence of Empagliflozin/Metformin (850 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open-label, Randomised, Single-dose, Four-way Crossover Study [NCT01672788]	Phase 1	36 participants (Actual)	Interventional	2012-08-31	Completed
The Effect of Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients [NCT03271879]	Phase 4	128 participants (Anticipated)	Interventional	2018-02-15	Not yet recruiting
An Open-label, Phase II Study to Determine Acute (After the First Dose Administration) and Chronic (After 28 Days of Treatment) Effects of the Sodium-glucose Co-transporter-2 (SGLT-2) Inhibitor Empagliflozin (BI 10773) (25 mg Once Daily) on Pre and Postpr [NCT01248364]	Phase 2	91 participants (Actual)	Interventional	2010-11-30	Completed
[NCT02964572]		61 participants (Actual)	Interventional	2016-11-30	Completed
Relative Bioavailability of Both BI 10773 50 mg and Pioglitazone 45 mg After Co-administration Compared to BI 10773 and Pioglitazone Alone in Healthy Male Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study) [NCT02276365]	Phase 1	20 participants (Actual)	Interventional	2009-06-30	Completed
Randomised, Open-label and Parallel Group Trial to Investigate the Effects of Oral BI 685509 Alone or in Combination With Empagliflozin on Portal Hypertension After 8 Weeks Treatment in Patients With Clinically Significant Portal Hypertension (CSPH) in Co [NCT05282121]	Phase 2	80 participants (Anticipated)	Interventional	2022-05-26	Recruiting
A Parallel-group Treatment, Phase 2, Double-blind, Three-arm Study to Assess Efficacy and Safety of Finerenone Plus Empagliflozin Compared With Either Finerenone or Empagliflozin Alone in Participants With Chronic Kidney Disease and Type 2 Diabetes. [NCT05254002]	Phase 2	807 participants (Anticipated)	Interventional	2022-06-23	Recruiting
Relative Bioavailability of Single Dose BI 10773 Co-administered With Multiple Doses of 600 mg Gemfibrozil Bid Compared to Single Dose Treatment of BI 10773 Alone in Healthy Volunteers - a Phase I, Open-label, Randomised, 2-way Crossover Trial [NCT01301742]	Phase 1	18 participants (Actual)	Interventional	2011-02-28	Completed
An Open-label, Two-period, Fixed-sequence Trial to Evaluate the Effect of Multiple Doses of BI 10773 on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Volunteers [NCT01328184]	Phase 1	18 participants (Actual)	Interventional	2011-04-30	Completed
Assessment of Safety and Efficacy of Sodium Glucose Co-transporter 2 Inhibitors Among Lupus Nephritis Patients [NCT06113900]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
Role of Empagliflozin in Kidney Dysfunction and Podocyte Specific Injury in African American Veterans With Non-Diabetic Chronic Kidney Disease (CKD) [NCT06110130]	Phase 4	60 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
Head-to-head Comparison of Quadruple Combination Therapy With Empagliflozin and Dapagliflozin in Patients With Poorly Controlled Type 2 Diabetes (T2D) Despite Three Existing Oral Antidiabetic Drugs (OAD) [NCT03748810]		600 participants (Actual)	Observational [Patient Registry]	2016-01-01	Completed
Relative Bioavailability of Empagliflozin/Metformin Fixed-dose Combination - Empagliflozin 12.5 mg + Metformin 850mg (Boehringer Ingelheim) Coated Tablet Versus Jardiance® 10mg (Reference 1: Boehringer Ingelheim) Coated Tablet and Glifage® 850mg (Referenc [NCT05083949]	Phase 1	32 participants (Actual)	Interventional	2021-07-23	Completed
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellit [NCT01164501]	Phase 3	741 participants (Actual)	Interventional	2010-07-31	Completed
Relative Bioavailability of BI 10773 and Simvastatin After Single and Combined Administration - an Open-label, Randomised, Crossover Trial in Healthy Subjects [NCT01304329]	Phase 1	18 participants (Actual)	Interventional	2011-02-28	Completed
Relative Bioavailability of 25 mg BI 10773 (Final Formulation) Compared to 25 mg BI 10773 XX (Trial Formulation 2) Following Oral Administration in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Study) [NCT01242176]	Phase 1	24 participants (Actual)	Interventional	2010-11-30	Completed
Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet and Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets in an Open, Randomised, Single Dose, Three-period Cross-over Study in Healthy M [NCT01451775]	Phase 1	18 participants (Actual)	Interventional	2011-10-31	Completed
Effects of SGLT-2 Inhibitor on Myocardial Perfusion, Function and Metabolism in Type 2 DM Patients at High Cardiovascular Risk: The SIMPle Randomized Clinical Trial [NCT03151343]	Phase 3	92 participants (Actual)	Interventional	2017-03-29	Completed
Real World Observation of SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients With Acute Myocardial Infarction, a Prospective, Multi-center Registry Study [NCT05770687]		1,000 participants (Anticipated)	Observational	2020-08-01	Recruiting
A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-3) [NCT02580591]	Phase 3	977 participants (Actual)	Interventional	2015-12-22	Completed
An Open-label 8-week Adjunctive-to-insulin and Renal Mechanistic Pilot Trial of BI 10773 in Type 1 Diabetes Mellitus (the ATIRMA Trial) [NCT01392560]	Phase 2	52 participants (Actual)	Interventional	2011-06-30	Completed
Post-authorisation Safety Study to Assess the Risk of Urinary Tract Malignancies in Relation to Empagliflozin Exposure in Patients With Type 2 Diabetes: a Multi-database European Study [NCT03464045]		98,000 participants (Actual)	Observational	2016-11-16	Active, not recruiting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Weeks Treatment With Three Oral Doses of BI 10773 as Tablets in Female and Male Patients With Type 2 Diabetes [NCT00558571]	Phase 1	78 participants (Actual)	Interventional	2008-01-31	Completed
SGLT2-inhibition With Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema (The SUPER-Trial) [NCT02985242]	Phase 4	6 participants (Actual)	Interventional	2017-06-12	Terminated(stopped due to difficulties to recruit planned numbers of patients within reasonable time frame)
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study [NCT05220917]		781,430 participants (Anticipated)	Observational	2021-08-01	Active, not recruiting
Empagliflozin Effect on Glucose Toxicity in Type 2 Diabetes Patients - a Randomized, Open-label, Controlled, Parallel Group, Exploratory Study [NCT03437330]	Phase 4	50 participants (Anticipated)	Interventional	2021-10-27	Active, not recruiting
Comparative Effects of Empagliflozin Versus Glimepiride After 26-weeks of Treatment Add on Metformin on Myocardial Metabolic Rate of Glucose Estimated Through 18FDG-PET in Patients With Type 2 Diabetes [NCT04183868]	Phase 4	26 participants (Actual)	Interventional	2016-04-30	Completed
Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors, Ketones, and Cardiovascular Benefit Research Plan [NCT05057806]	Early Phase 1	30 participants (Anticipated)	Interventional	2021-01-13	Recruiting
Empagliflozin in CFRD: Efficacy and Safety of SGLT2 Inhibitor Therapy in Overweight and Obese Subjects With Cystic Fibrosis-related Diabetes: a Pilot Study [NCT06149793]	Phase 2/Phase 3	15 participants (Anticipated)	Interventional	2023-12-30	Not yet recruiting
Effect of Empagliflozin on Cardiac Output in Patients With Acute Heart Failure (EMPA Acute Heart Failure) [NCT03554200]	Phase 2	19 participants (Actual)	Interventional	2018-06-11	Terminated(stopped due to COVID 19)
Uric Acid Excretion Study: Open-label Randomised Cross Over Study [NCT05210517]	Phase 4	10 participants (Actual)	Interventional	2020-10-01	Completed
A Single Arm, Open Label, Pilot Study to Evaluate the Safety and Efficacy of Once Daily 25mg Empagliflozin in Patients on Peritoneal Dialysis With Residual Kidney Function [NCT05715814]	Phase 3	20 participants (Anticipated)	Interventional	2024-02-01	Not yet recruiting
In-hospital Initiation of Empagliflozin for the Treatment of New-onset Acute Heart Failure Regardless of Ejection Fraction: A Pilot Study [NCT05556044]	Phase 3	200 participants (Anticipated)	Interventional	2022-09-27	Recruiting
Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients With Type 2 Diabetes [NCT02998970]	Phase 4	97 participants (Actual)	Interventional	2017-01-31	Active, not recruiting
A Randomized, Active-comparator Controlled, Parallel-group Study, to Evaluate the Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With Type 2 Diabetes Mellitus [NCT05140694]	Phase 4	135 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
Characteristics of Patients Initiating Empagliflozin or Other Non-insulin Glucose Lowering Drugs in the United Kingdom [NCT03050619]		31,908 participants (Actual)	Observational	2016-09-10	Completed
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release (10 mg/1000 mg) Compared With the Free Combination of Empagliflozin and Metformin Extended Release Tablets in Healthy Subjects Following a High-fat, High-caloric [NCT02266472]	Phase 1	30 participants (Actual)	Interventional	2014-11-30	Completed
Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects [NCT03027960]	Phase 1	21 participants (Actual)	Interventional	2017-06-27	Completed
A Phase II, Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Once Daily, Oral Doses of Empagliflozin as Adjunctive to Insulin Therapy for 28 Day [NCT02702011]	Phase 2	48 participants (Actual)	Interventional	2016-03-20	Completed
A Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Once Daily Oral Administration of BI 10773 25 mg/Linagliptin 5 mg and BI 10773 10 mg/Linagliptin 5 mg Fixed Dose Combination Tablets Compared With the Indivi [NCT01422876]	Phase 3	1,405 participants (Actual)	Interventional	2011-08-31	Completed
Efficacy and Safety of Empagliflozin in Patients With Glycogen Storage Disease Type Ib [NCT05960617]	Phase 2	10 participants (Anticipated)	Interventional	2023-07-15	Recruiting
Impact of SGLT2 on Glucosuria in HNF1A-MODY [NCT05417646]		21 participants (Actual)	Interventional	2022-06-22	Completed
A Phase 1 Study of Empagliflozin as Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency [NCT05078879]	Phase 1	10 participants (Anticipated)	Interventional	2021-11-16	Recruiting
Replication of the EMPA-REG OUTCOME Diabetes Trial in Healthcare Claims [NCT04215536]		103,752 participants (Actual)	Observational	2019-07-08	Completed
A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Jardiance® (Empagliflozin, 10mg) in Korean Patients With Chronic Heart Failure (NYHA Class II-IV) [NCT05236673]		600 participants (Anticipated)	Observational	2022-07-27	Recruiting
Use of Combination Empagliflozin/Linagliptin or Dapagliflozin/Saxagliptin vs Empagliflozin or Dapagliflozin Alone, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections. [NCT04735042]		60 participants (Anticipated)	Observational	2020-10-07	Recruiting
Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes: a Randomized, Placebo-controlled Study [NCT05174507]	Phase 2	26 participants (Anticipated)	Interventional	2022-06-24	Active, not recruiting
Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure (EMPATHY) - a Phase III Trial. [NCT05776043]	Phase 3	1,364 participants (Anticipated)	Interventional	2022-03-15	Recruiting
The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study. [NCT04342819]	Phase 2/Phase 3	25 participants (Actual)	Interventional	2020-01-01	Completed
Relative Bioavailability of Both BI 10773 and Warfarin and Pharmacodynamics of Warfarin After Co-administration Compared to Multiple Oral Doses of BI 10773 (25 mg Once Daily) and a Single Oral Dose of Warfarin (25 mg) Alone in Healthy Male Volunteers (an [NCT01111331]	Phase 1	18 participants (Actual)	Interventional	2010-05-31	Completed
Pharmacokinetics and Pharmacodynamics of BI 10773 After Single and Multiple Oral Dose of 10 mg and 25 mg BI 10773 in Chinese Male and Female Type 2 Diabetic Patients [NCT01316341]	Phase 1	24 participants (Actual)	Interventional	2011-03-31	Completed
The Effect of Empagliflozin Versus Metformin on Hormonal, Metabolic and Cardiovascular Risk Factors in Patients With Polycystic Ovary Syndrome (PCOS) - a Randomised Open-label Parallel Study. [NCT03008551]	Phase 2/Phase 3	40 participants (Actual)	Interventional	2017-08-18	Completed
Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics With Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM) [NCT04541797]		160 participants (Anticipated)	Interventional	2020-10-01	Recruiting
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release (25 mg/1000 mg) Compared With the Free Combination of Empagliflozin and Metformin Extended Release Tablets in Healthy Subjects Following a High-fat, High-caloric [NCT02230995]	Phase 1	30 participants (Actual)	Interventional	2014-09-30	Completed
Efficacy and Safety Of Different Hypoglycemic Regimens Compared With Premixed Insulin In Patients With Type 2 Diabetes Receiving Short-term Intensive Insulin Therapy [NCT05545800]	Phase 3	78 participants (Anticipated)	Interventional	2022-09-01	Recruiting
Evaluating the Safety and Efficacy of Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients.A Double-Blind, Randomized, Placebo-Controlled Trial [NCT05669742]	Phase 3	40 participants (Anticipated)	Interventional	2023-01-31	Not yet recruiting
A Double-blind, Placebo Controlled, Cross-over Renal Mechanistic Trial to Assess the Effect of Adding Empagliflozin Versus Placebo on Renal Hyperfiltration on a Background of the Angiotensin Converting Enzyme Inhibitor (ACEi) Ramipril: BETWEEN Study [NCT02632747]	Phase 2	31 participants (Actual)	Interventional	2016-05-10	Completed
CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients [NCT04906213]	Phase 2	72 participants (Anticipated)	Interventional	2022-07-25	Recruiting
Evaluation of Efficacy and Safety of Empagliflozin in Treatment of Neutropenia in Patients With Glycogenosis Ib [NCT04930627]	Phase 2	20 participants (Anticipated)	Interventional	2021-07-31	Not yet recruiting
Investigating the Protective Effect of Newer Antidiabetic Drugs on Cognitive Decline in Diabetic Patients [NCT05347459]		100 participants (Anticipated)	Observational	2022-03-02	Recruiting
Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease [NCT05638880]	Phase 2	60 participants (Anticipated)	Interventional	2022-12-20	Recruiting
Effect of Dulaglutide vs Empagliflozin on Non-alcoholic Fatty Liver Disease of Patients With Type 2 Diabetes Mellitus [NCT05946148]		78 participants (Actual)	Observational	2018-06-01	Completed
Comparative Clinical Study to Evaluate the Possible Beneficial Effect of Empagliflozin Versus Pioglitazone on Non-diabetic Patients With Non-Alcoholic Steatohepatitis [NCT05605158]	Phase 3	56 participants (Anticipated)	Interventional	2022-11-30	Not yet recruiting
CORDIALLY® - CEE: Characteristics of Patients With Type 2 Diabetes Treated With Modern Antidiabetic Drugs. A Real World Data Collection of Patient Baseline Characteristics, Treatment Patterns and Comorbidities in Central Eastern European (CEE) Countries [NCT03807440]		4,083 participants (Actual)	Observational	2019-08-26	Completed
An Open-label Mechanistic Study to Examine the Effect of Oral Empagliflozin (25 mg q.d.) on Kinetics of Renal Glucose Reabsorption in Patients With Type 2 Diabetes Mellitus and Healthy Controls [NCT01867307]	Phase 2	39 participants (Actual)	Interventional	2013-06-30	Completed
Bioequivalence of Empagliflozin/Metformin (500 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open-label, Randomised, Single-dose, Four-way Crossover Study [NCT01844531]	Phase 1	24 participants (Actual)	Interventional	2013-04-30	Completed
A Phase III, Randomised, Double-blind, Parallel Group, 52 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin and Linagliptin Fixed Dose Combination Compared With Linagliptin Plus Placebo in Japanese Type 2 Diabetes Mellitus Patients Wi [NCT02453555]	Phase 3	275 participants (Actual)	Interventional	2015-05-14	Completed
National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia. [NCT04602754]	Phase 3	228 participants (Anticipated)	Interventional	2023-03-31	Not yet recruiting
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single 50 mg Dose of BI 10773 in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Type 2 Diabetes and Normal Renal Function in a Monocentric, Open-label, Pa [NCT01907113]	Phase 1	40 participants (Actual)	Interventional	2009-07-31	Completed
A 28-day Randomised, Placebo-controlled, Double-blind Parallel Group Phase IIa Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once Daily Oral Doses of 2.5 mg, 10 mg, and 25 mg Empagliflozin as Adjunctive to Insulin in P [NCT01969747]	Phase 2	75 participants (Actual)	Interventional	2013-11-30	Completed
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging [NCT02833415]	Phase 4	40 participants (Actual)	Interventional	2016-03-31	Completed
Renal and Cardiovascular Effect of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibition in Combination With Loop Diuretics in Diabetic Patients With Chronic Heart Failure [NCT03226457]	Phase 4	23 participants (Actual)	Interventional	2017-12-11	Completed
Use of Empagliflozin to Treat Prediabetes - a Randomized, Double-blind, Placebo-controlled 13-week Intervention Trial [NCT05426525]	Phase 4	40 participants (Anticipated)	Interventional	2022-10-13	Recruiting
Treatment of T2DM Patients in Germany Receiving Empagliflozin: A Retrospective RWE Study Description of Treatment and Population Characteristics of Type 2 Diabetic Patients in Germany Receiving Empagliflozin: A Retrospective Real-World Evidence (RWE) Stud [NCT04098575]		9,571 participants (Actual)	Observational	2019-09-16	Completed
A Randomised, Open-label, Three-way Crossover Trial to Investigate the Effect of Rifampicin and Probenecid on Empagliflozin Pharmacokinetics in Healthy Male and Female Subjects [NCT01634100]	Phase 1	18 participants (Actual)	Interventional	2012-06-30	Completed
Comparing the Effects of Empagliflozin and Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity [NCT06140108]	Phase 2/Phase 3	70 participants (Anticipated)	Interventional	2023-12-15	Recruiting
Is the Stepping-down Approach a Better Option Than Multiple Daily Injections in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy? [NCT02846233]		22 participants (Actual)	Interventional	2016-08-31	Completed
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of Empagliflozin (10mg, 25mg) Administered Orally, Once Daily Over 24 Weeks in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus [NCT02182830]	Phase 3	166 participants (Actual)	Interventional	2014-07-25	Completed
Which Oral Combination of Anti-diabetes Medication May Work Better in Subjects With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: a Randomized Control Trial [NCT04976283]	Phase 4	123 participants (Anticipated)	Interventional	2021-09-15	Recruiting
Evaluation of Empagliflozin Effect Against Doxorubicin Induced Cardiomyopathy [NCT06103279]	Phase 2/Phase 3	40 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
The Use of Empagliflozin in Patients With Hypertrophic Cardiomyopathy [NCT05182658]	Phase 3	250 participants (Anticipated)	Interventional	2022-06-01	Recruiting
Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery disease_ELITE Trial [NCT03208465]	Phase 4	100 participants (Actual)	Interventional	2017-08-07	Completed
Evaluation of Safety and Efficacy of Empagliflozin for Neutropenia and Neutrophil Dysfunction in Children With Glycogen Storage Disease Type 1b (GSD1b) [NCT04986735]		11 participants (Anticipated)	Observational	2021-08-08	Recruiting
Randomized, Double-blind, Placebo Controlled, Crossover Clinical Study to Analyse the Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function [NCT02471963]	Phase 3	74 participants (Actual)	Interventional	2014-12-31	Completed
Effects on Blood Pressure and Central Sympathetic Nerve Traffic by SGLT2-inhibition With Empagliflozin Compared to Hydrochlorothiazide in Patients With Type 2 Diabetes Mellitus [NCT03254849]	Phase 4	75 participants (Actual)	Interventional	2017-12-08	Completed
Effect of Empagliflozin on Urinary Excretion of Adenosine and on Markers of Osteocyte Function and Glomerular Damage in Diabetic and Non-diabetic Patients With Chronic Kidney Disease [NCT04961931]		45 participants (Anticipated)	Interventional	2019-01-01	Recruiting
[NCT03050229]	Phase 4	174 participants (Actual)	Interventional	2017-01-31	Completed
A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus [NCT02597049]	Phase 3	424 participants (Actual)	Interventional	2015-11-30	Completed
A 52-week Randomised, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Empagliflozin Once Daily, as an add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control [NCT02589639]	Phase 4	269 participants (Actual)	Interventional	2015-10-28	Completed
An Open-label, Randomised, Single-dose, Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Two Fixed Dose Combination Tablets of Empagliflozin 12.5 mg and Metformin 500 mg Compared With the Free Combination of Em [NCT02577315]	Phase 1	25 participants (Actual)	Interventional	2015-09-30	Completed
Empagliflozin in Early Diabetic Kidney Disease [NCT03173963]	Phase 3	0 participants (Actual)	Interventional	2017-05-27	Withdrawn(stopped due to Original drug sponsor withdrew from study, replacement sponsor not obtained.)
SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI) [NCT05037695]	Phase 4	40 participants (Anticipated)	Interventional	2021-07-21	Recruiting
Decrease in Body Fat and Increase in Ketone Body After 6-month Treatment of Empagliflozin in Korean Patients With Type 2 Diabetes [NCT03877406]	Phase 4	200 participants (Anticipated)	Interventional	2018-08-01	Recruiting
Effect of Empagliflozin on the Renin-angiotensin System in Patients With Chronic [NCT03078101]	Phase 2	51 participants (Actual)	Interventional	2017-04-15	Completed
Effects of SGLT-2 Inhibition on Sympathetic Nervous System Activity in Humans [NCT03912909]	Phase 4	30 participants (Anticipated)	Interventional	2018-08-01	Recruiting
An Open-label, Randomised, Multicentre, Single-dose, Parallel Group Trial to Evaluate Pharmacokinetics and Pharmacodynamics of Empagliflozin in Children and Adolescents From 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus [NCT02121483]	Phase 1	27 participants (Actual)	Interventional	2014-06-30	Completed
Relative Bioavailability of Two Newly Developed FDC Tablet Strengths (25mg/1000mg and 12.5mg/750mg) of Empagliflozin/Metformin Extended Release Compared With the Free Combination of Empagliflozin and Metformin Extended Release in Healthy Subjects (an Open [NCT01975220]	Phase 1	72 participants (Actual)	Interventional	2013-10-31	Completed
A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to inSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2) [NCT02414958]	Phase 3	730 participants (Actual)	Interventional	2015-06-30	Completed
Post Marketing Surveillance in Japan on Drug Use of JARDIANCE® Tablets in Elderly Patients With Type 2 Diabetes Mellitus [NCT02367131]		423 participants (Actual)	Observational	2015-02-24	Completed
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Pati [NCT01719003]	Phase 3	1,413 participants (Actual)	Interventional	2012-10-31	Completed
National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia. [NCT04603508]	Phase 3	240 participants (Anticipated)	Interventional	2023-03-31	Not yet recruiting
Post-authorisation Safety Study in Patients With Type 2 Diabetes Mellitus to Assess the Risk of Acute Liver Injury, Acute Kidney Injury and Chronic Kidney Disease, Severe Complications of Urinary Tract Infection, Genital Infections, and Diabetic Ketoacido [NCT02864914]		99,000 participants (Actual)	Observational	2016-03-15	Completed
Clinical Study Evaluating the Efficacy and Safety of Metformin Versus Empagliflozin for Halting Chronic Kidney Disease Progression [NCT05373680]	Phase 2/Phase 3	90 participants (Anticipated)	Interventional	2022-01-01	Recruiting
Empagliflozin in ESKD - A Feasibility Study [NCT05687058]	Phase 1/Phase 2	24 participants (Anticipated)	Interventional	2023-10-01	Not yet recruiting
Relative Bioavailability of Empagliflozin (12.5 or 5 mg)/Metformin (850 mg or 500 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together to Healthy Chinese Male and Female Volunteers in an Open-label, Randomised, Single-dose, [NCT02102932]	Phase 1	96 participants (Actual)	Interventional	2014-05-31	Completed
Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes [NCT04203927]	Early Phase 1	50 participants (Anticipated)	Interventional	2020-02-01	Recruiting
A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy [NCT04520646]		10 participants (Anticipated)	Interventional	2020-09-01	Recruiting
Bioequivalence of Empagliflozin/Metformin Fixed Dose Combination Tablets Compared to Single Tablets Administered Together in Healthy Male and Female Volunteers Under Fed and Fasted Conditions (an Open-label, Randomised, Single-dose, Crossover Study) [NCT01811953]	Phase 1	48 participants (Actual)	Interventional	2013-03-31	Completed
Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between 25 mg BI 10773 and 25 mg Hydrochlorothiazide or 5 mg Torasemide Under Steady State Conditions in Patients With Type 2 Diabetes Mellitus in an Open-label, Randomised, Cross-over Tria [NCT01276288]	Phase 1	23 participants (Actual)	Interventional	2011-01-31	Completed
Anti-anginal and Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina:A Phase III, Multicentre, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg Administered Orally Once Daily) Compared t [NCT04143321]	Phase 4	75 participants (Actual)	Interventional	2018-09-10	Completed
Pharmacokinetics, Safety and Tolerability of BI 10773 50 mg Single Dose in Male and Female Subjects With Different Degrees of Liver Impairment (Child-Pugh Classification A, B and C) as Compared to Male and Female Healthy Subjects (a Non-blinded, Parallel [NCT01111318]	Phase 1	36 participants (Actual)	Interventional	2010-07-31	Completed
Comparative, Randomized, Single Dose, Two-way Crossover Bioequivalence Study to Determine the Bioequivalence of Empagliflozin & Metformin From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim Inter [NCT05132023]	Phase 1	26 participants (Actual)	Interventional	2019-03-26	Completed
Acute Effect of Empagliflozin vs Dapagliflozin vs Placebo Administration Over Pulse Wave Velocity in Patients With Type Two Diabetes [NCT05109949]	Phase 3	72 participants (Actual)	Interventional	2020-03-30	Active, not recruiting
Is SGLT2 Inhibitors a Better Prophylactic Agent Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease? A Multicenter Prospective Randomized Controlled Study [NCT04853615]		800 participants (Anticipated)	Observational	2021-07-01	Not yet recruiting
Effects of the SGLT2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-diabetic Subjects [NCT03093103]	Phase 2	45 participants (Actual)	Interventional	2017-03-16	Completed
Efficacy and Safety of Early Initiation of Oral Semaglutide 50 mg Once Daily Versus Empagliflozin 25 mg Once Daily in Younger Patients With Newly Diagnosed Type 2 Diabetes and Obesity [NCT05444153]	Phase 3	0 participants (Actual)	Interventional	2022-10-06	Withdrawn(stopped due to Sponsor decision)
Combined Active Treatment in Type 2 Diabetes With NASH [NCT04639414]	Phase 4	192 participants (Anticipated)	Interventional	2021-03-26	Recruiting
EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study Program [NCT03363464]		230,000 participants (Actual)	Observational	2017-10-16	Active, not recruiting
Relative Bioavailability of a Single Oral Dose of Digoxin (0.5 mg) When Administered Alone or in Combination With Multiple Oral Doses of BI 10773 (25 mg qd) in Healthy Male and Female Volunteers (an Open-label, Randomised, Two-way Crossover Study) [NCT01306175]	Phase 1	20 participants (Actual)	Interventional	2011-02-28	Completed
Relative Bioavailability of BI 10773 Given Alone and Together With Verapamil - an Open-label, Randomised, Crossover Trial in Healthy Subjects [NCT01276301]	Phase 1	16 participants (Actual)	Interventional	2011-01-31	Completed
National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus. [NCT04670666]	Phase 3	270 participants (Anticipated)	Interventional	2023-08-31	Not yet recruiting
Bioequivalence of Empagliflozin/Metformin (12.5mg/500mg) Fixed Dose Combination Tablets Compared to Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open Label, Randomised, Single Dose, Two Period, Two Sequence [NCT02028767]	Phase 1	32 participants (Actual)	Interventional	2014-01-31	Completed
A Phase III, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Linagliptin 5 mg Compared to Placebo, Administered as Oral Fixed Dose Combination With Empagliflozin 10 mg or 25 mg for 24 Weeks, in Patients With Type 2 Di [NCT01778049]	Phase 3	708 participants (Actual)	Interventional	2013-01-31	Completed
A Phase I, Open-label, Parallel-group Study to Investigate Pharmacokinetics, Pharmacodynamics and Safety of a Single 25 mg Dose of Empagliflozin in Japanese Type 2 Diabetes Patients With Different Degrees of Renal Impairment in Comparison to Type 2 Diabet [NCT01581658]	Phase 1	32 participants (Actual)	Interventional	2012-04-01	Completed
A Long-term, Randomized Study to Evaluate the Effects of Empagliflozin in Combination With Standard Hypoglycemic Therapy on Early and Long-term Results of Planned Percutaneous Coronary Interventions in Patients With Type 2 Diabetes. [NCT04497792]	Phase 4	40 participants (Actual)	Interventional	2016-11-30	Completed
The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1 [NCT06030843]	Phase 2/Phase 3	200 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
Efficacy and Safety of Early Initiation of Canagliflozin in Patients With Acute Decompansted Heart Failure [NCT05364190]	Phase 3	144 participants (Anticipated)	Interventional	2022-06-04	Recruiting
A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With [NCT01734785]	Phase 3	607 participants (Actual)	Interventional	2013-01-31	Completed
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function [NCT05972564]	Phase 1/Phase 2	74 participants (Anticipated)	Interventional	2023-09-06	Recruiting
Effectiveness of Empagliflozin on Cardiac-renal Injury in Patients With Acute ST-segment-elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention. [NCT03591991]		128 participants (Anticipated)	Interventional	2018-10-01	Not yet recruiting
Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes [NCT03132181]	Phase 2	40 participants (Actual)	Interventional	2017-04-24	Completed
Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. [NCT04662723]	Phase 4	878 participants (Anticipated)	Interventional	2023-05-01	Recruiting
SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus [NCT04201496]	Phase 1	34 participants (Actual)	Interventional	2020-02-24	Completed
Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study [NCT03202667]	Phase 2/Phase 3	17 participants (Actual)	Interventional	2017-12-15	Completed
Clinical and Economic Impact of 2nd Line Initiation of Empagliflozin After Metformin, as Compared to 2nd Line Initiation of Sulfonylurea After Metformin in Patients With Type 2 Diabetes and Cardiovascular Disease [NCT05102071]		0 participants (Actual)	Observational	2021-11-01	Withdrawn(stopped due to Study was canceled because database sample size was inadequate.)
A Randomized, Open-label, Multiple-dose, Cross-over Dosing Study to Evaluate Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin in Healthy Adults [NCT04431141]	Phase 1	32 participants (Actual)	Interventional	2020-09-15	Completed
A Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With the Sodium-glucose Transport Protein 2 (SGLT2) Inhibitor EmpaGliflozin in patiEnts With Non-alcoholic Steatohepatitis (NASH) and [NCT05232071]	Phase 2	63 participants (Anticipated)	Interventional	2022-06-29	Recruiting
Acute Effect of Dapagliflozin vs Empagliflozin Administration on Flow Mediated Dilation in Patients With Type 2 Diabetes Mellitus [NCT04195243]	Phase 3	24 participants (Anticipated)	Interventional	2019-12-02	Not yet recruiting
Dose Rationale for Dapagliflozin and Empagliflozin in Paediatric Heart Failure: a Phase II.a Pharmacokinetics, Ease-of-swallow, Safety and Proof-of-concept Study Among Children 6-18 Years of Age [NCT06012266]	Phase 2	12 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Sodium-Glucose CoTransporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production [NCT03852901]	Phase 1	21 participants (Actual)	Interventional	2019-03-28	Completed
A Randomised, Double-blind, Placebo-controlled, Parallel Group, 4-week Study to Evaluate the Efficacy of Empagliflozin (10 mg and 25 mg Administered Orally Once Daily) in Postprandial Glucose and 24-hour Glucose Variability in Japanese Patients With Type [NCT01947855]	Phase 3	60 participants (Actual)	Interventional	2013-09-30	Completed
Relative Bioavailability of Two Newly Developed FDC Tablet Strengths (10 mg/1000 mg and 5mg/750mg) of Empagliflozin/Metformin Extended Release Compared With the Free Combination of Empagliflozin and Metformin Extended Release in Healthy Subjects (an Open- [NCT02106923]	Phase 1	72 participants (Actual)	Interventional	2014-04-30	Completed
A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults With COVID-19 [NCT04505774]	Phase 4	880 participants (Actual)	Interventional	2020-09-04	Active, not recruiting
A Double-blind Randomized Study to Determine the Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With Prediabetes [NCT03227484]	Phase 2	42 participants (Actual)	Interventional	2017-06-09	Completed
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of [NCT01649297]	Phase 2	983 participants (Actual)	Interventional	2012-10-31	Completed
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Multiple Rising Oral Doses (2.5 mg to 100 mg) of BI 10773 Tablets in Male and Female Type 2 Diabetic Patients [NCT01924767]	Phase 1	48 participants (Actual)	Interventional	2007-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00558571 (19) [back to overview]	Cmax of Empagliflozin
NCT00558571 (19) [back to overview]	HbA1c
NCT00558571 (19) [back to overview]	Insulin AUEC0-5
NCT00558571 (19) [back to overview]	Insulin Emax (Maximum Measured Effect)
NCT00558571 (19) [back to overview]	Mean Daily Glucose (MDG) Measured in Blood
NCT00558571 (19) [back to overview]	t1/2 of Empagliflozin
NCT00558571 (19) [back to overview]	Tmax of Empagliflozin
NCT00558571 (19) [back to overview]	LI (Linearity Index).
NCT00558571 (19) [back to overview]	Fasting Plasma Glucose (FPG)
NCT00558571 (19) [back to overview]	AUC0-∞ of Empagliflozin
NCT00558571 (19) [back to overview]	Ae0-24 of Glucose
NCT00558571 (19) [back to overview]	Fasting Insulin
NCT00558571 (19) [back to overview]	Number of Subjects With Drug Related Adverse Events
NCT00558571 (19) [back to overview]	Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG
NCT00558571 (19) [back to overview]	CL/F of Empaglifozin
NCT00558571 (19) [back to overview]	fe0-24 of Empagliflozin
NCT00558571 (19) [back to overview]	Fructosamine
NCT00558571 (19) [back to overview]	Glucagon AUEC0-5
NCT00558571 (19) [back to overview]	Glucagon Emax (Maximum Measured Effect)
NCT00749190 (10) [back to overview]	Change of FPG From Baseline After 12 Weeks of Treatment
NCT00749190 (10) [back to overview]	Change of Body Weight After 12 Weeks of Treatment
NCT00749190 (10) [back to overview]	Change in Homeostasis Model Assessment Index for Insulin Resistance (HOMA-IR)
NCT00749190 (10) [back to overview]	Change in Homeostasis Model Assessment Index for Beta Cell Function (HOMA-%B)
NCT00749190 (10) [back to overview]	Change From Baseline to Week 12 in Fasting Plasma Insulin (FPI)
NCT00749190 (10) [back to overview]	Change From Baseline in HbA1c After 12 Weeks of Treatment
NCT00749190 (10) [back to overview]	Trough Concentrations of Empagliflozin in Plasma
NCT00749190 (10) [back to overview]	Change of HbA1c From Baseline Over Time
NCT00749190 (10) [back to overview]	Proportion of Patients Who Achieve an HbA1c Lowering of at Least 0.5% After 12 Weeks of Treatment
NCT00749190 (10) [back to overview]	Proportion of Patients Who Achieve an HbA1c ≤7.0% After 12 Weeks of Treatment
NCT00789035 (10) [back to overview]	Change of HbA1c From Baseline Over Time
NCT00789035 (10) [back to overview]	Trough Concentrations of Empagliflozin in Plasma
NCT00789035 (10) [back to overview]	Change in Homeostasis Model Assessment Index for Beta Cell Function (HOMA-%B)
NCT00789035 (10) [back to overview]	Change From Baseline to Week 12 in Fasting Plasma Insulin (FPI)
NCT00789035 (10) [back to overview]	Proportion of Patients Who Achieve an HbA1c Lowering of at Least 0.5% After 12 Weeks of Treatment
NCT00789035 (10) [back to overview]	Proportion of Patients Who Achieve an HbA1c ≤7.0% After 12 Weeks of Treatment
NCT00789035 (10) [back to overview]	Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment
NCT00789035 (10) [back to overview]	Change of FPG From Baseline After 12 Weeks of Treatment
NCT00789035 (10) [back to overview]	Change of Body Weight After 12 Weeks of Treatment
NCT00789035 (10) [back to overview]	Change in Homeostasis Model Assessment Index for Insulin Resistance (HOMA-IR)
NCT00881530 (8) [back to overview]	Change From Baseline to Week 78 in Lipid Parameters
NCT00881530 (8) [back to overview]	Change From Baseline in HbA1c Over Time
NCT00881530 (8) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) Over Time
NCT00881530 (8) [back to overview]	Hypoglycaemic Events
NCT00881530 (8) [back to overview]	Occurrence of a Relative Efficacy Response
NCT00881530 (8) [back to overview]	Occurrence of a Treat-to-target Response (HbA1c < 6.5%)
NCT00881530 (8) [back to overview]	Occurence of a Treat-to-target Response (HbA1c < 7.0%)
NCT00881530 (8) [back to overview]	Clinical Relevant Abnormalities for Physical Examination, Vital Signs, ECG and Laboratory Measurements
NCT00885118 (30) [back to overview]	t1/2,ss
NCT00885118 (30) [back to overview]	Vz/F
NCT00885118 (30) [back to overview]	Vz/F,ss
NCT00885118 (30) [back to overview]	CL/F,ss
NCT00885118 (30) [back to overview]	CL/F
NCT00885118 (30) [back to overview]	Change From Baseline in Urine Glucose Excretion
NCT00885118 (30) [back to overview]	Change From Baseline in the Area Under the Curve of Plasma Glucose Levels Until 4 Hours After Intake of a Standardised Food (Meal Tolerance Test)
NCT00885118 (30) [back to overview]	Change From Baseline in the Area Under the Curve of Insulin Levels Until 4 Hours After Intake of a Standardised Food (Meal Tolerance Test)
NCT00885118 (30) [back to overview]	Change From Baseline in the Area Under the Curve of Glucagon Levels Until 4 Hours After Intake of a Standardised Food (Meal Tolerance Test)
NCT00885118 (30) [back to overview]	Change From Baseline in HbA1c
NCT00885118 (30) [back to overview]	Change From Baseline in Fasting Plasma Glucose
NCT00885118 (30) [back to overview]	Change From Baseline in Fasting Insulin
NCT00885118 (30) [back to overview]	Change From Baseline in 8-point Glucose
NCT00885118 (30) [back to overview]	Change From Baseline in 1,5-anhydroglucitol
NCT00885118 (30) [back to overview]	AUCτ,ss
NCT00885118 (30) [back to overview]	AUCτ,1
NCT00885118 (30) [back to overview]	AUC0-tz
NCT00885118 (30) [back to overview]	AUC0-∞
NCT00885118 (30) [back to overview]	Ae0-24,ss
NCT00885118 (30) [back to overview]	Ae0-24
NCT00885118 (30) [back to overview]	Cmax
NCT00885118 (30) [back to overview]	Change From Baseline in Fructosamine
NCT00885118 (30) [back to overview]	Cmax,ss
NCT00885118 (30) [back to overview]	fe0-24
NCT00885118 (30) [back to overview]	fe0-24,ss
NCT00885118 (30) [back to overview]	RA,AUC
NCT00885118 (30) [back to overview]	RA,Cmax
NCT00885118 (30) [back to overview]	t1/2
NCT00885118 (30) [back to overview]	CLR,0-24
NCT00885118 (30) [back to overview]	CLR,ss
NCT01011868 (10) [back to overview]	Percent Change From Baseline in Fasting Plasma Glucose (FPG) After 18, 54 and 78 Weeks of Treatment
NCT01011868 (10) [back to overview]	Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5%) After 18, 54 and 78 Weeks of Treatment
NCT01011868 (10) [back to overview]	The Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <7.0% After 18, 54, and 78 Weeks of Treatment
NCT01011868 (10) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) After 18, 54 and 78 Weeks of Treatment
NCT01011868 (10) [back to overview]	Change From Baseline in Body Weight at Follow-up
NCT01011868 (10) [back to overview]	Change From Baseline in Body Weight After 18, 54 and 78 Weeks of Treatment
NCT01011868 (10) [back to overview]	Change From Baseline in Basal Insulin Dose/Day After 54 and 78 Weeks of Treatment
NCT01011868 (10) [back to overview]	Confirmed Hypoglycemic Events
NCT01011868 (10) [back to overview]	Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 18 Weeks of Treatment
NCT01011868 (10) [back to overview]	Change From Baseline in HbA1c After 54 and 78 Weeks of Treatment
NCT01111318 (14) [back to overview]	Apparent Clearance After Extravascular Administration (CL/F)
NCT01111318 (14) [back to overview]	Amount of Empagliflozin That is Eliminated in Urine (Ae0-96)
NCT01111318 (14) [back to overview]	Apparent Volume of Distribution During the Terminal Phase (Vz/F)
NCT01111318 (14) [back to overview]	Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01111318 (14) [back to overview]	Area Under the Curve 0 to Time of Last Quantifiable Data Point (AUC0-tz)
NCT01111318 (14) [back to overview]	Fraction of Empagliflozin Excreted Unchanged in Urine (fe0-96))
NCT01111318 (14) [back to overview]	Terminal Rate Constant (λz)
NCT01111318 (14) [back to overview]	Mean Residence Time (MRTpo)
NCT01111318 (14) [back to overview]	Renal Clearance After Extravascular Administration (CL R)
NCT01111318 (14) [back to overview]	Terminal Half-Life (t1/2)
NCT01111318 (14) [back to overview]	Time From Dosing to Maximum Concentration (Tmax)
NCT01111318 (14) [back to overview]	Urinary Glucose Excretion (UGE)
NCT01111318 (14) [back to overview]	Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Clinical Laboratory Tests and Assessment of Tolerability by the Investigator
NCT01111318 (14) [back to overview]	Maximum Measured Concentration (Cmax)
NCT01111331 (36) [back to overview]	Warfarin: Area Under the INR-time Curve From 0 to Last Measurable Data Point Adjusted to Baseline (INR AUEC0-tz,Base)
NCT01111331 (36) [back to overview]	Warfarin: Area Under the PT-time Curve From 0 to Last Measurable Data Point Adjusted to Baseline (PT AUEC0-tz,Base)
NCT01111331 (36) [back to overview]	Warfarin: Peak International Normalised Ratio (INRmax)
NCT01111331 (36) [back to overview]	Warfarin: Peak International Normalised Ratio Adjusted to Baseline (INRmax,Base)
NCT01111331 (36) [back to overview]	Warfarin: Peak Prothrombin Time (PTmax)
NCT01111331 (36) [back to overview]	Warfarin: Peak Prothrombin Time Adjusted to Baseline (PTmax,Base)
NCT01111331 (36) [back to overview]	Warfarin: Area Under the PT-time Curve From 0 to Last Measurable Data Point (PT AUEC0-tz)
NCT01111331 (36) [back to overview]	Warfarin R-enantiomers: Apparent Clearance After Extravascular Administration (CL/F)
NCT01111331 (36) [back to overview]	Warfarin R-enantiomers: Apparent Volume of Distribution Following Extravascular Administration (Vz/F)
NCT01111331 (36) [back to overview]	Warfarin R-enantiomers: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01111331 (36) [back to overview]	Warfarin R-enantiomers: Area Under the Curve 0 to Last Measurable Data Point (AUC0-tz)
NCT01111331 (36) [back to overview]	Warfarin R-enantiomers: Maximum Measured Concentration (Cmax)
NCT01111331 (36) [back to overview]	Warfarin R-enantiomers: Mean Residence Time After Oral Administration (MRTpo)
NCT01111331 (36) [back to overview]	Empagliflozin: Plasma Concentration 24 Hours After Administration of Dose (C24,N)
NCT01111331 (36) [back to overview]	Empagliflozin: Time to Maximum Plasma Concentration at Steady State (Tmax,ss)
NCT01111331 (36) [back to overview]	Warfarin R-enantiomers: Terminal Rate Constant (λz)
NCT01111331 (36) [back to overview]	Warfarin R-enantiomers: Time to Maximum Plasma Concentration (Tmax)
NCT01111331 (36) [back to overview]	Warfarin S-enantiomers: Apparent Clearance After Extravascular Administration (CL/F)
NCT01111331 (36) [back to overview]	Warfarin S-enantiomers: Apparent Volume of Distribution Following Extravascular Administration (Vz/F)
NCT01111331 (36) [back to overview]	Warfarin S-enantiomers: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01111331 (36) [back to overview]	Warfarin R-enantiomers: Terminal Half-life (t1/2)
NCT01111331 (36) [back to overview]	Warfarin S-enantiomers: Maximum Measured Concentration (Cmax)
NCT01111331 (36) [back to overview]	Warfarin S-enantiomers: Mean Residence Time After Oral Administration (MRTpo)
NCT01111331 (36) [back to overview]	Warfarin S-enantiomers: Terminal Half-life (t1/2)
NCT01111331 (36) [back to overview]	Warfarin S-enantiomers: Terminal Rate Constant (λz)
NCT01111331 (36) [back to overview]	Warfarin S-enantiomers: Time to Maximum Plasma Concentration (Tmax)
NCT01111331 (36) [back to overview]	Warfarin: Area Under the INR-time Curve From 0 to Last Measurable Data Point (INR AUEC0-tz)
NCT01111331 (36) [back to overview]	Warfarin S-enantiomers: Area Under the Curve 0 to Last Measurable Data Point (AUC0-tz)
NCT01111331 (36) [back to overview]	Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by Investigator
NCT01111331 (36) [back to overview]	Empagliflozin: Apparent Clearance at Steady State (CL/F,ss)
NCT01111331 (36) [back to overview]	Empagliflozin: Apparent Volume of Distribution Following Extravascular Administration (Vz/F,ss)
NCT01111331 (36) [back to overview]	Empagliflozin: Area Under the Curve for the Dosing Interval at Steady State (AUCτ,ss)
NCT01111331 (36) [back to overview]	Empagliflozin: Maximum Measured Concentration at Steady State(Cmax,ss)
NCT01111331 (36) [back to overview]	Empagliflozin: Mean Residence Time at Steady State After Oral Administration (MRTpo,ss)
NCT01111331 (36) [back to overview]	Empagliflozin: Terminal Half-life at Steady State (t1/2,ss)
NCT01111331 (36) [back to overview]	Empagliflozin: Terminal Rate Constant at Steady State (λz,ss)
NCT01131676 (7) [back to overview]	Percentage of Participants With New Onset Albuminuria
NCT01131676 (7) [back to overview]	Percentage of Participants With New Onset Macroalbuminuria
NCT01131676 (7) [back to overview]	Percentage of Participants With Silent MI
NCT01131676 (7) [back to overview]	Percentage of Participants With the Composite Microvascular Outcome
NCT01131676 (7) [back to overview]	Percentage of Participants With the Composite of All Events Adjudicated (4-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), Non-fatal Stroke and Hospitalization for Unstable Angina Pectoris
NCT01131676 (7) [back to overview]	Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke.
NCT01131676 (7) [back to overview]	Percentage of Participants With Heart Failure Requiring Hospitalisation (Adjudicated)
NCT01159600 (4) [back to overview]	Mean Daily Plasma Glucose (MDG) Change From Baseline
NCT01159600 (4) [back to overview]	Confirmed Hypoglycaemic Adverse Events
NCT01159600 (4) [back to overview]	Body Weight Change From Baseline
NCT01159600 (4) [back to overview]	HbA1c Change From Baseline
NCT01164501 (4) [back to overview]	HbA1c Change From Baseline in Patients With Moderate Renal Impairment
NCT01164501 (4) [back to overview]	HbA1c Change From Baseline in Patients With Mild or Moderate Renal Impairment
NCT01164501 (4) [back to overview]	HbA1c Change From Baseline in Patients With Mild Renal Impairment
NCT01164501 (4) [back to overview]	Hypoglycaemic Events
NCT01167881 (10) [back to overview]	The Occurrence of Confirmed Hypoglycaemic Events During 52 Weeks of Treatment.
NCT01167881 (10) [back to overview]	The Change in Body Weight From Baseline After 104 Weeks of Treatment.
NCT01167881 (10) [back to overview]	The Occurrence of Confirmed Hypoglycaemic Events During 104 Weeks of Treatment.
NCT01167881 (10) [back to overview]	The Change From Baseline in HbA1c After 52 Weeks of Treatment.
NCT01167881 (10) [back to overview]	The Change in Body Weight From Baseline After 52 Weeks of Treatment.
NCT01167881 (10) [back to overview]	The Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment.
NCT01167881 (10) [back to overview]	The Change in Systolic Blood Pressure (SBP) From Baseline After 52 Weeks of Treatment.
NCT01167881 (10) [back to overview]	The Change in Systolic Blood Pressure (SBP) From Baseline After 104 Weeks of Treatment.
NCT01167881 (10) [back to overview]	The Change in Diastolic Blood Pressure (DBP) From Baseline After 104 Weeks of Treatment.
NCT01167881 (10) [back to overview]	The Change in Diastolic Blood Pressure (DBP) From Baseline After 52 Weeks of Treatment.
NCT01177813 (4) [back to overview]	Confirmed Hypoglycaemic Adverse Events
NCT01177813 (4) [back to overview]	Change From Baseline to Week 24 in Systolic and Diastolic Blood Pressure (SBP and DBP)
NCT01177813 (4) [back to overview]	Change From Baseline to Week 24 in Body Weight
NCT01177813 (4) [back to overview]	Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 24 Weeks
NCT01189201 (21) [back to overview]	Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator
NCT01189201 (21) [back to overview]	Empagliflozin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01189201 (21) [back to overview]	Empagliflozin Fed vs Fasted: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)
NCT01189201 (21) [back to overview]	Empagliflozin Fed vs Fasted: Maximum Measured Concentration (Cmax)
NCT01189201 (21) [back to overview]	Empagliflozin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01189201 (21) [back to overview]	Empagliflozin Formulation Comparison: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)
NCT01189201 (21) [back to overview]	Empagliflozin: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01189201 (21) [back to overview]	Empagliflozin: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)
NCT01189201 (21) [back to overview]	Empagliflozin: Maximum Measured Concentration (Cmax)
NCT01189201 (21) [back to overview]	Empagliflozin: Time From Last Dosing to Maximum Measured Concentration (Tmax)
NCT01189201 (21) [back to overview]	Empagliflozin Formulation Comparison: Maximum Measured Concentration (Cmax)
NCT01189201 (21) [back to overview]	Linagliptin: Time From Last Dosing to Maximum Measured Concentration (Tmax)
NCT01189201 (21) [back to overview]	Linagliptin Formulation Comparison: Area Under the Curve 0 to 72 Hours (AUC0-72)
NCT01189201 (21) [back to overview]	Linagliptin Formulation Comparison: Maximum Measured Concentration (Cmax)
NCT01189201 (21) [back to overview]	Linagliptin: Area Under the Curve 0 to 72 Hours (AUC0-72)
NCT01189201 (21) [back to overview]	Linagliptin: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01189201 (21) [back to overview]	Linagliptin Fed vs Fasted: Maximum Measured Concentration (Cmax)
NCT01189201 (21) [back to overview]	Linagliptin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01189201 (21) [back to overview]	Linagliptin: Maximum Measured Concentration (Cmax)
NCT01189201 (21) [back to overview]	Linagliptin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01189201 (21) [back to overview]	Linagliptin Fed vs Fasted: Area Under the Curve 0 to 72 Hours (AUC0-72)
NCT01193218 (4) [back to overview]	Confirmed Hypoglycaemic Adverse Events
NCT01193218 (4) [back to overview]	Change From Baseline in HbA1c After 12 Weeks of Treatment.
NCT01193218 (4) [back to overview]	Change From Baseline in FPG
NCT01193218 (4) [back to overview]	Occurrence of Treat to Target Efficacy Response
NCT01195675 (10) [back to overview]	Empa 200mg: Mean QTcN Change From Baseline Between 1 and 4 Hours After Dosing
NCT01195675 (10) [back to overview]	Empa 25 mg: Mean QTcN Change From Baseline Between 30 Minutes and 24 Hours After Dosing
NCT01195675 (10) [back to overview]	Empa 25mg: Change From Mean Baseline in QTcN at Each Time Point Between 30 Minutes and 24 Hours After Dosings
NCT01195675 (10) [back to overview]	Empa 25mg: Mean QTcN Change From Baseline Between 1 and 4 Hours After Dosing
NCT01195675 (10) [back to overview]	Mean QTcN Change From Baseline Between 2 and 4 Hours After Dosing
NCT01195675 (10) [back to overview]	Time-matched Change From Placebo in QTcN Between 30 Minutes and 24 Hours After Dosing.
NCT01195675 (10) [back to overview]	Placebo Corrected Change From Mean Baseline at Any Time Point Between 30 Minutes and 24 Hours After Dosings.
NCT01195675 (10) [back to overview]	Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator
NCT01195675 (10) [back to overview]	Empa 200 mg: Mean QTcN Change From Baseline Between 30 Minutes and 24 Hours After Dosing
NCT01195675 (10) [back to overview]	Empa 200mg: Change From Mean Baseline in QTcN at Each Time Point Between 30 Minutes and 24 Hours After Dosings
NCT01210001 (5) [back to overview]	Body Weight Change From Baseline
NCT01210001 (5) [back to overview]	Fasting Plasma Glucose (FPG) Change From Baseline
NCT01210001 (5) [back to overview]	Hypoglycaemic Events
NCT01210001 (5) [back to overview]	HbA1c Change From Baseline for Pio and Met Background Medication Patients
NCT01210001 (5) [back to overview]	HbA1c Change From Baseline
NCT01211197 (13) [back to overview]	Metformin: Maximum Measured Concentration (Cmax)
NCT01211197 (13) [back to overview]	Apparent Clearance After Extravascular Administration (CL/F)
NCT01211197 (13) [back to overview]	Apparent Volume of Distribution During the Terminal Phase (Vz/F)
NCT01211197 (13) [back to overview]	Mean Residence Time in the Body After Oral Administration (MRTpo)
NCT01211197 (13) [back to overview]	Time to Maximum Measured Concentration (Tmax)
NCT01211197 (13) [back to overview]	Terminal Elimination Rate Constant in Plasma (λz)
NCT01211197 (13) [back to overview]	Terminal Half-life in Plasma (T1/2)
NCT01211197 (13) [back to overview]	Metformin: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT01211197 (13) [back to overview]	Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator.
NCT01211197 (13) [back to overview]	Empa: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01211197 (13) [back to overview]	Empa: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT01211197 (13) [back to overview]	Empa: Maximum Measured Concentration (Cmax)
NCT01211197 (13) [back to overview]	Metformin: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01242176 (3) [back to overview]	Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01242176 (3) [back to overview]	Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT01242176 (3) [back to overview]	Maximum Measured Concentration (Cmax)
NCT01248364 (10) [back to overview]	Change From Baseline in Glucose Metabolism (Pre-meal and Postprandial Glucose), PPG iAUC 5h, at Day 1
NCT01248364 (10) [back to overview]	Change From Baseline in Rate of Endogenous Glucose Production: iAUC 5h, at Day 1
NCT01248364 (10) [back to overview]	Change From Baseline in Rate of Endogenous Glucose Production: iAUC 5h, at Day 28
NCT01248364 (10) [back to overview]	Change From Baseline in Rate of Endogenous Glucose Production: Fast, at Day 28
NCT01248364 (10) [back to overview]	Change From Baseline in Rate of Endogenous Glucose Production: Fast, at Day 1
NCT01248364 (10) [back to overview]	Change From Baseline in Rate of Endogenous Glucose Production: AUC 5h, at Day 28
NCT01248364 (10) [back to overview]	Change From Baseline in Fasting Plasma Glucose at Day 28
NCT01248364 (10) [back to overview]	Change From Baseline in Fasting Plasma Glucose at Day 1
NCT01248364 (10) [back to overview]	Change From Baseline in Rate of Endogenous Glucose Production: AUC 5h, at Day 1
NCT01248364 (10) [back to overview]	Change From Baseline in Glucose Metabolism (Pre-meal and Postprandial Glucose), PPG iAUC 5h, at Day 28
NCT01276288 (27) [back to overview]	Area Under the Concentration-time Curve of Empa in Plasma (AUCτ,ss)
NCT01276288 (27) [back to overview]	Area Under the Concentration-time Curve of HCT in Plasma (AUCτ,ss)
NCT01276288 (27) [back to overview]	Area Under the Concentration-time Curve of TOR in Plasma (AUCτ,ss)
NCT01276288 (27) [back to overview]	Change in Body Weight From Baseline
NCT01276288 (27) [back to overview]	Change in pH in Capillary or Arterialised Blood From Baseline
NCT01276288 (27) [back to overview]	Change in Serum Concentration of Alkaline Phosphatase (ALP) From Baseline
NCT01276288 (27) [back to overview]	Change in Serum Concentration of Fibroblast Growth Factor-23 (FGF- 23) From Baseline
NCT01276288 (27) [back to overview]	Change in Serum Osmolality From Baseline
NCT01276288 (27) [back to overview]	Change in Urea Concentration in Urine
NCT01276288 (27) [back to overview]	Change in Urinary Excretion in a 24-hour Period of N-terminal Telopeptide (NTx) From Baseline
NCT01276288 (27) [back to overview]	Change in Urinary Weight From Baseline
NCT01276288 (27) [back to overview]	Change in Serum Concentration of Aldosterone From Baseline
NCT01276288 (27) [back to overview]	Change in Urine Osmolality From Baseline
NCT01276288 (27) [back to overview]	Maximum Measured Concentration of Empa in Plasma (Cmax, ss)
NCT01276288 (27) [back to overview]	Change in Urine pH From Baseline
NCT01276288 (27) [back to overview]	Number of Subjects With Clinical Relevant Abnormalities in Vital Signs, Clinical Laboratory Tests, 12-lead Resting Electrocardiogram (ECG), Physical Examination and Assessment of Tolerability by the Investigator
NCT01276288 (27) [back to overview]	Change in Serum Concentration of Renin, Intact Parathyroid Hormone (iPTH) and 1,25-dihydroxyvitamin D From Baseline
NCT01276288 (27) [back to overview]	Change in Serum Concentration of Creatinine and Uric Acid From Baseline
NCT01276288 (27) [back to overview]	Maximum Measured Concentration of TOR in Plasma (Cmax, ss)
NCT01276288 (27) [back to overview]	Maximum Measured Concentration of HCT in Plasma (Cmax, ss)
NCT01276288 (27) [back to overview]	Change in Clearance of Sodium, Potassium, Creatinine, Magnesium, Chloride,Calcium, Phosphate and Uric Acid From Baseline
NCT01276288 (27) [back to overview]	The Change in Micturition Frequency From the Baseline
NCT01276288 (27) [back to overview]	The Change in Total Muscle Sympathetic Nerve Activity (MSNA) From Off- Treatment
NCT01276288 (27) [back to overview]	Change in Serum Concentration of Sodium, Potassium, Magnesium, Calcium, Chloride, Phosphate, Glucose and Urea From Baseline
NCT01276288 (27) [back to overview]	Change in Urinary Excretion in a 24-hour Period of Sodium, Potassium, Magnesium, Chloride, Calcium, Phosphate, Creatinine, Uric Acid, Glucose From Baseline
NCT01276288 (27) [back to overview]	Changes in Bicarbonate Concentrations of Calcium, Bicarbonate Ions and Base Excess in Capillary or Arterialised Blood From Baseline
NCT01276288 (27) [back to overview]	Urinary Sodium Excretion Over 24-hour run-in Periods
NCT01276301 (12) [back to overview]	Assessment of Tolerability by Investigator
NCT01276301 (12) [back to overview]	Verapamil Plasma Concentration
NCT01276301 (12) [back to overview]	Time From 0 to Maximum Plasma Concentration (Tmax)
NCT01276301 (12) [back to overview]	Terminal Half-life in Plasma (t1/2)
NCT01276301 (12) [back to overview]	Terminal Elimination Rate Constant (λz)
NCT01276301 (12) [back to overview]	Apparent Volume of Distribution Following an Extravascular Dose (Vz/F)
NCT01276301 (12) [back to overview]	Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01276301 (12) [back to overview]	Area Under the Curve 0 to Time of Last Quantifiable Data Point (AUC0-tz)
NCT01276301 (12) [back to overview]	Maximum Measured Concentration (Cmax)
NCT01276301 (12) [back to overview]	Clinically Relevant Abnormalities for Physical Examination, Vital Signs, Blood Chemistry and Electrocardiogram (ECG).
NCT01276301 (12) [back to overview]	Mean Residence Time in the Body After Administration (MRTpo)
NCT01276301 (12) [back to overview]	Apparent Clearance in Plasma After Extravascular Administration (CL/F)
NCT01284621 (15) [back to overview]	Apparent Clearance After Extravascular Administration (CL/Fss)
NCT01284621 (15) [back to overview]	Apparent Volume of Distribution During the Terminal Phase (Vz/Fss)
NCT01284621 (15) [back to overview]	Empa: Predose Concentration Prior to Administration of the Nth Dose (Cpre,N)
NCT01284621 (15) [back to overview]	Mean Residence Time (MRTpo,ss)
NCT01284621 (15) [back to overview]	Ramiprilat: Predose Concentration Prior to Administration of the Nth Dose (Cpre,N)
NCT01284621 (15) [back to overview]	Terminal Half-life (T 1/2,ss)
NCT01284621 (15) [back to overview]	Time From Last Dosing to the Maximum Measured Concentration (Tmax,ss)
NCT01284621 (15) [back to overview]	Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Tolerability
NCT01284621 (15) [back to overview]	Total Empa: Area Under the Curve at Steady-state Over a Uniform Dosing Interval (AUCτ,ss)
NCT01284621 (15) [back to overview]	Total Empa: Maximum Measured Concentration (Cmax,ss)
NCT01284621 (15) [back to overview]	Terminal Rate Constant (λz,ss)
NCT01284621 (15) [back to overview]	Total Ramipril: Maximum Measured Concentration (Cmax,ss)
NCT01284621 (15) [back to overview]	Total Ramiprilat: Area Under the Curve at Steady-state Over a Uniform Dosing Interval (AUCτ,ss).
NCT01284621 (15) [back to overview]	Total Ramipril: Area Under the Curve at Steady-state Over a Uniform Dosing Interval (AUCτ,ss).
NCT01284621 (15) [back to overview]	Total Ramiprilat: Maximum Measured Concentration (Cmax,ss)
NCT01289990 (13) [back to overview]	Waist Circumference (cm) Change From Baseline After 76 Weeks of Treatment
NCT01289990 (13) [back to overview]	Changes From Baseline in HbA1c (%) After 76 Weeks of Treatment
NCT01289990 (13) [back to overview]	Systolic Blood Pressure: Change From Baseline After 76 Weeks of Treatment
NCT01289990 (13) [back to overview]	Waist Circumference (cm) Change From Baseline After 52 Weeks of Treatment
NCT01289990 (13) [back to overview]	Fasting Plasma Glucose Change From Baseline After 76 Weeks of Treatment
NCT01289990 (13) [back to overview]	Systolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment
NCT01289990 (13) [back to overview]	HbA1c (%) Changes From Baseline After 76 Weeks of Treatment
NCT01289990 (13) [back to overview]	Fasting Plasma Glucose Change From Baseline After 52 Weeks of Treatment
NCT01289990 (13) [back to overview]	Diastolic Blood Pressure: Change From Baseline After 76 Weeks of Treatment
NCT01289990 (13) [back to overview]	Diastolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment
NCT01289990 (13) [back to overview]	Body Weight (kg) Change From Baseline After 52 Weeks of Treatment
NCT01289990 (13) [back to overview]	Body Weight (kg) Change From Baseline After 76 Weeks of Treatment
NCT01289990 (13) [back to overview]	Changes From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 52 Weeks of Treatment
NCT01301742 (3) [back to overview]	Total Empa: Maximum Measured Concentration (Cmax)
NCT01301742 (3) [back to overview]	Total Empa: Area Under the Curve 0 to Time of Last Quantifiable Data Point (AUC0-tz)
NCT01301742 (3) [back to overview]	Total Empa: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01304329 (6) [back to overview]	Empa: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01304329 (6) [back to overview]	Empa: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT01304329 (6) [back to overview]	Empa: Maximum Measured Concentration (Cmax)
NCT01304329 (6) [back to overview]	Simvastatin: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01304329 (6) [back to overview]	Simvastatin: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT01304329 (6) [back to overview]	Simvastatin: Maximum Measured Concentration (Cmax)
NCT01306175 (3) [back to overview]	Digoxin: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01306175 (3) [back to overview]	Digoxin: Area Under the Curve 0 to Last Quantifiable Data Point (AUC0-tz)
NCT01306175 (3) [back to overview]	Digoxin: Maximum Measured Concentration (Cmax)
NCT01306214 (4) [back to overview]	Change From Baseline in Insulin Dose After 52 Weeks of Treatment
NCT01306214 (4) [back to overview]	Change From Baseline in HbA1c After 52 Weeks of Treatment
NCT01306214 (4) [back to overview]	Change From Baseline in HbA1c After 18 Weeks of Treatment
NCT01306214 (4) [back to overview]	Change From Baseline in Body Weight After 52 Weeks of Treatment
NCT01316341 (29) [back to overview]	Fraction of Empagliflozin Excreted Unchanged in Urine in the Time Interval 0 Hours to 24 Hours (fe 0-24).
NCT01316341 (29) [back to overview]	Time From Last Dosing to Maximum Measured Concentration Over a Uniform Dosing Interval at Steady State (Tmax,ss)
NCT01316341 (29) [back to overview]	Time to Maximum Measured Concentration (Tmax)
NCT01316341 (29) [back to overview]	Predose Plasma Concentration Before Planned Dose x (Cpre,x)
NCT01316341 (29) [back to overview]	Urinary Glucose Excretion (UGE) Change From Baseline
NCT01316341 (29) [back to overview]	Amount of Analyte Eliminated in Urine at Steady State in Time Interval 0 Hours to 24 Hours (Ae 0-24,ss)
NCT01316341 (29) [back to overview]	Apparent Volume of Distribution During the Terminal Phase λz (Vz/Fss)
NCT01316341 (29) [back to overview]	Terminal Rate Constant in Plasma at Steady State (λz,ss)
NCT01316341 (29) [back to overview]	Area Under the Concentration-time Curve in Plasma at Steady State Over a Uniform Dosing Interval (AUCτ,ss)
NCT01316341 (29) [back to overview]	Area Under the Curve 0 to Infinity (AUC0-∞) After Single Dosing
NCT01316341 (29) [back to overview]	Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT01316341 (29) [back to overview]	Clinical Relevant Abnormalities for Protocol-Specified Significant Adverse Events, Hypoglycaemic Events, Vital Signs, Blood Chemistry, Rescue Therapy, Body Weight and Waist Circumference
NCT01316341 (29) [back to overview]	Fasting Plasma Glucose (FPG) Change From Baseline
NCT01316341 (29) [back to overview]	Fraction of Empagliflozin Excreted Unchanged in Urine at Steady State in the Time Interval 0 Hours to 24 Hours (fe 0-24,ss)
NCT01316341 (29) [back to overview]	Maximum Measured Concentration (Cmax)
NCT01316341 (29) [back to overview]	Maximum Measured Concentration Over a Uniform Dosing Interval (Cmax,ss)
NCT01316341 (29) [back to overview]	Mean Residence Time at Steady State (MRTpo,ss)
NCT01316341 (29) [back to overview]	Apparent Volume of Distribution During the Terminal Phase λz (Vz/F)
NCT01316341 (29) [back to overview]	Apparent Clearance of Empagliflozin After Extravascular Administration (CL/Fss)
NCT01316341 (29) [back to overview]	Apparent Clearance of Empagliflozin After Extravascular Administration (CL/F)
NCT01316341 (29) [back to overview]	Amount of Empagliflozin Eliminated in Urine in the Time Interval 0 Hours to 24 Hours (Ae 0-24)
NCT01316341 (29) [back to overview]	Mean Residence Time (MRTpo)
NCT01316341 (29) [back to overview]	Renal Clearance After Extravascular Administration (CL R,0-48)
NCT01316341 (29) [back to overview]	Renal Clearance at Steady State (CL R,ss)
NCT01316341 (29) [back to overview]	Terminal Half-life (t1/2)
NCT01316341 (29) [back to overview]	Terminal Half-life in Plasma at Steady State (t1/2,ss)
NCT01316341 (29) [back to overview]	Terminal Rate Constant (λz)
NCT01316341 (29) [back to overview]	Accumulation Ratio Based on Cmax (R A,Cmax)
NCT01316341 (29) [back to overview]	Accumulation Ratio Based on AUC (R A,AUC)
NCT01328184 (18) [back to overview]	Ethinylestradiol: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)
NCT01328184 (18) [back to overview]	Ethinylestradiol: Terminal Rate Constant at Steady State (λz,ss)
NCT01328184 (18) [back to overview]	Ethinylestradiol: Terminal Half-life at Steady State (t1/2,ss)
NCT01328184 (18) [back to overview]	Ethinylestradiol: Mean Residence Time at Steady State (MRTpo,ss)
NCT01328184 (18) [back to overview]	Ethinylestradiol: Maximum Measured Concentration (Cmax,ss)
NCT01328184 (18) [back to overview]	Ethinylestradiol: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)
NCT01328184 (18) [back to overview]	Ethinylestradiol: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)
NCT01328184 (18) [back to overview]	Ethinylestradiol: Apparent Clearance at Steady State (CL/Fss)
NCT01328184 (18) [back to overview]	Levonorgestrel: Apparent Clearance at Steady State (CL/Fss)
NCT01328184 (18) [back to overview]	Levonorgestrel: Mean Residence Time at Steady State (MRTpo,ss)
NCT01328184 (18) [back to overview]	Levonorgestrel: Maximum Measured Concentration (Cmax,ss)
NCT01328184 (18) [back to overview]	Levonorgestrel: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)
NCT01328184 (18) [back to overview]	Levonorgestrel: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)
NCT01328184 (18) [back to overview]	Assessment of Tolerability
NCT01328184 (18) [back to overview]	Number of Participants With Clinically Relevant Abnormalities in Physical Examination, Vital Signs, ECG and Clinical Laboratory Tests.
NCT01328184 (18) [back to overview]	Levonorgestrel: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)
NCT01328184 (18) [back to overview]	Levonorgestrel: Terminal Rate Constant at Steady State (λz,ss)
NCT01328184 (18) [back to overview]	Levonorgestrel: Terminal Half-life at Steady State (t1/2,ss)
NCT01368081 (3) [back to overview]	Number of Patients With Drug Related Adverse Events
NCT01368081 (3) [back to overview]	Confirmed Hypoglycaemic Adverse Events
NCT01368081 (3) [back to overview]	Change From Baseline in HbA1c
NCT01370005 (16) [back to overview]	Body Weight Change From Baseline
NCT01370005 (16) [back to overview]	Trough Mean Seated Diastolic Blood Pressure (DBP) Change From Baseline
NCT01370005 (16) [back to overview]	Nighttime Mean Systolic Blood Pressure (SBP) Change From Baseline
NCT01370005 (16) [back to overview]	Trough Mean Seated Systolic Blood Pressure (SBP) Change From Baseline
NCT01370005 (16) [back to overview]	Proportion of Patients Reaching Blood Pressure <130/80 mmHg
NCT01370005 (16) [back to overview]	Orthostatic Blood Pressure
NCT01370005 (16) [back to overview]	Composite Endpoint of Change From Baseline of HbA1c, Systolic Blood Pressure and Body Weight
NCT01370005 (16) [back to overview]	Nighttime Mean Diastolic Blood Pressure (DBP) Change From Baseline
NCT01370005 (16) [back to overview]	Mean 24-hour Systolic Blood Pressure Change From Baseline
NCT01370005 (16) [back to overview]	Mean 24-hour Diastolic Blood Pressure Change From Baseline
NCT01370005 (16) [back to overview]	HbA1c Change From Baseline
NCT01370005 (16) [back to overview]	Fasting Plasma Glucose (FPG) Change From Baseline
NCT01370005 (16) [back to overview]	Daytime Mean Systolic Blood Pressure (SBP) Change From Baseline
NCT01370005 (16) [back to overview]	Proportion of Patients With HbA1c <7%
NCT01370005 (16) [back to overview]	Daytime Mean Diastolic Blood Pressure (DBP) Change From Baseline
NCT01370005 (16) [back to overview]	Confirmed Hypoglycaemic Adverse Events
NCT01392560 (1) [back to overview]	Change in Glomerular Filtration Rate (GFR) After 8 Weeks of Treatment With Empagliflozin Under Controlled Conditions of Euglycaemia and Hyperglycaemia
NCT01422876 (8) [back to overview]	Change From Baseline in Body Weight for Metformin Background Patients
NCT01422876 (8) [back to overview]	Change From Baseline in Fasting Plasma Glucose at Week 24 for Metformin Background Patients
NCT01422876 (8) [back to overview]	Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Metformin Background Patients
NCT01422876 (8) [back to overview]	Change From Baseline in Body Weight for Treatment Naive Patients
NCT01422876 (8) [back to overview]	Change From Baseline in Fasting Plasma Glucose at Week 24 for Treatment Naive Patients
NCT01422876 (8) [back to overview]	Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Treatment Naive Patients
NCT01422876 (8) [back to overview]	Occurrence of Treat to Target Efficacy Response for Metformin Background Patients
NCT01422876 (8) [back to overview]	Occurrence of Treat to Target Efficacy Response for Treatment Naive Patients
NCT01451775 (3) [back to overview]	Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01451775 (3) [back to overview]	Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Clinical Laboratory Tests and Assessment of Tolerability by the Investigator.
NCT01451775 (3) [back to overview]	Maximum Measured Concentration (Cmax)
NCT01581658 (3) [back to overview]	Maximum Concentration
NCT01581658 (3) [back to overview]	Change From Baseline in Total Urinary Glucose Excretion (UGE)
NCT01581658 (3) [back to overview]	Area Under the Concentration Time Curve of the Analyte in Plasma
NCT01634100 (3) [back to overview]	Total Empagliflozin: Area Under the Curve 0 to Time of Last Quantifiable Data Point (AUC0-tz)
NCT01634100 (3) [back to overview]	Total Empagliflozin: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01634100 (3) [back to overview]	Total Empa: Maximum Measured Concentration (Cmax)
NCT01649297 (2) [back to overview]	Fasting Plasma Glucose (FPG) Change From Baseline at Week 16
NCT01649297 (2) [back to overview]	HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 16
NCT01672788 (6) [back to overview]	Metformin: Maximum Measured Concentration (Cmax)
NCT01672788 (6) [back to overview]	Metformin: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT01672788 (6) [back to overview]	Metformin: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01672788 (6) [back to overview]	Empa: Maximum Measured Concentration (Cmax)
NCT01672788 (6) [back to overview]	Empa: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT01672788 (6) [back to overview]	Empa: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01719003 (3) [back to overview]	HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 24
NCT01719003 (3) [back to overview]	FPG (Fasting Plasma Glucose) Change From Baseline at Week 24
NCT01719003 (3) [back to overview]	Body Weight Change From Baseline at Week 24
NCT01734785 (3) [back to overview]	HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment
NCT01734785 (3) [back to overview]	Fasting Plasma Glucose (FPG) Change From Baseline After 24 Weeks of Double-blind Treatment.
NCT01734785 (3) [back to overview]	Body Weight Change From Baseline After 24 Weeks of Double-blind Treatment
NCT01778049 (2) [back to overview]	Fasting Plasma Glucose (FPG) Change From Baseline at 24 Weeks.
NCT01778049 (2) [back to overview]	Change From Baseline of HbA1c After 24 Weeks of Treatment.
NCT01811953 (6) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Metformin
NCT01811953 (6) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Empagliflozin
NCT01811953 (6) [back to overview]	Maximum Measured Concentration of the Analyte in Plasma, Metformin
NCT01811953 (6) [back to overview]	Maximum Measured Concentration of the Analyte in Plasma, Empagliflozin
NCT01811953 (6) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Metformin
NCT01811953 (6) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Empagliflozin
NCT01844531 (6) [back to overview]	AUC0-tz for Empagliflozin
NCT01844531 (6) [back to overview]	Cmax for Empagliflozin
NCT01844531 (6) [back to overview]	AUC0-tz for Metformin
NCT01844531 (6) [back to overview]	AUC0-∞ for Empagliflozin
NCT01844531 (6) [back to overview]	AUC0-∞ for Metformin
NCT01844531 (6) [back to overview]	Cmax for Metformin
NCT01867307 (1) [back to overview]	Change From Baseline of Renal Tubular Maximum Reabsorptive Capacity for Glucose (TmG) at End of Empagliflozin Treatment (Day 14)
NCT01907113 (16) [back to overview]	Time to Maximum Concentration of the Analyte in Plasma
NCT01907113 (16) [back to overview]	Terminal Rate Constant in Plasma
NCT01907113 (16) [back to overview]	Renal Clearance of the Analyte in Plasma After Extravascular Administration
NCT01907113 (16) [back to overview]	fe0-96 (Fraction of Analyte Excreted Unchanged in Urine From Time Points 0 to 96 Hours)
NCT01907113 (16) [back to overview]	Cmax (Maximum Concentration of the Analyte in Plasma)
NCT01907113 (16) [back to overview]	Plasma Protein Binding
NCT01907113 (16) [back to overview]	AUC0-∞ (Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 to Infinity)
NCT01907113 (16) [back to overview]	%AUCtz-∞ (Percentage of Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From the Time of the Last Quantifiable Data Point Extrapolated to Infinity)
NCT01907113 (16) [back to overview]	Apparent Clearance of the Analyte in the Plasma After Extravascular Administration
NCT01907113 (16) [back to overview]	Safety: Physical Examination, Vital Signs, ECG and Laboratory Measurements
NCT01907113 (16) [back to overview]	Apparent Volume of Distribution During the Terminal Phase Lz
NCT01907113 (16) [back to overview]	Ae0-96 (Amount of Analyte That is Eliminated in Urine Over the Time Interval 0 to 96 h)
NCT01907113 (16) [back to overview]	Half-life and Mean Residence Time of the Analyte in Plasma
NCT01907113 (16) [back to overview]	Assessment of Tolerability by Investigator
NCT01907113 (16) [back to overview]	Total Urinary Glucose Excretion (UGE)
NCT01907113 (16) [back to overview]	AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)
NCT01924767 (21) [back to overview]	Terminal Rate Constant in Plasma
NCT01924767 (21) [back to overview]	Time to Maximum Concentration of the Analyte in Plasma
NCT01924767 (21) [back to overview]	Change From Baseline to Day 8 in Urinary Glucose Excretion
NCT01924767 (21) [back to overview]	Fasting Plasma Glucose
NCT01924767 (21) [back to overview]	Linearity Index
NCT01924767 (21) [back to overview]	Mean Daily Glucose
NCT01924767 (21) [back to overview]	Peak Trough Fluctuation
NCT01924767 (21) [back to overview]	Accumulation Ratios
NCT01924767 (21) [back to overview]	Amount of Analyte Eliminated in Urine
NCT01924767 (21) [back to overview]	Apparent and Renal Clearance of the Analyte in Plasma
NCT01924767 (21) [back to overview]	Apparent Volume of Distribution During the Terminal Phase
NCT01924767 (21) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval (AUC)
NCT01924767 (21) [back to overview]	Assessment of Tolerability by Investigator
NCT01924767 (21) [back to overview]	Concentration of the Analyte in Plasma
NCT01924767 (21) [back to overview]	Fraction of Analyte Excreted Unchanged in Urine
NCT01924767 (21) [back to overview]	Half-life and Mean Residence Time of the Analyte in Plasma
NCT01924767 (21) [back to overview]	Micturition Frequency
NCT01924767 (21) [back to overview]	Percentage of Participants With Clinically Relevant Findings in Electrocardiogram (ECG) Results
NCT01924767 (21) [back to overview]	Percentage of Participants With Clinically Relevant Findings in Physical Examination, Vital Signs and Clinical Laboratory Tests
NCT01924767 (21) [back to overview]	Serum Insulin
NCT01924767 (21) [back to overview]	Serum Insulin
NCT01947855 (1) [back to overview]	Change in Area Under the Concentration-time Curve (AUC1-4h) for Postprandial Plasma Glucose From Baseline After 28 Days of Treatment
NCT01969747 (1) [back to overview]	Change From Baseline in 24 h UGE (g/24 h) After Seven Days of Treatment With Empagliflozin 2.5 mg, 10 mg, or 25 mg, or Placebo
NCT01975220 (6) [back to overview]	Cmax (Maximum Measured Concentration of the Analyte in Plasma); Metformin
NCT01975220 (6) [back to overview]	Cmax (Maximum Measured Concentration of the Analyte in Plasma); Empagliflozin
NCT01975220 (6) [back to overview]	AUC 0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity); Metformin
NCT01975220 (6) [back to overview]	AUC 0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity); Empagliflozin
NCT01975220 (6) [back to overview]	Area Under the Concentration -Time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC 0-tz); Empagliflozin
NCT01975220 (6) [back to overview]	AUC 0-tz (Area Under the Concentration -Time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point); Metformin
NCT02028767 (3) [back to overview]	AUC (0-infinity) (Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)
NCT02028767 (3) [back to overview]	AUC (0-tz) (Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point)
NCT02028767 (3) [back to overview]	Cmax (Maximum Measured Concentration of Metformin in Plasma)
NCT02102932 (6) [back to overview]	Cmax for Metformin
NCT02102932 (6) [back to overview]	Cmax for Empagliflozin
NCT02102932 (6) [back to overview]	AUC(0-∞) for Empagliflozin
NCT02102932 (6) [back to overview]	AUC(0-∞) for Metformin
NCT02102932 (6) [back to overview]	AUC(0-tz) of Empagliflozin
NCT02102932 (6) [back to overview]	AUC(0-tz) of Metformin
NCT02106923 (6) [back to overview]	Cmax (Maximum Measured Concentration of the Analyte in Plasma, for Empagliflozin
NCT02106923 (6) [back to overview]	AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point), for Empagliflozin
NCT02106923 (6) [back to overview]	AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Metformin
NCT02106923 (6) [back to overview]	AUC0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity), for Empagliflozin
NCT02106923 (6) [back to overview]	AUC0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity), for Metformin
NCT02106923 (6) [back to overview]	Cmax (Maximum Measured Concentration of the Analyte in Plasma, for Metformin
NCT02121483 (8) [back to overview]	Cmax
NCT02121483 (8) [back to overview]	AUC0-inf
NCT02121483 (8) [back to overview]	Change From Baseline in Urinary Glucose Excretion (UGE) Over 24 h After Study Drug Intake
NCT02121483 (8) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at 24 h After Study Drug Intake
NCT02121483 (8) [back to overview]	Change From Baseline in 8-point Plasma Glucose Profile Over 24 h After Study Drug Intake
NCT02121483 (8) [back to overview]	Tmax
NCT02121483 (8) [back to overview]	AUC0-tz
NCT02121483 (8) [back to overview]	t1/2
NCT02182830 (11) [back to overview]	Change From Baseline in Trough Seated SBP at Week 12
NCT02182830 (11) [back to overview]	Change From Baseline in Trough Seated DBP (mmHg) at Week 12
NCT02182830 (11) [back to overview]	Change From Baseline in Trough Seated DBP (mmHg) at Week 24
NCT02182830 (11) [back to overview]	Changes From Baseline in Trough Mean Ambulatory SBP at Week 12
NCT02182830 (11) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (SBP) at Week 12
NCT02182830 (11) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory SBP (mmHg) at Week 24
NCT02182830 (11) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (DBP) at Week 12
NCT02182830 (11) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory DBP (mmHg) at Week 24
NCT02182830 (11) [back to overview]	Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeks
NCT02182830 (11) [back to overview]	Change From Baseline in Trough Seated SBP (mmHg) at Week 24
NCT02182830 (11) [back to overview]	Change From Baseline in Body Weight at Week 24
NCT02230995 (6) [back to overview]	AUC0-infinity of Metformin in Plasma
NCT02230995 (6) [back to overview]	AUC0-infinity of Empagliflozin in Plasma
NCT02230995 (6) [back to overview]	AUC0-tz of Empagliflozin in Plasma
NCT02230995 (6) [back to overview]	Cmax of Metformin in Plasma
NCT02230995 (6) [back to overview]	Cmax of Empagliflozin in Plasma
NCT02230995 (6) [back to overview]	AUC0-tz of Metformin in Plasma
NCT02266472 (6) [back to overview]	AUC0-infinity of Empagliflozin in Plasma
NCT02266472 (6) [back to overview]	Cmax of Metformin in Plasma
NCT02266472 (6) [back to overview]	Cmax of Empagliflozin in Plasma
NCT02266472 (6) [back to overview]	AUC0-tz of Metformin in Plasma
NCT02266472 (6) [back to overview]	AUC0-tz of Empagliflozin in Plasma
NCT02266472 (6) [back to overview]	AUC0-infinity of Metformin in Plasma
NCT02367131 (3) [back to overview]	Change From Baseline in Fasting Plasma Glucose at the Last Observation During the Observation Period
NCT02367131 (3) [back to overview]	Change From Baseline in HbA1c at the Last Observation During the Observation Period
NCT02367131 (3) [back to overview]	Percentage of Patients With Adverse Drug Reactions (ADRs)
NCT02414958 (8) [back to overview]	Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26
NCT02414958 (8) [back to overview]	Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD) )
NCT02414958 (8) [back to overview]	Change From Baseline in Interstitial Glucose Variability Based on the Interquartile Range (IQR) as Determined by CGM in Weeks 23 to 26
NCT02414958 (8) [back to overview]	Change From Baseline in Percentage of Time Spent in Target Glucose Range From Weeks 23 to 26
NCT02414958 (8) [back to overview]	Change From Baseline in Total Daily Insulin Dose (TDID) at Week 26
NCT02414958 (8) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26
NCT02414958 (8) [back to overview]	Rate Per Patient-year of Investigator-reported Symptomatic Hypoglycaemia Adverse Events (AEs) With Confirmed Plasma Glucose (PG)
NCT02414958 (8) [back to overview]	Change From Baseline in Body Weight at Week 26
NCT02453555 (5) [back to overview]	Change in HbA1c From Baseline at Week 52 (All Empagliflozin Versus All Placebo)
NCT02453555 (5) [back to overview]	Change in HbA1c From Baseline at Week 52 (Empagliflozin 25 mg/Linagliptin 5 mg Versus Linagliptin 5 mg + Placebo 25 mg)
NCT02453555 (5) [back to overview]	Change in HbA1c From Baseline at Week 52 (Empagliflozin 25 mg/Linagliptin 5 mg Versus All Placebo)
NCT02453555 (5) [back to overview]	Change of Glycosylated Haemoglobin A1c (Glycosylated Haemoglobin A1c After 24 Weeks of Double-blind Treatment From Baseline)
NCT02453555 (5) [back to overview]	Change in HbA1c From Week 28 at Week 52 (Empagliflozin 25 mg/Linagliptin 5 mg Only)
NCT02489942 (3) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at the Last- Observation During Observation Period
NCT02489942 (3) [back to overview]	Change From Baseline in Haemoglobin A1c (HbA1c) at the Last Observation During the Observation Period
NCT02489942 (3) [back to overview]	Number of Patients With Adverse Drug Reactions (ADRs)
NCT02489968 (1) [back to overview]	Change in Glycated Haemoglobin A1c (HbA1c) (%) From Baseline After 24 Weeks of Treatment
NCT02577315 (6) [back to overview]	Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)
NCT02577315 (6) [back to overview]	Maximum Measured Concentration of the Metformin in Plasma (Cmax)
NCT02577315 (6) [back to overview]	Maximum Measured Concentration of the Empagliflozin in Plasma (Cmax)
NCT02577315 (6) [back to overview]	Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT02577315 (6) [back to overview]	Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)
NCT02577315 (6) [back to overview]	Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT02580591 (6) [back to overview]	Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Full Analysis Set (FAS) (Observed Cases [OC])
NCT02580591 (6) [back to overview]	Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD))
NCT02580591 (6) [back to overview]	Change From Baseline in Total Daily Insulin Dose (TDID) at Week 26
NCT02580591 (6) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26
NCT02580591 (6) [back to overview]	Rate Per Patient-year of Investigator-reported Symptomatic Hypoglycemic Adverse Events (AEs) With Confirmed Plasma Glucose (PG)
NCT02580591 (6) [back to overview]	Change From Baseline in Body Weight at Week 26
NCT02589626 (2) [back to overview]	Percentage of Patients With Drug-related Adverse Events (AEs) During 52 Weeks of Treatment
NCT02589626 (2) [back to overview]	Change From Baseline in HbA1c After 52 Weeks of Treatment
NCT02589639 (2) [back to overview]	Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 16 Weeks of Treatment.
NCT02589639 (2) [back to overview]	Percentage of Patients With Investigator Defined Drug-Related Adverse Events (AEs)
NCT02597049 (11) [back to overview]	Change From Baseline in Body Weight at 24 Weeks
NCT02597049 (11) [back to overview]	Number of Participants With Adjudicated Acute Pancreatitis Events
NCT02597049 (11) [back to overview]	Number of Participants Requiring Rescue Therapy Due to Severe Persistent Hyperglycemia
NCT02597049 (11) [back to overview]	Change From Baseline in the HbA1c at 24 Weeks (Efficacy Estimand)
NCT02597049 (11) [back to overview]	Change From Baseline in Hemoglobin A1c (HbA1c) at 24 Weeks (Treatment-regimen Estimand)
NCT02597049 (11) [back to overview]	Change From Baseline in 6-Point Self-Monitored Plasma Glucose (SMPG) Profile at 24 Weeks
NCT02597049 (11) [back to overview]	Rate of Hypoglycemic Events Adjusted Per 30 Days
NCT02597049 (11) [back to overview]	Percentage of Participants With HbA1c <7%
NCT02597049 (11) [back to overview]	Number of Participants With Adjudicated Cardiovascular (CV) Events
NCT02597049 (11) [back to overview]	Change From Baseline in Fasting Serum Glucose (Central Laboratory) at 24 Weeks
NCT02597049 (11) [back to overview]	Change From Baseline in Fasting Glucagon at 24 Weeks
NCT02632747 (1) [back to overview]	Glomerular Filtration Rate (GFR) Under Euglycaemic Conditions After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril.
NCT02702011 (1) [back to overview]	Change From Baseline in 24 Hour UGE on Day 7
NCT02758171 (6) [back to overview]	AUC0-72 (Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours)
NCT02758171 (6) [back to overview]	AUC0-infinity (Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)
NCT02758171 (6) [back to overview]	Cmax (Maximum Measured Concentration of Empagliflozin Analyte in Plasma)
NCT02758171 (6) [back to overview]	Cmax (Maximum Measured Concentration of Linagliptin Analyte in Plasma)
NCT02758171 (6) [back to overview]	AUC0-tz (Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point)
NCT02758171 (6) [back to overview]	AUC0-infinity (Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)
NCT02815644 (7) [back to overview]	AUC 0-tz for Linagliptin
NCT02815644 (7) [back to overview]	AUC0-72 for Linagliptin
NCT02815644 (7) [back to overview]	AUC0-infinity for Empagliflozin
NCT02815644 (7) [back to overview]	AUC0-infinity for Linagliptin
NCT02815644 (7) [back to overview]	Cmax for Empagliflozin
NCT02815644 (7) [back to overview]	Cmax for Linagliptin
NCT02815644 (7) [back to overview]	AUC 0-tz for Empagliflozin
NCT02821910 (9) [back to overview]	Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72)
NCT02821910 (9) [back to overview]	Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)
NCT02821910 (9) [back to overview]	Area Under the Concentration-time Curve of the Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
NCT02821910 (9) [back to overview]	Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
NCT02821910 (9) [back to overview]	Maximum Measured Concentration of Empagliflozin in Plasma (Cmax)
NCT02821910 (9) [back to overview]	Maximum Measured Concentration of Linagliptin in Plasma (Cmax)
NCT02821910 (9) [back to overview]	Maximum Measured Concentration of Metformin in Plasma (Cmax)
NCT02821910 (9) [back to overview]	Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
NCT02821910 (9) [back to overview]	Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)
NCT02833415 (1) [back to overview]	Change in Glycerol Enrichment
NCT02846233 (8) [back to overview]	Changes in Blood Pressure
NCT02846233 (8) [back to overview]	Changes in Weight
NCT02846233 (8) [back to overview]	Changes in Heart Rate
NCT02846233 (8) [back to overview]	Changes in Serum Creatinine
NCT02846233 (8) [back to overview]	Changes in LDL
NCT02846233 (8) [back to overview]	Changes in Total Cholesterol
NCT02846233 (8) [back to overview]	Changes in Treatment Satisfaction Scores (DM-SAT Total Score)
NCT02846233 (8) [back to overview]	Change in A1c at the End of Study Period
NCT02848833 (10) [back to overview]	Change From Baseline in Body Weight at Last Visit
NCT02848833 (10) [back to overview]	Change From Baseline in Diastolic Blood Pressure (DBP) at Last Visit
NCT02848833 (10) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Last Visit
NCT02848833 (10) [back to overview]	Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Last Visit
NCT02848833 (10) [back to overview]	Percentage of Participants With Adverse Events Relating to Study Drug
NCT02848833 (10) [back to overview]	Percentage of Participants With Adverse Events of Special Interest
NCT02848833 (10) [back to overview]	Percentage of Participants With Any Adverse Events
NCT02848833 (10) [back to overview]	Percentage of Participants With Unexpected Adverse Events
NCT02848833 (10) [back to overview]	Percentage of Participants With Adverse Events Leading to Discontinuation of the Drug
NCT02848833 (10) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) at Last Visit
NCT02863328 (50) [back to overview]	Change in Body Mass Index
NCT02863328 (50) [back to overview]	Change in Body Weight (%)
NCT02863328 (50) [back to overview]	Change in Body Weight (Kg)
NCT02863328 (50) [back to overview]	Change in C-reactive Protein (Ratio to Baseline)
NCT02863328 (50) [back to overview]	Change in CoEQ: Scores From the 4 Domains and the 19 Items
NCT02863328 (50) [back to overview]	Change in ECG
NCT02863328 (50) [back to overview]	Change in Fasting C-peptide (Ratio to Baseline)
NCT02863328 (50) [back to overview]	Change in Fasting Free Fatty Acids (Ratio to Baseline)
NCT02863328 (50) [back to overview]	Change in Fasting Glucagon (Ratio to Baseline)
NCT02863328 (50) [back to overview]	Change in Fasting HDL Cholesterol (Ratio to Baseline)
NCT02863328 (50) [back to overview]	Change in Fasting Insulin (Ratio to Baseline)
NCT02863328 (50) [back to overview]	Change in Fasting LDL Cholesterol (Ratio to Baseline)
NCT02863328 (50) [back to overview]	Change in Fasting Plasma Glucose
NCT02863328 (50) [back to overview]	Change in Fasting Pro-insulin (Ratio to Baseline)
NCT02863328 (50) [back to overview]	Change in Fasting Total Cholesterol (Ratio to Baseline)
NCT02863328 (50) [back to overview]	Change in Fasting Triglycerides (Ratio to Baseline)
NCT02863328 (50) [back to overview]	Change in Fasting VLDL Cholesterol (Ratio to Baseline)
NCT02863328 (50) [back to overview]	Change in HbA1c
NCT02863328 (50) [back to overview]	Change in HOMA-B (Ratio to Baseline)
NCT02863328 (50) [back to overview]	Change in Physical Examination
NCT02863328 (50) [back to overview]	Participants Who Achieve HbA1c <7.0 % (53 mmol/Mol) ADA Target (Yes/no)
NCT02863328 (50) [back to overview]	Participants Who Achieve HbA1c <7.0 % (53 mmol/Mol) Without Hypoglycaemia (Severe or BG Confirmed Symptomatic Hypoglycaemia) and no Weight Gain (Yes/no)
NCT02863328 (50) [back to overview]	Participants Who Achieve Weight Loss ≥10% (Yes/no)
NCT02863328 (50) [back to overview]	Change in Eye Examination
NCT02863328 (50) [back to overview]	Time to Rescue Medication
NCT02863328 (50) [back to overview]	Time to Additional Anti-diabetic Medication
NCT02863328 (50) [back to overview]	SNAC Plasma Concentrations
NCT02863328 (50) [back to overview]	Semaglutide Plasma Concentrations for Population PK Analyses
NCT02863328 (50) [back to overview]	Change in Waist Circumference
NCT02863328 (50) [back to overview]	Participants Who Achieve HbA1c ≤6.5% (48 mmol/Mol), AACE Target (Yes/no)
NCT02863328 (50) [back to overview]	Participants Who Achieve HbA1c Reduction ≥1% (10.9 mmol/Mol) and Weight Loss ≥3% (Yes/no)
NCT02863328 (50) [back to overview]	Participants Who Achieve Weight Loss ≥5% (Yes/no)
NCT02863328 (50) [back to overview]	Change in SMPG : Mean Postprandial Increment Over All Meals
NCT02863328 (50) [back to overview]	Change in SMPG : Mean of the 7-point Profile
NCT02863328 (50) [back to overview]	Change in Short Form Health Survey Version 2.0 (SF-36v2™, Acute Version) Health Survey: Scores From the 8 Domains and Summaries of the Physical Component Score (PCS) and the Mental Component Score (MCS)
NCT02863328 (50) [back to overview]	Change in Pulse Rate
NCT02863328 (50) [back to overview]	Change in Lipase (Ratio to Baseline)
NCT02863328 (50) [back to overview]	Change in Body Weight (kg)
NCT02863328 (50) [back to overview]	Change in HbA1c (%)
NCT02863328 (50) [back to overview]	Number of Treatment-emergent Adverse Events (TEAE)
NCT02863328 (50) [back to overview]	Change in HOMA-IR (Ratio to Baseline)
NCT02863328 (50) [back to overview]	Number of Treatment-emergent Severe or Blood Glucose-confirmed Symptomatic Hypoglycaemic Episodes
NCT02863328 (50) [back to overview]	Occurrence of Anti-semaglutide Binding Antibodies (Yes/no)
NCT02863328 (50) [back to overview]	Occurrence of Anti-semaglutide Binding Antibodies Cross Reacting With Native GLP-1 (Yes/no)
NCT02863328 (50) [back to overview]	Occurrence of Anti-semaglutide Neutralising Antibodies (Yes/no)
NCT02863328 (50) [back to overview]	Occurrence of Anti-semaglutide Neutralising Antibodies Cross Reacting With Native GLP-1 (Yes/no)
NCT02863328 (50) [back to overview]	Participants With Treatment-emergent Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes (Yes/no)
NCT02863328 (50) [back to overview]	Anti-semaglutide Binding Antibody Levels
NCT02863328 (50) [back to overview]	Change in Amylase (Ratio to Baseline)
NCT02863328 (50) [back to overview]	Change in Blood Pressure (Systolic and Diastolic Blood Pressure)
NCT03030222 (16) [back to overview]	Change in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) From Baseline to Follow-up (Defined as Average of Measurements at 6 and 12 Weeks) Between Empagliflozin and Placebo.
NCT03030222 (16) [back to overview]	Proportion of Patients With a ≥ 5 Point Increase From Baseline in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) at Either 6 Weeks or 12 Weeks of Follow-up Between Empagliflozin and Placebo.
NCT03030222 (16) [back to overview]	Proportion of Patients With a ≥ 20% Decrease From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Either 6 Weeks or 12 Weeks of Follow-up Between Empagliflozin and Placebo.
NCT03030222 (16) [back to overview]	Change in Pulmonary Artery Diastolic Pressure From Baseline to End of Treatment Period (Defined as Average of Pulmonary Artery Diastolic Pressure Measurements Between Weeks 8-12) Between Empagliflozin and Placebo
NCT03030222 (16) [back to overview]	Change in Mean Pulmonary Artery Pressure From Baseline to End of Treatment Period (Week 12) Between Empagliflozin and Placebo.
NCT03030222 (16) [back to overview]	Number of Participants With Diuretic Medication Adjustments During the Treatment Period Between Empagliflozin and Placebo
NCT03030222 (16) [back to overview]	Proportion of Patients With a ≥ 20% Decrease From Baseline in Brain Natriuretic Peptide (BNP) at Either 6 Weeks or 12 Weeks of Follow-up Between Empagliflozin and Placebo.
NCT03030222 (16) [back to overview]	Change From Baseline in Pulmonary Artery Systolic Pressure at Each Interim Time Point (Wks 1, 2, 3, 4, 5, 6, 7, 8, 9,10,11,12) Between Empagliflozin and Placebo.
NCT03030222 (16) [back to overview]	Change From Baseline in Pulmonary Artery Diastolic Pressure at Each Interim Timepoint (Wks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12) Between Empagliflozin and Placebo.
NCT03030222 (16) [back to overview]	Change From Baseline in Mean Pulmonary Artery Pressure at Each Interim Time Point (Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12) Between Empagliflozin and Placebo.
NCT03030222 (16) [back to overview]	Proportion of Patients With Both a ≥ 5 Point Increase From Baseline in KCCQ-OS and a ≥ 20% Decrease From Baseline in NT-proBNP at Either 6 Weeks or 12 Weeks of Follow-up Between Empagliflozin and Placebo.
NCT03030222 (16) [back to overview]	Change in Hemoglobin A1c From Baseline to Follow-up (Defined as Average of Measurements at 6 and 12 Weeks) Between Empagliflozin and Placebo.
NCT03030222 (16) [back to overview]	Change in Heart Failure Related Quality of Life, Using the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) From Baseline to Follow-up (Defines as Average of Measurements at 6 and 12 Weeks) Between Empagliflozin and Placebo.
NCT03030222 (16) [back to overview]	Change in Brain Natriuretic Peptide (BNP) From Baseline to Follow-up (Defined as Average of Measurements at 6 and 12 Weeks) Between Empagliflozin and Placebo.
NCT03030222 (16) [back to overview]	Change in 6 Minute Walk Test From Baseline to Follow-up (Defined as Average of Measurements at 6 and 12 Weeks) Between Empagliflozin and Placebo.
NCT03030222 (16) [back to overview]	Change in Pulmonary Artery Systolic Pressure From Baseline to End of Treatment Period (Week 12) Between Empagliflozin and Placebo.
NCT03050619 (21) [back to overview]	Baseline Characteristics (as Measured by Estimated Glomerular Filtration Rate (eGFR)) of Patients Starting Index Prescriptions Off-label
NCT03050619 (21) [back to overview]	Baseline Characteristics (as Measured by Laboratory Tests) of Patients Starting Index Prescriptions Off-label
NCT03050619 (21) [back to overview]	Baseline Characteristics (as Measured b Yglycated Haemoglobin (HbA1c)) of Patients Starting Index Prescriptions Off-label
NCT03050619 (21) [back to overview]	Baseline Characteristics (as Measured by Life Style Factors (Blood Pressure)) of Patients Starting Index Prescriptions Off-label
NCT03050619 (21) [back to overview]	Baseline Characteristics of Adults (as Measured by Comorbidities) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK
NCT03050619 (21) [back to overview]	Baseline Characteristics (as Measured by Creatinine Serum (SCR)) of Patients Starting Index Prescriptions Off-label
NCT03050619 (21) [back to overview]	Baseline Characteristics of Adults (as Measured by Glycated Haemoglobin (HbA1c)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK
NCT03050619 (21) [back to overview]	Baseline Characteristics of Adults (as Measured by Concomitant Medications) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK
NCT03050619 (21) [back to overview]	Baseline Characteristics of Adults (as Measured by Demographics) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK
NCT03050619 (21) [back to overview]	Baseline Characteristics of Adults (as Measured by Laboratory Tests) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK
NCT03050619 (21) [back to overview]	Baseline Characteristics (as Measured by Life Style Factors (Smoking and Alcohol Use)) of Patients Starting Index Prescriptions Off-label
NCT03050619 (21) [back to overview]	Baseline Characteristics (as Measured by Comorbidities) of Patients Starting Index Prescriptions Off-label
NCT03050619 (21) [back to overview]	Baseline Characteristics (as Measured by Concomitant Medications) of Patients Starting Index Prescriptions Off-label
NCT03050619 (21) [back to overview]	Baseline Characteristics (as Measured by Demographics) of Patients Starting Index Prescriptions Off-label
NCT03050619 (21) [back to overview]	Baseline Characteristics (as Measured by Life Style Factors (BMI)) of Patients Starting Index Prescriptions Off-label
NCT03050619 (21) [back to overview]	Baseline Characteristics of Adults (as Measured by Creatinine Serum (SCR)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK
NCT03050619 (21) [back to overview]	Baseline Characteristics of Adults (as Measured by Life Style Factors (BMI)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK
NCT03050619 (21) [back to overview]	Extent of Off-label Use
NCT03050619 (21) [back to overview]	Baseline Characteristics of Adults (as Measured by Life Style Factors (Smoking and Alcohol Use)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK
NCT03050619 (21) [back to overview]	Baseline Characteristics of Adults (as Measured by Life Style Factors (Blood Pressure)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK
NCT03050619 (21) [back to overview]	Baseline Characteristics of Adults (as Measured by Estimated Glomerular Filtration Rate (eGFR)) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK
NCT03057951 (10) [back to overview]	Time to First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF)
NCT03057951 (10) [back to overview]	Time to the First Event in the Composite Renal Endpoint: Chronic Dialysis, Renal Transplant, or Sustained Reduction in eGFR (CKD-EPI)cr
NCT03057951 (10) [back to overview]	Time to Onset of Diabetes Mellitus (DM) in Patients With Pre-DM
NCT03057951 (10) [back to overview]	Occurrence of Adjudicated Hospitalisation for Heart Failure (HHF) (First and Recurrent)
NCT03057951 (10) [back to overview]	Time to First Adjudicated Hospitalisation for Heart Failure (HHF)
NCT03057951 (10) [back to overview]	Time to All-cause Mortality
NCT03057951 (10) [back to overview]	Time to Adjudicated Cardiovascular (CV) Death
NCT03057951 (10) [back to overview]	Occurrence of All-cause Hospitalisation (First and Recurrent)
NCT03057951 (10) [back to overview]	eGFR (CKD-EPI) cr Slope of Change From Baseline
NCT03057951 (10) [back to overview]	Change From Baseline in Kansas City Cardiomyopathy Questionaire (KCCQ) Clinical Summary Score at Week 52
NCT03057977 (10) [back to overview]	Time to Onset of Diabetes Mellitus (DM)
NCT03057977 (10) [back to overview]	Time to First Event in Composite Renal Endpoint: Chronic Dialysis, Renal Transplant or Sustained Reduction of eGFR(CKD-EPI)cr
NCT03057977 (10) [back to overview]	Time to First Adjudicated Hospitalisation for Heart Failure (HHF)
NCT03057977 (10) [back to overview]	Time to All-cause Mortality
NCT03057977 (10) [back to overview]	Number of All-cause Hospitalizations (First and Recurrent)
NCT03057977 (10) [back to overview]	Time to Adjudicated Cardiovascular (CV) Death
NCT03057977 (10) [back to overview]	Occurrence of Adjudicated Hospitalisation for Heart Failure (HHF) (First and Recurrent)
NCT03057977 (10) [back to overview]	Time to the First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF)
NCT03057977 (10) [back to overview]	Change From Baseline in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary Score at Week 52
NCT03057977 (10) [back to overview]	eGFR (CKD-EPI) cr Slope of Change From Baseline
NCT03152552 (41) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Bone Mineral Density (BMD) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Fasting Lipid Profile (Lipoproteins) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Fasting Lipid Profile (Lipoproteins) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Fasting Lipid Profile (Total Cholesterol) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Fasting Lipid Profile (Total Cholesterol) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Fasting Lipid Profile (Triglycerides (TG)) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Fasting Lipid Profile (Triglycerides (TG)) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Number of Participants With New York Heart Association (NYHA) Class I, II, II or IV
NCT03152552 (41) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Left Atrial Volume at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Glycated Hemoglobin (HbA1c) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Body Composition Assessed by Bio-impedance (Lean Body Mass) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Body Composition Assessed by DXA (Total Body Fat Mass) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Body Weight at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Body Weight at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Bone Mineral Density (BMD) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Glycated Hemoglobin (HbA1c) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in High Sensitive C-reactive Protein (hsCRP) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in High Sensitive C-reactive Protein (hsCRP) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Left Atrial Size at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Left Atrial Size at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Left Atrial Volume at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Sitting Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Sitting Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Number of Participants With Change From Baseline in New York Heart Association (NYHA) Class at Week 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 12
NCT03152552 (41) [back to overview]	Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 36
NCT03152552 (41) [back to overview]	24 Hour Urinary Phosphate Excretion at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in 24 Hour Sodium Excretion at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in 24 Hour Urinary Calcium Excretion at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in 24 Hour Urinary Glucose Excretion (UGE) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Body Composition Assessed by Bio-impedance (Lean Body Mass) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Body Composition Assessed by Bio-impedance (Total Body Fat Mass) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Body Composition Assessed by Bio-impedance (Total Body Fat Mass) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Body Composition Assessed by Bio-impedance (Visceral Fat Level) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Body Composition Assessed by Bio-impedance (Visceral Fat Level) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Body Composition Assessed by DXA (Lean Body Mass) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Body Composition Assessed by DXA (Lean Body Mass) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Body Composition Assessed by DXA (Total Body Fat Mass) at Weeks 12 and 36
NCT03152552 (41) [back to overview]	Change From Baseline in Body Composition Assessed by DXA (Total Body Fat Mass) at Weeks 12 and 36
NCT03200860 (8) [back to overview]	Inhospital Worsening Heart Failure, All Cause Mortality or Heart Failure Readmission at Day 60
NCT03200860 (8) [back to overview]	Plasma NTproBNP
NCT03200860 (8) [back to overview]	Serious Adverse Events
NCT03200860 (8) [back to overview]	Length of Stay
NCT03200860 (8) [back to overview]	All Cause Mortality
NCT03200860 (8) [back to overview]	Death and/or Heart Failure Re-admission
NCT03200860 (8) [back to overview]	Diuretic Response
NCT03200860 (8) [back to overview]	Dyspnea
NCT03226457 (7) [back to overview]	The Effect of Empagliflozin Versus Placebo on the Change to the Renal Biomarker, Cystatin C.
NCT03226457 (7) [back to overview]	The Effect of Empagliflozin Versus Placebo on the Change in Serum Creatinine.
NCT03226457 (7) [back to overview]	Number of Participants With a Change in CKD Category as Dictated by the Glomerular Filtration Rate
NCT03226457 (7) [back to overview]	The Effect of Empagliflozin Versus Placebo on the Change to Urinary Protein/Creatinine Ratio.
NCT03226457 (7) [back to overview]	The Effect of Empagliflozin Versus Placebo on the Change to Urinary Albumin/Creatinine Ratio.
NCT03226457 (7) [back to overview]	The Effect of Empagliflozin Versus Placebo on the Change in Urine Output.
NCT03226457 (7) [back to overview]	The Effect of Empagliflozin Versus Placebo on the Change in Urinary Sodium Excretion.
NCT03259490 (9) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72) for Linagliptin
NCT03259490 (9) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity) for Empagliflozin (AUC(0-∞)
NCT03259490 (9) [back to overview]	Maximum Measured Concentration of the Empagliflozin in Plasma (Cmax)
NCT03259490 (9) [back to overview]	Cmax for Metformin in Plasma
NCT03259490 (9) [back to overview]	Cmax for Linagliptin in Plasma
NCT03259490 (9) [back to overview]	AUC0-tz for Metformin.
NCT03259490 (9) [back to overview]	AUC(0-∞) for Metformin
NCT03259490 (9) [back to overview]	AUC(0-∞) for Linagliptin
NCT03259490 (9) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) for Empagliflozin
NCT03332212 (1) [back to overview]	Change From Baseline to Week 12 in PCr/ATP Ratio in the Resting State Measured by 31P Cardiac Magnetic Resonance Spectroscopy (MRS).
NCT03351478 (8) [back to overview]	Percentage of Participants With HbA1c <7.0% at Week 26
NCT03351478 (8) [back to overview]	Percentage of Participants With HbA1c <6.5% at Week 26
NCT03351478 (8) [back to overview]	Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 12 in Participants With Baseline SBP ≥ 130 mmHg
NCT03351478 (8) [back to overview]	Change From Baseline in Sitting SBP at Week 12 for All Participants
NCT03351478 (8) [back to overview]	Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26
NCT03351478 (8) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26
NCT03351478 (8) [back to overview]	Change From Baseline in Body Weight at Week 26
NCT03351478 (8) [back to overview]	Change From Baseline in 2-hour Postprandial Glucose (PPG) Following a Mixed Meal at Week 26
NCT03448406 (6) [back to overview]	Change From Baseline in Clinical Congestion Score at Week 12
NCT03448406 (6) [back to overview]	Change From Baseline to Week 12 in Chronic Heart Failure Questionnaire Self- Administered Standardized Format (CHQ-SAS) Dyspnea Score
NCT03448406 (6) [back to overview]	Change From Baseline to Week 12 in Exercise Capacity as Measured by the Distance Walked in 6 Minutes in Standardised Conditions (6MWTD)
NCT03448406 (6) [back to overview]	Change From Baseline to Week 12 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score (TSS)
NCT03448406 (6) [back to overview]	Change From Baseline to Week 6 in Exercise Capacity as Measured by the Distance Walked in 6 Minutes
NCT03448406 (6) [back to overview]	Relative Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NTproBNP) at Week 12
NCT03448419 (6) [back to overview]	Relative Change From Baseline to Week 12 in N-terminal Pro-brain Natriuretic Peptide (NTproBNP)
NCT03448419 (6) [back to overview]	Change From Baseline to Week 6 in Exercise Capacity as Measured by the 6-Minutes-Walking-Test (6MWT) Distance
NCT03448419 (6) [back to overview]	Change From Baseline to Week 12 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score (TSS)
NCT03448419 (6) [back to overview]	Change From Baseline to Week 12 in Exercise Capacity as Measured by the 6-Minutes-Walking-Test (6MWT) Distance
NCT03448419 (6) [back to overview]	Change From Baseline to Week 12 in Clinical Congestion Score
NCT03448419 (6) [back to overview]	Change From Baseline to Week 12 in Chronic Heart Failure Questionnaire Self- Administered Standardized Format (CHQ-SAS) Dyspnea Score
NCT03485222 (6) [back to overview]	Change in VO2 Consumption
NCT03485222 (6) [back to overview]	Change in LV-end Diastolic Volume (EDV)
NCT03485222 (6) [back to overview]	Change in LV-Ejection Fraction Index
NCT03485222 (6) [back to overview]	Change in Kansas Cardiomyopathy Questionnaire (KCCQ-12)
NCT03485222 (6) [back to overview]	Change in 6 Min Walk Test
NCT03485222 (6) [back to overview]	Change in Left Ventricle-end Systolic Volume (ESV)
NCT03594110 (7) [back to overview]	Interventional Part: Time to First Occurrence of Kidney Disease Progression
NCT03594110 (7) [back to overview]	Interventional Part: Time to First Occurrence Cardiovascular Death ('as Adjudicated') or End Stage Kidney Disease (ESKD)
NCT03594110 (7) [back to overview]	Interventional Part: Time to Cardiovascular Death ('as Adjudicated')
NCT03594110 (7) [back to overview]	Interventional Part: Time to First Occurrence of Kidney Disease Progression or Cardiovascular Death ('as Adjudicated')
NCT03594110 (7) [back to overview]	Key Secondary Endpoint: Interventional Part - Time to Death From Any Cause ('as Adjudicated')
NCT03594110 (7) [back to overview]	Key Secondary Endpoint: Interventional Part - Time to First Hospitalization for Heart Failure ('as Adjudicated') or Cardiovascular Death ('as Adjudicated')
NCT03594110 (7) [back to overview]	Key Secondary Endpoint: Interventional Part - Time to Occurrences of All-cause Hospitalizations (First and Recurrent Combined)
NCT03629054 (10) [back to overview]	Area Under the Concentration-time Curve of the Metformin Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
NCT03629054 (10) [back to overview]	Maximum Measured Concentration of the Empagliflozin in Plasma (Cmax)
NCT03629054 (10) [back to overview]	Area Under the Concentration-time Curve of the Empagliflozin Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
NCT03629054 (10) [back to overview]	Maximum Measured Concentration of the Linagliptin in Plasma (Cmax)
NCT03629054 (10) [back to overview]	Maximum Measured Concentration of the Metformin in Plasma (Cmax)
NCT03629054 (10) [back to overview]	Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT03629054 (10) [back to overview]	Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT03629054 (10) [back to overview]	Percentage of Patients With Drug-related Adverse Events (AEs)
NCT03629054 (10) [back to overview]	Area Under the Concentration-time Curve of the Linagliptinin Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
NCT03629054 (10) [back to overview]	Area Under the Concentration-time Curve of the Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (h) (AUC0-72)
NCT03642717 (10) [back to overview]	Percentage of Participants With Adverse Events Relating to Study Drug
NCT03642717 (10) [back to overview]	Percentage of Participants With Any Adverse Events
NCT03642717 (10) [back to overview]	Change in the Systolic Blood Pressure (SBP) at Last Visit From Baseline
NCT03642717 (10) [back to overview]	Percentage of Participants With Adverse Events Leading to Discontinuation of the Drug
NCT03642717 (10) [back to overview]	Percentage of Participants With Unexpected Adverse Events
NCT03642717 (10) [back to overview]	Change in the Body Weight at Last Visit From Baseline
NCT03642717 (10) [back to overview]	Change in the Diastolic Blood Pressure (DBP) at Last Visit From Baseline
NCT03642717 (10) [back to overview]	Change in the Fasting Plasma Glucose (FPG) at Last Visit From Baseline
NCT03642717 (10) [back to overview]	Change in the Glycosylated Hemoglobin (HbA1c) at Last Visit From Baseline
NCT03642717 (10) [back to overview]	Percentage of Participants With Adverse Events of Special Interest
NCT03764631 (8) [back to overview]	Number of Participants With Ketoacidosis During Ramadan Periods
NCT03764631 (8) [back to overview]	Number of Participants With Severe Urinary Tract Infections (UTIs) During Ramadan Periods
NCT03764631 (8) [back to overview]	Number of Participants With Volume Depletion During Ramadan Periods
NCT03764631 (8) [back to overview]	Number of Participants With Ketoacidosis
NCT03764631 (8) [back to overview]	Number of Participants With Severe Urinary Tract Infections (UTIs)
NCT03764631 (8) [back to overview]	Number of Participants With Volume Depletion
NCT03764631 (8) [back to overview]	Number of Participants With Dehydration
NCT03764631 (8) [back to overview]	Number of Participants With Dehydration During Ramadan Periods
NCT03807440 (29) [back to overview]	Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
NCT03807440 (29) [back to overview]	Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant T2D Medications at Study Index Date 1 According to Prescribing Specialist
NCT03807440 (29) [back to overview]	Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
NCT03807440 (29) [back to overview]	Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
NCT03807440 (29) [back to overview]	Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
NCT03807440 (29) [back to overview]	Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
NCT03807440 (29) [back to overview]	Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
NCT03807440 (29) [back to overview]	Baseline Characteristic: Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
NCT03807440 (29) [back to overview]	Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant Cardiovascular Disease (CVD) and/or Chronic Kidney Disease (CKD) Medication at Study Index Date 1 According to Prescribing Specialist
NCT03807440 (29) [back to overview]	Number of Patients for Each Type of Physician Specialties Involved in Decision for T2D Therapy Discontinuation According to Prescribing Specialist
NCT03807440 (29) [back to overview]	Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
NCT03807440 (29) [back to overview]	Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
NCT03807440 (29) [back to overview]	Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
NCT03807440 (29) [back to overview]	Number of Patients With Documentation of Estimated Glomerular Filtration Rate (eGFR) / Urine Albumin Creatinine Ratio (UACR) Status
NCT03807440 (29) [back to overview]	Number of Patients With Chronic Kidney Disease (CKD) by Physician's Assessment
NCT03807440 (29) [back to overview]	Number of Patients With Chronic Kidney Disease (CKD) by Estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) Status
NCT03807440 (29) [back to overview]	Time to Discontinuation of Type 2 Diabetes (T2D) Treatment According to Study Medication
NCT03807440 (29) [back to overview]	10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
NCT03807440 (29) [back to overview]	10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
NCT03807440 (29) [back to overview]	Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
NCT03807440 (29) [back to overview]	10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
NCT03807440 (29) [back to overview]	Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
NCT03807440 (29) [back to overview]	Number of Patients With Chronic Kidney Disease (CKD) by eGFR and UACR Status According to Prescribing Specialist
NCT03807440 (29) [back to overview]	Number of Patients With Any Type of Cardiovascular Disease (CVD)
NCT03807440 (29) [back to overview]	Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
NCT03807440 (29) [back to overview]	Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
NCT03807440 (29) [back to overview]	Number of Patients in Each Category of the Different Types of Cardiovascular Disease
NCT03807440 (29) [back to overview]	Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
NCT03807440 (29) [back to overview]	Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
NCT03852901 (8) [back to overview]	Change in 1H MRS Glutamate (Glu)
NCT03852901 (8) [back to overview]	Change in 1H MRS Glutamine (Gln)
NCT03852901 (8) [back to overview]	Change in Plasma Glucose
NCT03852901 (8) [back to overview]	Change in Plasma Insulin
NCT03852901 (8) [back to overview]	Change in Serum Acetoacetate (AcAc)
NCT03852901 (8) [back to overview]	Change in Serum Non-esterified Fatty Acids (NEFAs)
NCT03852901 (8) [back to overview]	Change in Serum β-hydroxybutyrate (BHB)
NCT03852901 (8) [back to overview]	Change in 1H MRS BHB
NCT04098575 (14) [back to overview]	Duration of Diabetes
NCT04098575 (14) [back to overview]	Percentage of Participants With Previous Glucose-lowering Treatment
NCT04098575 (14) [back to overview]	Percentage of Patients Participated in Disease Management Programme (DMP) Type 2 Diabetes
NCT04098575 (14) [back to overview]	Weight of Participants
NCT04098575 (14) [back to overview]	Dosage of Empagliflozin
NCT04098575 (14) [back to overview]	Percentage of Participants by Age Category
NCT04098575 (14) [back to overview]	Percentage of Participants With Previous Occurence of Other Typical Diabetes Complications
NCT04098575 (14) [back to overview]	Percentage of Participants With Antidiabetic and Cardiovascular Co-medication
NCT04098575 (14) [back to overview]	Glycated Hemoglobin (HbA1c)
NCT04098575 (14) [back to overview]	Fasting Plasma Glucose (FPG)
NCT04098575 (14) [back to overview]	Height of Participants
NCT04098575 (14) [back to overview]	Number of Participants With Hospitalizations
NCT04098575 (14) [back to overview]	Percentage of Male Participants
NCT04098575 (14) [back to overview]	Percentage of Participants With Previous Occurence of Cardiovascular Comorbidities
NCT04157751 (11) [back to overview]	Percentage of Days Alive and Out of Hospital (DAOH) From Study Drug Initiation Until 30 Days After Initial Hospital Discharge
NCT04157751 (11) [back to overview]	Number of Participants With Improvement of at Least 10 Points in KCCQ-TSS After 90 Days of Treatment
NCT04157751 (11) [back to overview]	Number of Participants With Hospitalization for Heart Failure (HHF) Until 30 Days After Initial Hospital Discharge
NCT04157751 (11) [back to overview]	Incidence Rate of First Occurrence of Cardiovascular (CV) Death or Heart Failure Event (HFE) Until End of Trial Visit
NCT04157751 (11) [back to overview]	Composite Renal Endpoint: Number of Participants With Chronic Dialysis, Renal Transplant, Sustained Reduction in eGFR(CKD-EPI)cr
NCT04157751 (11) [back to overview]	Change From Baseline in Log-transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) Area Under the Curve (AUC) Over 30 Days of Treatment
NCT04157751 (11) [back to overview]	Change From Baseline in KCCQ-TSS After 90 Days of Treatment
NCT04157751 (11) [back to overview]	Percentage of Pairwise Comparisons With Wins of Clinical Benefit, a Composite of Death, Number of Heart Failure Events (HFEs), Time to the First HFE and ≥5-point Difference in CfB in KCCQ-TSS After 90 Days of Treatment
NCT04157751 (11) [back to overview]	Weight Change Per Mean Daily Loop Diuretic Dose After 30 Days of Treatment
NCT04157751 (11) [back to overview]	Weight Change Per Mean Daily Loop Diuretic Dose After 15 Days of Treatment
NCT04157751 (11) [back to overview]	Percentage of Days Alive and Out of Hospital (DAOH) From Study Drug Initiation Until 90 Days After Randomisation
NCT04233801 (9) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
NCT04233801 (9) [back to overview]	Number of Participants With Adjudicated Diabetic Ketoacidosis (DKA) Events
NCT04233801 (9) [back to overview]	Number of Participants With Confirmed Hypoglycaemic Events
NCT04233801 (9) [back to overview]	Percentage of Participants With HbA1c<7.0% at Week 24
NCT04233801 (9) [back to overview]	Change From Baseline in 2-hour Post-prandial Glucose (PPG) at Week 24
NCT04233801 (9) [back to overview]	Change From Baseline in Diastolic Blood Pressure (DBP) at Week 24
NCT04233801 (9) [back to overview]	Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 24
NCT04233801 (9) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) at Week 24
NCT04233801 (9) [back to overview]	Change in Body Weight From Baseline to Week 24
NCT04907214 (5) [back to overview]	Change in the Plasma Inflammatory Cytokine IL-6 After 3 Months
NCT04907214 (5) [back to overview]	Change in Liver Steatosis at 3 Months
NCT04907214 (5) [back to overview]	Change in Flow-mediated Dilation After 3 Months
NCT04907214 (5) [back to overview]	Change in Adipose Pro-inflammatory T Helper Type 1 Cell Percentages After 3 Months
NCT04907214 (5) [back to overview]	Change in Adipose Pro-inflammatory T Helper Type 1 Cell Percentages After 2 Weeks
NCT05083949 (14) [back to overview]	Elimination Rate Constant (Kel) for Metformin
NCT05083949 (14) [back to overview]	Percentage (%) of the AUC of Empagliflozin That Has Been Derived After Extrapolation
NCT05083949 (14) [back to overview]	Percentage (%) of the AUC of Metformin That Has Been Derived After Extrapolation
NCT05083949 (14) [back to overview]	Terminal Half-life of Empagliflozin in Plasma (t1/2)
NCT05083949 (14) [back to overview]	Maximum Measured Concentration of Metformin (Cmax)
NCT05083949 (14) [back to overview]	Time From Last Dosing to the Maximum Measured Concentration of Empagliflozin in Plasma (Tmax)
NCT05083949 (14) [back to overview]	Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT05083949 (14) [back to overview]	Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
NCT05083949 (14) [back to overview]	Terminal Half-life of Metformin in Plasma (t1/2)
NCT05083949 (14) [back to overview]	Elimination Rate Constant (Kel) for Empagliflozin
NCT05083949 (14) [back to overview]	Dose-normalized Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞ )
NCT05083949 (14) [back to overview]	Time From Last Dosing to the Maximum Measured Concentration of Metformin in Plasma (Tmax)
NCT05083949 (14) [back to overview]	Dose-normalized Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT05083949 (14) [back to overview]	Dose-normalized Maximum Measured Concentration of Empagliflozin (Cmax)

Cmax of Empagliflozin

maximum concentration of the analyte in plasma after first dose (Cmax, Day 1 ) and at steady state over a uniform dosing interval (Cmax,ss, Day 28). (NCT00558571)
Timeframe: 0:05 before drug administration and 0:15 0:30 0:45 1:00 1:30 2:00 2:30 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 hours(h) after drug administration on day 1 and 28

Intervention	nmol/L (Geometric Mean)
	Cmax	Cmax,ss
100mg Empagliflozin	2630	2390
10mg Empagliflozin	309	259
25mg Empagliflozin	722	687

Intervention	percentage of hemoglobin (Mean)
	baseline (day -1)	change from baseline to day 28 (N=13, 13, 15, 28)
100mg Empagliflozin	7.1	-0.36
10mg Empagliflozin	7.15	-0.27
25mg Empagliflozin	7.45	-0.22
Placebo	6.89	-0.18

Intervention	µU*h/mL (Mean)
	baseline (day -1)	change from baseline to day 28 (N=16, 16, 16, 29)
100mg Empagliflozin	121.53	8.83
10mg Empagliflozin	117.34	3.24
25mg Empagliflozin	102.44	3.8
Placebo	108.16	24.37

Intervention	mg/dL (Mean)
	baseline (day -2)	change from baseline to day 1	change from baseline to day 7	change from baseline to day 14	change from baseline to day 21	change from baseline to day 27
100mg Empagliflozin	149.43	-23.02	-21.17	-12.03	-13.93	-23.87
10mg Empagliflozin	164.83	-14.69	-25.45	-26.97	-26.47	-19.57
25mg Empagliflozin	166.26	-23.51	-28.58	-20.43	-19.68	-26.37
Placebo	152.06	2.13	-2.4	2.68	-3.41	-4.69

Intervention	hours (Median)
	tmax	tmax,ss
100mg Empagliflozin	1.50	1.50
10mg Empagliflozin	1.50	1.50
25mg Empagliflozin	1.50	1.50

Intervention	ratio (Geometric Mean)
10mg Empagliflozin	1.09
25mg Empagliflozin	1.1
100mg Empagliflozin	1.04

Intervention	mg/dL (Mean)
	baseline (day -1)	change from baseline to day 28 (N=15, 15, 16, 28)
100mg Empagliflozin	149.92	-28.69
10mg Empagliflozin	186.18	-43.7
25mg Empagliflozin	167.49	-34.22
Placebo	153.87	-4.08

Intervention	mg (Geometric Mean)
	Ae0-24 on day -2 (N=15,16,15,26)	Ae0-24 on day -1 (N=13,15,16,25)	Ae0-24 on day 1 (N=15,15,16,29)	Ae0-24 on day 27 (N=14,13,14,27)	Ae0-24 on day 28 (N=13,13,11,23)
100mg Empagliflozin	6050	6190	87000	81300	73900
10mg Empagliflozin	7760	8450	81500	78000	75400
25mg Empagliflozin	5340	8150	95700	82900	83400
Placebo	4270	6490	3970	3790	6310

Intervention	µU/mL (Mean)
	baseline (day -1) (N=12,12,14,23)	change from baseline to day 1 (N=11,12,14,22)	change from baseline to day 7 (N=9,10,9,18)	change from baseline to day 14 (N=12,11,14,22)	change from baseline to day 21 (N=10,11,14,21)	change from baseline to day 28 (N=11,11,12,20)
100mg Empagliflozin	9.3	0.15	-0.2	1.37	1.53	-2.1
10mg Empagliflozin	11.43	-1.56	-2.49	-1.16	-0.17	-2.89
25mg Empagliflozin	8.74	-1.1	-1	0.18	-1.21	-1.73
Placebo	10	-1.08	0.48	2.32	1.84	-1.2

Intervention	participants (Number)
	Lipase increased	Blood triglycerides increased	Blood creatine phosphokinase increased	Ventricular extrasystoles
100mg Empagliflozin	2	0	1	0
10mg Empagliflozin	0	1	0	1
25mg Empagliflozin	1	0	0	0
Placebo	0	0	0	0

Intervention	percentage of Empagliflozin (Geometric Mean)
	fe0-24 (N=14,16,30)	fe0-24,ss
100mg Empagliflozin	13.7	17.5
10mg Empagliflozin	12.5	18.3
25mg Empagliflozin	13.3	17.8

Intervention	µmol/L (Mean)
	baseline (day -1)	change from baseline to day 14 (N=14, 16, 15, 29)	change from baseline to day 28 (N=14, 15, 16, 28)
100mg Empagliflozin	237.07	18.31	-26.29
10mg Empagliflozin	251.88	24.75	-24.33
25mg Empagliflozin	257.88	13.07	-22.06
Placebo	237.27	19.57	-23.57

Intervention	ng*h/L (Mean)
	baseline (day -1)	change from baseline to day 28 (N=14, 14, 16, 28)
100mg Empagliflozin	303.06	40.65
10mg Empagliflozin	310.76	59.69
25mg Empagliflozin	291.09	33.6
Placebo	290.66	9.01

Intervention	mg/dL (Mean)
Placebo	4.75
Empagliflozin 1 mg	-1.70
Empagliflozin 5 mg	-15.84
Empagliflozin 10 mg	-22.14
Empagliflozin 25 mg	-26.83
Empagliflozin 50 mg	-27.91
Sitagliptin OL	-12.92

Intervention	mU/L x mmol/L (Mean)
Placebo	0.23
Empagliflozin 1 mg	-0.11
Empagliflozin 5 mg	-0.60
Empagliflozin 10 mg	-1.04
Empagliflozin 25 mg	-0.52
Empagliflozin 50 mg	-1.10
Sitagliptin OL	0.48

Intervention	mU / mmol (Mean)
Placebo	0.30
Empagliflozin 1 mg	0.08
Empagliflozin 5 mg	0.36
Empagliflozin 10 mg	1.55
Empagliflozin 25 mg	6.68
Empagliflozin 50 mg	4.01
Sitagliptin OL	12.38

Intervention	nmol/L (Geometric Mean)
	Day 28 (N=58, 65, 62, 58, 63)	Day 56 (N=56, 64, 64, 61, 61)	Day 84 (N=53, 61, 59, 57, 57)
Empagliflozin 1 mg	3.19	2.93	2.87
Empagliflozin 10 mg	27.3	23.0	23.4
Empagliflozin 25 mg	92.5	75.4	71.0
Empagliflozin 5 mg	13.1	11.5	11.2
Empagliflozin 50 mg	119	119	112

Intervention	percentage of HbA1c (Mean)
	Week 4	Week 8	Week 12
Empagliflozin 1 mg	-0.12	-0.14	-0.08
Empagliflozin 10 mg	-0.32	-0.57	-0.57
Empagliflozin 25 mg	-0.31	-0.52	-0.59
Empagliflozin 5 mg	-0.16	-0.30	-0.27
Empagliflozin 50 mg	-0.36	-0.53	-0.50
Placebo	0.02	0.05	0.12
Sitagliptin OL	-0.26	-0.40	-0.45

Intervention	percentage of participants (Number)
Placebo	21.1
Empagliflozin 1 mg	31.0
Empagliflozin 5 mg	40.8
Empagliflozin 10 mg	60.6
Empagliflozin 25 mg	60.0
Empagliflozin 50 mg	48.6
Sitagliptin OL	53.5

Intervention	percentage of participants (Number)
Placebo	15.5
Empagliflozin 1 mg	23.9
Empagliflozin 5 mg	21.1
Empagliflozin 10 mg	38.0
Empagliflozin 25 mg	37.1
Empagliflozin 50 mg	35.7
Sitagliptin OL	33.8

Intervention	nmol/L (Geometric Mean)
	Day 28 (N=67, 75, 77)	Day 56 (N=69, 73, 75)	Day 84 (N=70, 77, 75)
Empagliflozin 10 mg	61.7	51.6	55.3
Empagliflozin 25 mg	117	127	118
Empagliflozin 5 mg	31.6	20.3	22.9

empagliflozin

Cross-References

Synonyms (77)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (4)

Protein Targets (2)

Inhibition Measurements

Activation Measurements

Biological Processes (18)

Molecular Functions (12)

Ceullar Components (9)

Bioassays (8)

Research

Studies (1,395)

Market Indicators

Research Demand Index: 125.60

Study Types

Clinical Trials (382)

Trial Overview

Trial Outcomes

Cmax of Empagliflozin

HbA1c

Insulin AUEC0-5

Insulin Emax (Maximum Measured Effect)

Mean Daily Glucose (MDG) Measured in Blood

t1/2 of Empagliflozin

Tmax of Empagliflozin

LI (Linearity Index).

Fasting Plasma Glucose (FPG)

AUC0-∞ of Empagliflozin

Ae0-24 of Glucose

Fasting Insulin

Number of Subjects With Drug Related Adverse Events

Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG

CL/F of Empaglifozin

fe0-24 of Empagliflozin

Fructosamine

Glucagon AUEC0-5

Glucagon Emax (Maximum Measured Effect)

Change of FPG From Baseline After 12 Weeks of Treatment

Change of Body Weight After 12 Weeks of Treatment

Change in Homeostasis Model Assessment Index for Insulin Resistance (HOMA-IR)

Change in Homeostasis Model Assessment Index for Beta Cell Function (HOMA-%B)

Change From Baseline to Week 12 in Fasting Plasma Insulin (FPI)

Change From Baseline in HbA1c After 12 Weeks of Treatment

Trough Concentrations of Empagliflozin in Plasma

Change of HbA1c From Baseline Over Time

Proportion of Patients Who Achieve an HbA1c Lowering of at Least 0.5% After 12 Weeks of Treatment

Proportion of Patients Who Achieve an HbA1c ≤7.0% After 12 Weeks of Treatment

Change of HbA1c From Baseline Over Time

Trough Concentrations of Empagliflozin in Plasma

Change in Homeostasis Model Assessment Index for Beta Cell Function (HOMA-%B)

Change From Baseline to Week 12 in Fasting Plasma Insulin (FPI)

Proportion of Patients Who Achieve an HbA1c Lowering of at Least 0.5% After 12 Weeks of Treatment

Proportion of Patients Who Achieve an HbA1c ≤7.0% After 12 Weeks of Treatment

Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment

Change of FPG From Baseline After 12 Weeks of Treatment

Change of Body Weight After 12 Weeks of Treatment

Change in Homeostasis Model Assessment Index for Insulin Resistance (HOMA-IR)

Change From Baseline to Week 78 in Lipid Parameters

Change From Baseline in HbA1c Over Time

Change From Baseline in Fasting Plasma Glucose (FPG) Over Time

Hypoglycaemic Events

Occurrence of a Relative Efficacy Response

Occurrence of a Treat-to-target Response (HbA1c < 6.5%)

Occurence of a Treat-to-target Response (HbA1c < 7.0%)

Clinical Relevant Abnormalities for Physical Examination, Vital Signs, ECG and Laboratory Measurements

t1/2,ss

Vz/F

Vz/F,ss

Intervention	mU / mmol (Mean)
Placebo	-5.20
Empagliflozin 5 mg	4.22
Empagliflozin 10 mg	1.09
Empagliflozin 25 mg	2.13
Metformin OL	6.69

Intervention	mU/L (Mean)
Placebo	-0.95
Empagliflozin 5 mg	-0.90
Empagliflozin 10 mg	-1.02
Empagliflozin 25 mg	-0.90
Metformin OL	-0.01

Intervention	percentage of participants (Number)
Placebo	25.6
Empagliflozin 5 mg	46.9
Empagliflozin 10 mg	59.3
Empagliflozin 25 mg	59.8
Metformin OL	71.3

Intervention	percentage of participants (Number)
Placebo	22.0
Empagliflozin 5 mg	33.3
Empagliflozin 10 mg	29.6
Empagliflozin 25 mg	45.1
Metformin OL	45.0

Intervention	percentage of HbA1c (Mean)
Placebo	0.09
Empagliflozin 5 mg	-0.43
Empagliflozin 10 mg	-0.48
Empagliflozin 25 mg	-0.63
Metformin OL	-0.75

Intervention	mU/L x mmol/L (Mean)
Placebo	-0.19
Empagliflozin 5 mg	-0.85
Empagliflozin 10 mg	-0.83
Empagliflozin 25 mg	-0.79
Metformin OL	-0.37

Intervention	mmol/L (Mean)
	Total Cholesterol	HDL	LDL (N=102, 108, 52, 161, 159, 55)	Triglyceride
Empagliflozin 10 mg	-0.13	0.08	-0.02	-0.5
Empagliflozin 10 mg + Metformin	0.19	0.06	0.13	0.1
Empagliflozin 25 mg	0.09	0.07	0.05	-0.0
Empagliflozin 25 mg + Metformin	0.13	0.07	0.07	-0.1
Metformin	-0.24	0.06	-0.13	-0.5
Sitaglipin + Metformin	-0.05	0.03	0.00	-0.2

Intervention	percentage of HbA1c (Mean)
	Week 6 (N=104, 108, 55, 162, 163, 54)	Week 18 (N=93, 105, 53, 149, 157, 48)	Week 30 (N=93, 99, 50, 140, 151, 45)	Week 42 (N=85, 93, 46, 132, 140, 44)	Week 54 (N=78, 85, 44, 128, 136, 41)	Week 66 (N=80, 87, 43, 120, 127, 39)	Week 78 (N=72, 84, 42, 115, 121, 38)
Empagliflozin 10 mg	-0.40	-0.58	-0.47	-0.59	-0.66	-0.55	-0.50
Empagliflozin 10 mg + Metformin	-0.36	-0.51	-0.58	-0.65	-0.62	-0.59	-0.56
Empagliflozin 25 mg	-0.57	-0.72	-0.61	-0.74	-0.71	-0.71	-0.55
Empagliflozin 25 mg + Metformin	-0.55	-0.70	-0.76	-0.79	-0.75	-0.73	-0.71
Metformin	-1.03	-0.92	-0.95	-1.10	-1.13	-1.04	-0.80
Sitaglipin + Metformin	-0.75	-0.79	-0.68	-0.51	-0.79	-0.78	-0.66

Intervention	mg/dL (Mean)
	Week 6 (N=102, 108, 55, 156, 160, 53)	Week 18 (N=94, 103, 51, 144, 153, 45)	Week 30 (N=92, 101, 51, 133, 147, 43)	Week 42 (N=85, 93, 46, 126, 140, 42)	Week 54 (N=80, 88, 44, 124, 134, 39)	Week 66 (N=80, 86, 43, 116, 125, 38)	Week 78 (N=72, 84, 43, 112, 121, 36)
Empagliflozin 10 mg	-30.6	-35.5	-32.3	-35.8	-32.1	-28.0	-27.9
Empagliflozin 10 mg + Metformin	-25.7	-30.6	-29.9	-30.8	-28.2	-21.7	-24.7
Empagliflozin 25 mg	-35.8	-33.7	-35.0	-31.3	-31.0	-28.6	-25.4
Empagliflozin 25 mg + Metformin	-36.7	-37.6	-37.9	-36.8	-36.8	-29.6	-31.9
Metformin	-29.9	-30.4	-28.5	-31.0	-31.8	-26.4	-22.9
Sitaglipin + Metformin	-32.6	-16.7	-25.6	-18.5	-29.4	-32.5	-25.7

Intervention	percentage of participants (Number)
	Alanine aminotransferase increased	Aspartate aminotransferase increased	Gamma-glutamyltransferase increased	Blood alkaline phosphatase increased	Blood creatine phosphokinase increased	Granulocyte count decreased	Hepatic enzyme increased	Blood creatinine increased	Creatinine renal clearance decreased	Weight decreased	Sick sinus syndrome	Tachycardia
Empagliflozin 10 mg	0.9	1.9	0.9	0.9	0.9	0.9	0.0	0.9	0.0	0.0	0.9	0.9
Empagliflozin 10 mg + Metformin	0.6	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.6	0.0	0.0	0.6
Empagliflozin 25 mg	0.9	0.0	0.0	0.0	0.0	0.0	0.9	0.9	0.0	0.9	0.0	1.8
Empagliflozin 25 mg + Metformin	0.6	0.6	1.2	0.0	0.0	0.0	0.0	0.6	0.0	0.6	0.0	0.6
Metformin	3.6	1.8	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Sitaglipin + Metformin	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0